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1. ABSTRACT
1. ABSTRACT
The  microarray  technology  has  revolutionized  the  study of  the  complexity  in  the 
biological systems and of the biological responses to the environment. In order to define new 
scenarios and new biological pathways, the aim of this PhD thesis was the acquisition of a 
mastery in the management and analysis of microarray data, deepening the basic concepts of 
statistical analysis, to make knowledgeably choices about the test more suitable to a particular 
set  of data.  After  in-depth knowledge of  the different  phases,  the aim was to  build up a 
generic pipeline that can be used to analyze any type of microarray data. The computational  
pipeline for processing raw microarray data (images) was implemented in R, using mostly 
Bioconductor packages. Implementation aimed to define gene expression levels, to provide 
experiment quality assessment and significative statistical tests. 
During the first part of the PhD thesis my purpose was the determination of the gene function 
combining experiments of silencing with the gene expression analysis. 
Caspase-2 is a member of the cystein-protease family of enzymes, which carry out important 
roles in apoptosis  and in inflammation.  Although  CASP2 is highly conserved through the 
evolution and was the first caspase identified, several contradictory results are found in the 
literature.  Being expressed at  high level  during the neurological  development  and with a 
strong involvement in the apoptotic processes in the adult central nervous system, we decided 
to proceed with its silencing in glioblastoma cells, to evaluate the effect on gene expression. 
The  comparative  analysis  of  expression  profiles  of  silenced  cells  respect  to  the  control, 
highlighted the relation between  CASP2 and genes involved in the cholesterol metabolism. 
Previous studies have suggested for this enzyme a role in the control of intracellular level of 
this  metabolite.  Therefore,  we decided to  use data  stored in  public  databases  in  order  to 
extend the investigation,  including all  the  other  caspases  and all  the  genes  in  some way 
connected to cholesterol. Computational analysis of the correlation between expression levels 
of these different genes families, has allowed us to: i) define correlations among cholesterol 
genes and caspases and ii) perform a hierarchical clustering of the different caspases in term 
of correlational profile. The analysis was expanded to normal brain and liver tissues and a 
correlation between expression levels  of certain caspases  and aging was found in human 
brain. 
During the second part of the work, I performed gene expression profile analysis to define 
1
1. ABSTRACT
signaling  pathways  and  resistance  mechanisms  elicited  after  treatment  of  chronic  B 
lymphocytic  leukemia  cells  with  a  new  class  of  ubiquitin-proteasome  system  (UPS) 
inhibitors.
Through the comparison of transcriptional profiles before and after treatments, many genes 
and relative pathways, whose expression was altered by the UPS inhibitor, were identified. 
These  genes  have  allowed  us  to  define  new  mechanisms  of  drug  action.  Furthermore, 
considering the difference in terms of responsiveness of the analyzed patients, we propose 
some genes as responsible for the differential cellular reactivity to the specific inhibitor.
2
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2. INTRODUCTION
2.1 MICROARRAY
The microarray technique, developed in the 90s (Schena, 1995), enables the analysis 
of gene expression by monitoring at once the RNA products of thousands of genes.
Thanks to the production of high quality platforms, the creation of standardized experimental 
protocols, the construction of sophisticated devices for the recording of the intensity values 
and the development  of robust computational tools  for data management,  this  technology 
became a  technique  of  everyday use  in  biological  laboratories  (Hoheisel,  2006;  Trevino, 
2007).
Unlike traditional investigation techniques, that make use of probes labeled with fluorescent 
substances  directed  against  specific  sequences  of  DNA  anchored  to  a  solid  support, 
microarray technology overturns  this  relationship:  in  this  case the non-labeled probes  are 
fixed  on  the  same  support  and  the  labeled  sample  is  instead  in  the  liquid  phase.  The 
hybridization of all  the probes and their  respective targets occurs simultaneously and this 
produces  information  on  the  global  transcriptional  state  of  the  sample.  After  removal  of 
excess solution that did not interact with the probes, the bond between the probe and target is 
translated into a numerical value, after recording the emitted fluorescence, which is supposed 
to  be proportional to the amount of the respective transcript  present  in the sample under 
investigation.
The  microarray  analysis  provides  a  matrix  of  genes  (along  rows)  and  samples  (along 
columns). The values in the matrix are intensity measurements that are proportional to the 
mRNA quantity of each gene present in a cell.
MICROARRAY TECHNOLOGY
The  choice  of  the  material  for  the  microarray  construction  has  a  fundamental 
importance. At the beginning, DNA arrays were based on nylon membranes. Nowadays, both 
porous and non-porous materials can be selected for their construction, each of them with 
specific advantages. The non-porous ones, such as glass, are the most useful, given the low 
intrinsic fluorescence and the poor dissemination.
These features allow to create small sized spots in a very precise way, permitting the use of an 
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extremely low sample quantity. Unfortunately the glass has a high affinity for dust and for the 
other contaminants present in the air and a smaller binding surface with respect to the other 
porous materials.
A recent technology makes use of glass beads to which the probes are linked before being 
spotted in a completely random way. The positions are then determined through a complex 
pseudo-sequencing  process.  The  small  bead  size  allows  for  greater  number  of  spots  per 
microarray slide and as many as 12 simultaneous sample analyses on a single platform are 
possible.
An additional microarray classification is made on the basis of the support dimensionality: 
there are 2D-microarray and 3D-microarray. In this  case each probe (specific for a single 
gene) is linked to the microchannel walls, process that allows to increase in a considerable 
way the  quantity  of  probes  used  (therefore  with  an  augmentation  of  sensitivity)  and the 
possibility to use the much more stable chemiluminescence (instead of the fluorescence).
Three techniques for microarray manufacturing exist.
In the first technique single strand cDNA molecules (length between 200 and 2000 bases) or 
pre-synthesized oligonucleotides (50-100 bases) in solution are deposited onto a solid support 
through the use of a robot. These are spotted microarray.
The second technique exploits the in-situ synthesis of 60-bases oligonucleotides through ink-
jet printing technology (Agilent): this is a very flexible method that allows the production of 
personalized array for two-dye experiments. A computer controls the printing process and the 
sequences  of  all  the  oligonucleotides  are  contained  in  a  file.  This  methodology  makes 
particularly  efficient  the  manufacturing  process  of  custom  microarray.  Another  positive 
feature is the uniformity of the spot shape and dimension.
In the third technology small oligonucleotides are directly synthesized on a silica support, 
through photolithographic techniques (Affymetrix) that make use of masks and light-reactive 
compounds with the selective activation of specific nucleotides in well-determined positions. 
The sequential use of different masks leads to the synthesis of all probes essential for the 
whole genome analysis.
The  high  cost  of  this  technology  does  not  justify  the  realization  of  custom  array.  The 
maximum oligonucleotide length allowed is 25 bases and the density reached on the spot is 
very high (over 700000 probes),  more than 10 times higher with respect to that obtained 
through other techniques.
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In  order  to  represent  each  gene,  a  combination  (called  probeset)  of  11-20  different 
oligonucleotides  are  used  in  the  PM  (Perfect  Match)  form  and  likewise  in  the  MM 
(MisMatch) form, each of them interrogating a different part of the sequence of a specific 
gene.
In particular, the PM oligos are perfectly complementary to the transcribed mRNA, while the 
MM oligo are exactly like the equivalent PM except that the central-position nucleotide (the 
thirteenth) is substituted by its complementary (A↔T, C↔G) base.
The MM oligos are used to highlight the non-specific hybridization of the corresponding PM, 
which is useful to quantify weakly-expressed mRNA.
A further classification of microarray platform is based on whether one-dye or two 
dyes are used. The RNA extracted from the sample is labeled with a fluorescent molecule and 
then it incubated with the support. Different fluorescent substances can be used to hybridize 
simultaneously with two samples on the same platform. In this case the competitive binding 
between the two targets and the probes in the array is exploited. The experiment goes on with 
the scanning step and the recording of emitted signals using lights with different wave-length 
to excite the two fluorophores (red and green fluorescence: excitation at 550 nm and 640 nm, 
emission at 581 nm and 670 nm, respectively). The ratio of the signals reveals the relative 
abundance of the different mRNAs between the two samples.
In the alternative scheme (the case of the genechip Affymetrix), only a single sample is used, 
it  commonly  emits  yellow  fluorescence.  The  final  result  of  this  procedure  generates 
monochromatic 16 bits images,  the pixel intensities can range in value from 0 (black) to 
65535 (white) shades of gray.
IMAGE ANALYSIS: gridding, segmentation, intensity extraction
Gridding
The array is physically scanned to produce a digital record. After the hybridization of 
fluorescently labeled cDNA molecules to the platform, the array is stimulated with a laser and 
the emitted fluorescence is measured. Several scanner settings can be varied to improve the 
sensitivity of the resulting image, with the brightest  pixels settled just  below the level of 
saturation in order to increase the power of the analysis in the case of less bright pixels. The 
first step of the analysis is the gridding that is usually a semi- or fully automated process. It 
consists in overlaying a rectangular grid onto the pixels in a manner that isolates each spot 
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within a platform, identifying spots through coordinates.
In the Affymetrix platforms, control probes located at the corners of the probe array are used 
to align a grid to delineate the probe cells.
Segmentation
The  second  step  is  the  segmentation:  every  single  pixel  has  to  be  classified  as 
foreground or background. The signal observed is a combination of the foreground and the 
background, the specific hybridization of interest and the non-specific one, respectively.
The  background  is  due  to  non-specific  bindings,  to  contamination  and  to  the  intrinsic 
fluorescence emitted from other chemicals on the glass. The classical approach performs the 
simple  subtraction  of  the  background  value  from  the  mean  or  from  the  median  of  the 
foreground intensity. A global background can be considered (global background correction), 
by subtracting the same value from all the spots in the platform. The background level is 
calculated by considering a set of negative control spots or, alternatively, the third percentile 
of the intensities can be taken as global background.
Another possibility is to consider a local background. Depending on the tool used to analyze 
the image, the areas around each spot taken as a reference for the background assessment are 
different.
In the case of high-density array, it is possible to consider wider areas (subgrids) to do this.
For the foreground evaluation, there are spatial and distributional methods. 
Fixed or adaptive segmentation: the first category tries to establish the spot shape, by defining 
a  fixed circle  with a constant  diameter,  not optimal  in the most cases,  or a circle  with a 
variable diameter or another shape that considers the real appearance of each spot.
In this case, we have a Fixed circle segmentation, Adaptive circle segmentation and Adaptive 
shape segmentation, respectively.
The second method called histogram segmentation summarizes  instead the signal  coming 
from all  pixels,  not  necessarily  connected,  that  are  over  a  treshold,  commonly  included 
between  the  5th and  the  20th percentile  of  the  signal  intensities.  After  foreground  pixels 
identification, the intensity value for the spot is usually estimated as the average of all these 
measurements.
Intensity extraction
The extraction of reliable intensities from foreground and background pixels involves 
6
2. INTRODUCTION
methods to control the effects of all the possible sources of variation during the experimental 
procedures. It includes several substeps.
– Filtering
The aim of this procedure is to reduce the data variability and dimension by removing all the 
genes whose measurements are not enough accurate and by deleting genes weakly-expressed 
or with an almost constant expression (low variance of log ratio across samples).
– Summarization
This  is  the  final  stage  in  preprocessing  Affymetrix  GeneChip  data.  It  is  the  process  of 
combining the multiple probe intensities for each probeset to produce a unique expression 
value, by combining them in some manner.
– Normalization
The normalization  process  has  the  aim the  removing of  all  the  variability  sources  (bias) 
without biological origin. These contributions can be classified in this way:
i) Dye-effect: it depends on the different level of incorporation of the fluorophores used in 
two-dye  experiments.  The  Cy5  molecule  is  more  bulky  and  labile:  the  red  emission  is 
systematically less intense that the green one.
ii) Print-tip effect: it is due to the difference in term of genetic material spotted on the glass 
because of the microscopic differences in the tip conformations (used by the robot to print the 
platform).
iii) Array-effect: it can derive from the differences in the global intensities between the arrays 
that  are  linked  to  the  different  conditions  of  preparation,  extraction,  hybridization  of  the 
sample and to the scanning step.
Normalization can be carried out within each array or between arrays. The common approach 
to normalize the data is the global one. Averages of the overall expression for all genes within 
an  array  are  set  to  be  the  same  across  different  arrays.  The  amount  of  transcription  is 
essentially similar across samples and over-expressed genes and under-expressed ones are 
roughly balanced.
Normalization procedures can be divided as follow:
– Total intensity normalization: this kind of procedure assumes the same mRNA quantity for 
both samples.  A Constant K is  searched so that the two samples have the same mean or 
median.
– Normalization based on regression methods: it starts from the assumption that most of the 
genes are expressed at the same level. There are several regression techniques: 
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linear regression (the coefficient of the regression line has an angular coefficient equal to 1) 
or local linear regression (LOWESS - “LOcally WEighted Scatter plot Smoothing”). In this 
case,  instead  of  having  a  single  correction  factor,  a  function  that  compensates  for  bias 
intensity dependent is used (Cleveland, 1979).
Other methods that consider only a small part of all genes exist.
We can choose the normalization procedure that uses housekeeping genes: these are genes 
that are expressed at the same level ubiquitously. They are involved in the maintenance of the 
steady-state and in the survival. Often, however, it is difficult to define which genes actually 
belong to this category. Affymetrix has inserted in its platforms a set of genes that have very 
low variability among a big set of experiments with samples coming from different tissues 
and that can be considered as real housekeeping genes.
Over the years, several algorithms have been developed to normalize the microarray data.
Currently over 50 methods are described and compared at http:// affycomp.biostat.jhsph.edu/. 
The most popular ones for affymetrix arrays are RMA e MAS5.
With Microarray Analysis Suite (MAS) 5.0, proposed by Affymetrix (Statistical Algorithms 
Description Document (2002 Affymetrix Inc.),  the chip is divided in 16 zones, for each of 
them the 2% of the lower intensities are used to calculate the local background. This value is 
subtracted from all the intensities in the region, taking into account the distance of the spot 
from the centroid of the grid. In this way, the algorithm corrects both PM and MM values, 
before using both for the assessment of the final result.
Because approximately 30% of the MM intensities are higher than the respective PM, in this 
cases an ideal mismatch is used.
MAS5  normalizes  each  array  independently  and  sequentially,  after  the  summarization 
process. The results are not log transformed.
Robust Multi-array Average (RMA) proposed by Irizarray in 2003 (Irizarry,  2003) uses a 
multi-chip model. It imposes the same empirical distribution of intensities in each array. RMA 
does not use the mismatch probes, because their intensities are often higher than the match 
probes, making them unreliable as indicators of non-specific binding. RMA values are in log2 
units,  so  they  are  not  directly  comparable  with  MAS5  normalized  data.  Nevertheless, 
normalized data are log-transformed at the end. The advantage of using this transformation is 
that the resulting data reflect the up-regulation and down-regulation values in a symmetrical 
scale. Without log conversion, ratios of down-regulated genes have their values between 1 
and 0, while up-regulated ratios can have large values.
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GRAPHICAL PRESENTATION OF THE DATA
Graphic displays can help assess the success of the experiment, guide the choice of 
analysis tools, and highlight specific problems. The first and most obvious diagnostic graphic 
is the well-known image in which the scanned microarray output images of the Cy3 and Cy5 
channels  are  false-colored  green and red,  respectively,  with  yellow representing an equal 
balance  of  the  two.  Co-registration  and  overlay  of  the  two  channels  offers  a  quick 
visualization  of  the  experiment,  revealing  information  on  color  balance,  uniformity  of 
hybridization, spot uniformity, background, and artifacts such as dust or scratches.
Boxplots:  comparison of  intensity  distribution among the  arrays  of  a  dataset.  The box is 
delimited by the 3rd and the 1st quartile values. The line in the middle of the box is the 
median value. The horizontal lines connected to the box via the dash line represent the higher 
and the lower values, without considering the outliers.  Median is more robust to outliers than 
the mean.
An  alternative  way  of  representing  the  data  is  provided  by  histograms,  which  give 
information on the distribution of intensity values.
Figure 1 Boxplots and smoothed histograms of unprocessed log scale probe intensities for 6 arrays from the 
same data set.  
QUALITY ASSESSMENT OF AFFYMETRIX GENECHIP
There are several useful tools implemented to assess the quality of microarray data. A 
typical first step is to look at pseudo-images created starting from the raw probe-level data: in  
this way it is possible to identify artifacts on the array. RNA Degradation Plot gives a good 
indication of the quality of the sample that has been hybridized to the array. Because this kind 
of degradation starts at the 5’ end of the molecule and progresses to the 3’ end it can be easily 
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measured using oligonucleotide arrays, where each PM probe is numbered sequentially from 
the 5’ end of the targeted mRNA transcript. When RNA degradation is advanced, PM probe 
intensity at the 3’ end of a probeset should be higher when compared with the 5’ end one. In 
the graph, the lines have to be shifted from the original data for a clearer view, but, if there 
are no problems, the slopes remain unchanged because it is platform specific.
Figure 2 Each plot represents an microarray experiment realized on a specific platform. Plotted on the Y axis is  
mean intensity by probeset position. Intensities have been shifted from original data for a clearer view, 
but slope is unchanged.
Another quality assessment method uses the probe level model (Bolstad, 2004). According to 
this  model,  the  intensity  value  of  each  probe  depends  on  the  actual  expression  of  the 
corresponding gene in the array, the sequence of the probe and the error of measurement. This 
model uses the robust linear regression that is able to highlight whether the errors in the 
measurements are not uniformly distributed or whether several outliers are present. Based on 
this model, several quality assessment tools were constructed. Different pseudo-images can 
be created pointing out subtle artifacts that might otherwise be missed completely. 
             A           B        C
Figure 3  Chip pseudo-images based on PLM fit  make visible subtle artifacts.  Images of  A) the raw probe 
intensities (log transformed) B) weights and C) residuals.
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Two  different  plots  are  constructed  based  on  the  probe  level  model.  The  Relative  Log 
Expression (RLE) plot shows for each array and for each gene across all arrays, the deviation 
of gene expression level from the median gene expression level. The majority of genes does 
not change the mRNA quantities. Hence, the boxplot with the difference calculated between 
the estimated expression value derived from the regression and the median across arrays 
should be centered around zero with a small spread. An array with quality problems may 
show significantly different values compared to the majority of arrays, resulting in a RLE box 
with greater spread or a median that deviates from 0.
The Normalized Unscaled Standard Error (NUSE) plot portrays the chip-wise distribution of 
standard error estimates, obtained for each gene on each array. To account for the fact that 
variability differs considerably between each gene, the error estimates are standardized so that 
the median standard error across arrays is 1 for each gene.
Figure 4 RLE plot and NUSE plot for the same data set. The array with the spatial effect deviates considerably  
from the other arrays. 
DIFFERENTIALLY EXPRESSED GENES
The most common and basic question in DNA microarray experiments is  whether 
genes  appear  to  be  down-regulated  (the  expression  has  decreased)  or  up-regulated  (the 
expression has increased) between two or more groups of samples.
Assessing  the  differential  expression  of  genes  allows  a  deeper  understanding  about  the 
difference between two groups of samples when the biological functions of those genes are 
well-known. Additionally the results can suggest possible functions for genes.
A gene is considered differentially expressed if its expression value between the compared 
conditions are significantly different. The relative gene expression value also known as "fold 
11 
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change" (FC) is expressed as the logarithm of the ratio between the intensity value of the gene 
in an experimental condition and that in the reference condition. A threshold has to be fixed in 
order to distinguish up-regulated or down-regulated genes.
It is important to keep in mind that the absolute difference of expression simply quantifies the 
degree of intensity variation between the two groups, whereas it is essential to understand if 
the  observed  difference  is  significant.  One  of  the  most  used  methods  to  determine  the 
significance of differentially expressed genes between two experimental conditions is the t-
test.  It  compares  the  averages  of  the  two  groups  of  values  (normalized  by  the  standard 
deviation) in order to assess if their difference is significant, or whether it is only due to 
chance.
The bigger is the value of the t-statistics, the more significant is the difference between the 
expression in the two experimental conditions. t assumes high values when the averages are 
very  different  or  when  the  variances  of  the  two  groups  are  low,  indicating  a  very  low 
dispersion  (spread)  of  the  data.  The  latter  conditions  may  be  due  to  chance  in  case  of 
insufficient sampling.
The t-test is useful when the experimental conditions to be compared are only two. When the 
goal of a study is to compare several experimental conditions it is necessary to perform an 
analysis of variance (ANOVA) among the samples (Pavlidis, 2003). Anova is one of the most 
used methods to identify differentially expressed genes in complex experimental designs.
A multiple-testing correction such as FDR (false discovery rate) can be performed at the end 
to control the expected proportion of false positives among the declared significant results.
CLUSTERING
The values of gene expression can be used to classify conditions or gene expression 
profiles. The clustering procedure is complex. There are many different techniques to deal 
with it and also in only a few cases a unique solution is found. Nevertheless, any reasonable 
solution can help to simplify data analysis.  Depending on the way in which the data  are 
clustered  we  can  distinguish  between  hierarchical  and  non-hierarchical  clustering  and 
supervised and unsupervised clustering (Eisen,  1998;  Chipman,  2003; Gollub,  2006).  The 
hierarchical techniques allow to establish an ordered relation among clusters, while, the non-
hierarchical  procedures,  or  at  least  most  of  these,  allocate  the  expression  profiles  into  a 
predefined number of clusters, without providing information on mutual ordering relations 
among them.
12
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An unsupervised clustering is performed when no previous information about the samples is 
used to classify them and therefore the clustering is a consequence of data alone.
In the case of supervised clustering, instead, previous knowledge about the data is used to 
create different groups in order to make a class comparison with the extraction of a list of 
differentially expressed genes. The usage in grouping genes is based on the premise that co-
expression  is  a  result  of  co-regulation  (Do,  2008). Genes  with  an  identical  profile  of 
expression  may  represent  a  co-ordinate  response  to  a  stimulus.  In  order  to  quantify  this 
relationship, and therefore compare the expression profile of two different genes, we need to 
use an appropriate metric. This metric can be changed in relation to the features, which are 
more important to be analyzed. Among the several metrics that can be defined in the context 
of gene expression profile analysis, the two most widely used are the Euclidean distance and 
Pearson correlation coefficient. The first metric is used to select genes whit similar magnitude 
of expression; the second is generally employed   to search for genes expressed at different 
level but with the same overall profile (Dopazo, 2001).
Having  defined  a  metric,  one  of  the  most  used  hierarchical  clustering  algorithm  for 
microarray  is  UPGMA (Unweighted  Pair  Group  Method  with  Arithmetic  mean).  In  this 
method at each step two gene expression profiles and/or groups of gene expression profiles, 
which average distance is the shortest are clustered together, until no gene expression profile 
is  left.  UPGMA indeed is  just  a  particular  case of the so-called Linkage method.  In this 
method the scheme is similar to that described for UPGMA with the difference that instead of 
choosing the average distance as the distance between two clusters (Average Linkage) we can 
choose the minimum distance of each member of a cluster from each member of the other  
(Single Linkage) or the maximum distance among them (Complete Linkage). 
PCA
Clustering techniques can be used in combination with other exploratory methods that 
allow to visualize the complexity of the data in a two or three-dimensional space. PCA is able 
to select a small  number of variables that can explain the most variability of the data by 
removing the background noise from the dataset. At the end of this procedure, some principal 
components  are  identified:  weighted  combinations  of  the  original  variables  that  have 
maximum variance and that are uncorrelated with one another (Alter, 2000; Raychaudhuri, 
2000; Wall, 2001).
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PUBLIC DATABASES OF GENE EXPRESSION PROFILES
Given the huge amount of data produced and the enormous utility derived from the 
opportunity to compare data coming from different experiments, several public repositories 
have  been  created  to  store  and  retrieve  datasets  of  gene  expression  profile  experiments. 
Moreover,  to  make  the  different  data  comparable,  in  2001,  a  standard  called  MIAME 
(Minimal  Information  About  a  Microarray  Experiment)  has  been  developed  in  order  to 
correctly  and  homogenously  depositing  microarray  data  (Brazma,  2001).  The  required 
information allow the right interpretation of the results and the possibility of reproducing the 
experiments.
The main public databases are Arrayexpress at the EBI – European Bioinformatics Institute 
(http://www.ebi.ac.uk/arrayexpress/)  and  GEO  at  the  NCBI  –  National  Center  of 
Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo/). In addition to these databases 
that  contain  data  with different  origin,  there  are  others  that  store data  related to  specific 
sectors,  such as caArray at  the NCI – National  Cancer Institute  and Stanford Microarray 
Database.
BIOLOGICAL INTERPRETATION OF THE RESULTS
Gene Set Enrichment Analysis (GSEA) is  a computational method for interpreting 
gene  expression  data  that  determines  whether  an  a  priori  defined  set  of  genes  shows 
statistically significance, concordant differences between two biological states (Subramanian, 
2005).  All  analysis  can  be  performed  using  the  GSEA  software  available  at 
http://www.broadinstitute.org/gsea/index.jsp
DAVID is  an  integrated  biological  knowledge-base  and  analytic  tool  (available  at 
http://david.abcc.ncifcrf.gov) that allows to extract biological meaning from large gene lists 
derived from high-throughput genomic experiments (Sherman, 2007). It uses more than 40 
publicly available functional annotation sources and a novel agglomeration algorithm in order 
to  define for  each gene  some identifiers.  This  analysis  permits  to  associate  not  simply a 
biological enriched themes but also a set of gene clusters, a gene functional groups involved 
in well-defined functional pathways.
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2.2 CASPASES
Caspases (cysteinyl  aspartate proteinases) are a family of aspartate-specific cysteine 
proteases whose catalytic activity depends on the presence of a cysteine residue inside the 
highly  conserved  active  site  (pentamer  QACRG).  Caspases  act  on  their  substrate  in  a 
selective way: they recognize at least 4 contiguous amino acids in their substrate and they 
cleave the peptide bond after  the 1st residue,  which is  usually  an aspartic  acid (Alnemri, 
1996).  Cys side chain is  used as a  nucleophile  to  accomplish peptide bond hydrolysis  in 
several protease families. 
Caspases are involved in the launch and in the execution of the apoptotic process, one of the 
most well-studied forms of programmed cell death. This process is genetically controlled and 
evolutionary  conserved  because  of  its  fundamental  role  for  the  embryogenesis  and  the 
maintaining of the tissue homeostasis in the adult organism. Moreover, caspases are involved 
in  different  processes  such  as  inflammatory  responses,  proliferation  and  differentiation 
(Launay, 2005; Lamkanfi, 2007). They were discovered initially in Caenorhabditis elegans, 
the  organism  where  for  the  first  time  the  apoptotic  phenomenon  was  observed  and 
characterized during the normal development. Until now, 11 genes, coding for 11 different 
caspases, are known in humans (Li, 2008). They are widely expressed with the exception of 
caspase-14 that is limited to keratinocytes (Denecker, 2008). 
Caspases are synthesized like zymogens constituted by a small and a larger subunit  and their  
activation necessitates the proteolytic  removal of N-terminal  prodomain.  Caspases can be 
classified in two different ways: or in relation to the main function, as pro-apoptotic and pro-
inflammation enzymes or on the bases of the prodomain dimension, as initiatior and effector 
caspases.  Initiator  caspases  contain  a  long  prodomain  that  mediates  both  homotypic 
interaction forming dimers or oligomers or heterotypic interaction with additional proteins 
that  can  exhibit  both  repressive  and  activation  functions.  In  the  initiator  caspases  the 
prodomains  are  structurally  defined  domains  characterized  by  6  alpha-helices.  Two 
principally sub-types of pro-domain exist:  the CARD (CAspase Recruitment Domain) and 
the DED (Death Effector Domain) both involved in interacting with the upstream adaptor 
molecules (Figure 5). 
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Figure 5 Domain organization of caspases.
Effector caspases present a short prodomain. They perform the downstream execution steps 
of apoptosis by cleaving multiple cellular substrates and are typically processed and activated 
by upstream caspases (Jin, 2005). Over 400 different substrates are known, information about 
these can be found in a public databases (Lüthi, 2007). 
Caspases are not all equally active from the proteolytic point of view. The initiators seem to 
be  more  specific  respect  to  the  effectors,  they  are  not  able  to  cleave  many substrates  in 
addition to the precursors and the downstream caspases. Differently, effector caspases and 
caspase-3 in particular are responsible for most of the proteolytic processes occurring during 
apoptosis (Thornberry, 1998; Slee, 1999; Barnhart, 2003). 
CASPASE-2
Caspase-2, initially described as Nedd-2/Ich-1 has been identified as a protein related 
to the C. elegans cell death protein CED-3 and mammalian interleukin-1β-converting enzyme 
(caspase-1). Despite the high degree of conservation, the contribution of caspase-2 to cell 
death is still mysterious and the mechanism controlling its regulation and function is much 
less understood when compared to other regulative caspases (Vakifahmetoglu-Norberg, 2010; 
Krumschnabel, 2009).
Caspase-2 was initially identified as a neuronal expressed gene that is down-regulated during 
brain  development.  Its  mRNA level  is  much  higher  in  developing  CNS  than  in  fully 
differentiated adult brain (Kumar, 1992). It presents a CARD domain followed by the large 
(p19)  and  the  small  subunits  (p12),  separated  by  a  linker  region.  The  two  subunits  are 
generated after proteolytic processing at Asp residues. The proenzyme can undergo to auto-
processing and both subunits contribute to the formation of the catalytic site.
Two distinct caspase-2 mRNA species derived from alternative splicing encode two proteins, 
caspase-2L  and  caspase-2S.  Overexpression  of  caspase-2L  induces  cell  death,  whereas 
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overexpression of caspase-2S can antagonize cell death. Caspase-2L is the dominant isoform 
that is expressed in most tissues (Wang, 1994).  
CASP2 shows sequence homology with CASP9 and CASP1, but a specificity of cleavage 
similar  to  CASP3  and  CASP7.  Importantly  its  preference  goes  toward  a  pentapeptide 
(VDVAD/G) instead of the classical tetrapeptide (DEVD/G). In summary this protein shares 
features both with initiator and effector caspases.
Caspase-2 presents two signals for nuclear localization in the prodomain region. Mutation of 
a specific lysine residue within these NLS is sufficient to prevent the nuclear accumulation 
and to induce its accumulation into the cytoplasm (Paroni, 2002). There are evidences that in 
untreated cells, the only caspase present in the nucleus is CASP2, while after the activation of 
the  apoptotic  program  both  CASP2  and  CASP3  can  be  found  in  the  nuclear  fraction 
(Zhivotovsky, 1999). CASP2 has been also localized in the mitocondria, in the endoplasmic 
reticulum and in Golgi-like structures, although the relative data are controversial.
CASP2 activation is primed by its dimerization. Subsequently, removal of the CARD domain 
and cleavages at the linker region between the large and the small subunits can be observed, 
to generate the tetrameric form. Caspase-2 is activated by proximity-induced oligomerization 
and trans-cleavage in vitro, and ectopic overexpression is sufficient for its activation in cells. 
In fact at high concentrations, self-association and subsequent oligomerization through the 
CARD domain occurs (Baliga, 2004). 
Through its card domain, CASP2 interacts with several proteins. In response to DNA damage, 
the  PIDDosome  has  been  proposed  to  control  CASP2  activation.  The  PIDDosome  is  a 
multiproteins  complex  containing  the  PIDD,  encoded  by  a  TP53–induced  gene  and 
CRADD/RAIDD (Tinel,  2004;  Park,  2007).  The  latter  contains  one  CARD and one  DD 
domain, which respectively associate with the CARD domain of CASP2 and the DD domain 
of PIDD, respectively. PIDD may act as a switch molecule controlling the balance between 
cell  survival  and cell  death in response to DNA damage.  By increasing its  expression or 
inhibiting  its  activity,  it  is  possible  to  promote  or  to  attenuate  p53-mediated  apoptosis, 
respectively (Lin, 2000; Tinel, 2004; Baptiste-Okoh, 2008).
Both  apoptosis  and  CASP2  processing  have  been  studied  in  PIDD-deficient  mice. 
PIDDosome is not essential for DNA damage-induced cell death, but it is able to modulate 
CASP2 activity in processes leading to cell survival rather than cell death. Moreover, in cell  
types where CASP2 localization is mainly nuclear the PIDDosome is needed for its activation 
(Vakifahmetoglu, 2008; Shi, 2009). In other cells where the protein remains in the cytosol the 
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activation is independent from this complex (Vakifahmetoglu, 2006; Olsson, 2009; Manzl, 
2009).  These  results  suggest  that  there  are  other  protein  complexes  involved  in  CASP2 
activation (Manzl, 2012) (several evidences published) or in some cases, it is possible that 
this  process is due to an autoproteolytic cleavage without the requirement of any adaptor 
protein for their oligomerization (Baliga, 2003). Furthermore in PIDD-null cells, CASP2 can 
be cleaved by CASP3 or CASP7 (Manzl, 2009), while in CASP9 deficient cells apoptotic 
stimuli abolish proteolytic processing of CASP2 (Paroni, 2001; Samraj, 2007).
In summary it remains unclear whether CASP2 really requires an activation platform or it 
may dimerize,  auto-process and autoactivate in the absence of such a platform. It  is also 
possible that different mechanisms of activation may be involved in response to different 
cellular stresses.
Different mechanisms act to regulate CASP2 activity. The first is the production of PIDD-
fragment  whit  different  dimensions,  where  the  shorter  is  produced  when  cells  undergo 
apoptosis, while the longer when repair mechanisms are needed after DNA damage (Janssens, 
2005; Tinel, 2007).
Differential expression levels have been found for the two splicing variants 2L e 2S: the latter  
has a protective role against cell death probably through the formation of inactive caspase-
2L/S heterodimers at the expense of pro-apoptotic, active caspase-2L homo-dimers (Droin, 
2001). 
CASP2 can be inactivated through phosphorylation of several residues and it can undergo N-
terminal acetylation or SUMOylation (important for its subcellular localization) (Shirakura, 
2005).
Function: Casp2-deficient mice don't help to evaluate the requirement for this enzyme in the 
apoptosis  or  in  other  physiological  process.  Mice  carrying  a  null  mutation  for  caspase-2 
develop normally without severe phenotypic abnormalities (Bergeron, 1998). It is likely that 
other  caspases  compensate  for  its  deficiency.  Hence,  this  study  did  not  contributed 
significantly to clarify the biological function of this protease.
Several  studies  have  proposed  several  interaction  partners  for  CASP2,  suggesting  the 
involvement of this protease in different signaling pathway. Here, a brief summary of the 
CASP2 possible functions as hypothesized in the literature (see Krumschnabel, 2009; Fava, 
2012 and references cited therein). 
Caspase-2 was proposed to be involved in DNA damage response (Zhivotovsky, 2005) but 
the exact role is debated and controversial. Some results suggest its engagement as initiator, 
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before the release of the cytochrome c and the apoptosome formation (Guo, 2002), others 
contradict  this  idea  by  indicating  a  role  as  downstream caspase  in  genotoxic  cell  death 
(Paroni, 2001; Paroni, 2002; O'Reilly, 2002; He, 2004; Bonzon, 2006).
Caspase-2 activation after DNA damage seems to be under the control of ataxia telangiectasia 
mutated (ATM) kinase, that is able to induce its activation through the phosphorylation of 
PIDD that leads to the PIDDosome formation (Ando, 2012). CASP2 is involved also in ER 
stress: under this condition IRE1α promotes a rapid degradation of microRNAs that target its 
mRNA, causing a fast protein synthesis, contributing to the induction of apoptosis (Upton, 
2012).
Several  non-apoptotic  functions  have  been  proposed  to  be  influenced  by  caspases.  An 
increase of CASP2 activity during the cell cycle leads to a delay in the G2 phase progression 
into  M  phase  in  an  ATM-dependent  manner  (Shi,  2009).  Caspase-2  is  a  sensor  of  the 
metabolic state of the cell: the phosphorylation of Ser135 by CaMKII kinase and the opposite 
process catalyzed by PP1 are both under the metabolic control (Nutt, 2005).  Treatment of 
Xenopus  oocytes  with  glucose-6-P  activates  the  kinase  that  inhibits  CASP2.  When 
phosphorylated CASP2 is bound by 14-3-3ζ proteins and in this way maintained in an active 
state. Nutrient depletion promotes CASP2 dephosphorylation thanks to the action of PP1 and 
the release from the 14-3-3 (Nutt, 2009). Glucose-6-P acts on the interaction ability of 14-3-
3ζ proteins, controlling in a still undefined manner its acetylation state (Andersen, 2011).
CASP2 is involved in aging: loss of CASP2 induces a premature aging due to an increase of 
oxidative stress (Shalini, 2012). It is also considered a tumor suppressor (reviewed in Puccini, 
2013a and Olsson, 2014) since its absence provides some advantages in terms of oncogene-
induced transformation  (Ho, 2009; Parsons, 2013; Puccini, 2013b) even though in a tissue 
and context-specific manner (Dorstyn, 2014).
Sequence  analysis  of  a  5-kb  region  upstream of  the  first  non-coding  exon  of  caspase-2 
revealed the presence of 6 different putative binding site for the sterol regulatory element 
binding  proteins  SREBPs  (Logette,  2005).  Experiments  of  progressive  deletions  and 
mutations in these putative sites coupled with a ChIP assay, confirmed the binding of these 
TFs to the promoter region of CASP2. Using lipid-lowering drugs, such as the statins, which 
are able to trigger cholesterol depletion and a compensatory feedback mechanism that induces 
SREBP maturation,  the transcription of their  target  genes  as  well  as the level  of CASP2 
mRNA increase. Overexpression of the SREBPs result in a large increase of lipid levels; the 
simultaneous silencing of CASP2 reduces this augmentation by 50%.
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CASPASES in the Central Nervous System (CNS)
Several studies have confirmed the engagement of caspases in the apoptotic processes that 
occur in CNS (Hyman, 2012). They are involved in the normal neuronal development and in 
programmed cell death events that accompanies normal cerebral processes or the appearance 
of acute and chronic neurodegenerative diseases. The global and full activation of caspases 
leads to  apoptosis,  whereas maintaining limited and localized activations  it  is  possible  to 
control normal physiology in living neurons (Hyman, 2012). 
Apoptosis  strongly  characterized  brain  homeostasis.  Approximately  30–70%  of  newly 
generated neurons in the adult brain undergo programmed cell death within 1 month of their 
initial  production.  Neurons  undergo  apoptosis  also  in  case  of  trophic  factor  deprivation. 
Several caspases are involved in this process, both in developing and mature brain (Haviv, 
1997; Deshmukh, 1997; Li, 1998). 
Caspases have also non-apoptotic roles in CNS. They are able to regulate important neuronal 
functions,  such as axon pruning and synapse elimination,  processes that  are  the bases  of 
neuronal plasticity, essential to refine mature neuronal circuits (Williams, 2006; Li, 2012). 
Caspases are involved in normal synaptic physiology. The long-term depression (LTD), in 
which synapses become less sensitive to stimuli with a significant change in the dendrites'  
size at the spine level, can be blocked after inhibition of either caspase-3 and caspase-9 (Li, 
2010).
Not surprisingly in chronic neurological diseases, like Alzheimer's disease and other forms of 
dementia caspases can play a role. They are activated after an acute neurological injury such 
as ischaemia in a region-specific and in a time-dependent manner. Generally at early times, in 
the necrotic core, caspase-8 and caspase-1 activation can be observed whereas at later point,  
in the surrounding region the involvement of caspase-9 was reported (Benchoua, 2001).
With regard to caspase-2, it is expressed at high level during brain development but it has also 
a strong involvement in the apoptotic processes of the adult CNS. Caspase-2 has been shown 
to be required for neuronal death induced by several stimuli, including NGF (nerve growth 
factor) deprivation and Aβ (β-amyloid) (Troy, 2000).
Both  NGF deprivation and Aβ treatment  of  neurons induce caspase-2 activation  and this 
activation depends on RAIDD expression, but is independent from PIDD expression (Ribe, 
2012).
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2.3 CHRONIC LYMPHOCYTIC LEUKEMIA
In the second part of my PhD thesis I used the microarray technology to define the 
genetic elements of responsible for the responsiveness of B-cell chronic lymphoid leukemia 
(B-CLL) to a new inhibitor of the ubiquitin proteasome system (Aleo, 2006; Fontanini, 2009; 
Foti, 2009).
Leukemias  are  malignant  diseases  characterized  by  a  tumor  proliferation  of  lymphoid  or 
myeloid tissues, with the development of lymphoproliferative or myeloproliferative disorders, 
respectively. In both cases, the tissues present a decrease in differentiation and alterations in 
the mechanisms controlling programmed cell  death.  It  can occur in an acute form, if  the 
proliferation of tumor tissues affects cells unable to differentiate, or in a chronic form, when 
proliferation concerns cells able to differentiate, although not completely.
The  chronic  lymphoid  leukemia  (CLL)  is  a  chronic  lymphoproliferative  disorder 
characterized  by  the  proliferation  and  subsequent  accumulation  of  mature  lymphocytes 
inactive from the immunological point of view and not able to divide (Bertilaccio,  2010; 
Klein, 2010; Zenz, 2010) . 
Accumulation of these lymphocytes affects the primary lymphoid organs (bone marrow) and 
secondary (lymph nodes and spleen). Compared to the other type of leukemia, CLL usually 
grows slowly and many patients may not have any symptom for years. It is generally harder  
to cure than acute leukemias. In some cases, the patient has several infections in the period 
before the diagnosis (Dameshek, 1967; Twomey, 1973).
There are two different subtypes of CLL. A subtype grows very slowly and for this reason it  
may take a long time before the patient needs treatment. On the opposite the second subtype 
grows faster and is a more serious disease (Rosenwald, 2001).
CLL is the most common form of leukemia in Western countries. It is a disease typical of the 
adult life with a median age at diagnosis of about 65 years, twice as common in males. 95% 
of  CLL cases  is  derived  from  B  cells,  and  only  the  remaining  5%  by  T  lymphocytes 
(Seligmann, 1973).
The most widely used staging systems for CLL are two: the Rai staging system (Rai, 1975) 
and the Binet classification (Binet, 1981).
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Table 1 Rai and Binet staging systems for classification of CLL.
These two staging systems, although they are the most widely used in clinical practice and 
they are able to predict the clinical course of the disease in terms of survival from diagnosis,  
have limitations and not consider a number of biological parameters introduced recently that 
have now a fundamental role in the prognostic stratification of the disease and sometimes in 
the diversification of the therapeutic treatment (Döhner, 2000; Montillo, 2005; Hallek, 2008; 
Zenz; 2011).
The most important prognostic factors in CLL, in addition to the clinical stage, are markers of 
tumour load (the lymphocyte count, the lymphocyte doubling time, the serum LDH level or 
the bone marrow (BM) infiltration pattern), cellular protein expression (ZAP70 and CD38) 
and  genetic  parameters  including  immunoglobulin  heavy  chain  variable  gene  segment 
(IGHV) mutational status, genomic aberrations and individual gene mutations (Kröber, 2002).
B-cell response to antigen is mediated through the B cell receptor (BCR) in normal 
and malignant B cells.  CLL patients  can be classified based on the assessment of B cell  
receptor mutational status (Hamblin, 1999; Hamblin, 2002).
While CLL with unmutated IGHV follows an unfavorable course with rapid progression and 
earlier death, CLL with mutated IGHV often shows slow progression and long survival.
Approximately  80%  of  CLL  cases  exhibit  aberrations  in  a  few  recurrently  affected 
chromosomal regions (Stilgenbauer, 2000). The aberrations linked to short survival have a 
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higher incidence in the case of IGHV unmutated status, even if both mutated and unmutated 
present genomic alterations (Stilgenbauer, 2002).
Principal genetic alterations in CLL
Deletion 13q14 occurs in more than half of the cases, it  correlates with the best survival  
expectancy. In contrast to other recurrent aberrations, 13q14 deletions may be hetero- or (less 
commonly)  homozygous.  Studies  of  serial  samples  suggest  that  heterozygous  deletion  of 
13q14 is an early event, whereas deletion of the second copy of this region occurs at a later  
stage (Shanafelt, 2006; Stilgenbauer, 2007).
Deletions of 11q22-q23:  it affects patients (about 25%), which have a more rapid disease 
progression.  These deletions  often  lead  to  a  hemizygous  loss  of  the  ataxia  telangiectasia 
(ATM) gene in almost all cases. No homozygous 11q deletions have been described. The 
ATM is a protein kinase involved in the response to DNA damage and DNA double-strand 
breaks. ATM disruption in CLL may occur by mutation, deletion, or a combination of both 
events: mutations of the ATM gene have been shown to occur in 12% of patients with CLL 
and 30% of patients with 11q deletion (Austen, 2005; Austen, 2007).
Trisomy 12 is a frequent aberration in CLL (10–20%), resulting in an intermediate outcome.
The  molecular  genetic  defects  associated  with  these  risk  categories  are  unknown.  For 
trisomies in general,  it  is often assumed that there is a gene dosage effect of a candidate 
oncogene  on  the  additional  chromosome,  but  such  a  gene  has  yet  to  be  identified  on 
chromosome 12 (Winkler, 2005; Porpaczy, 2009).
Deletions 17p.  It is often associated with unmutated IgHV and it confers the highest risk 
(poor prognosis and refractory disease).
While  the  deletion  frequently  encompasses  most  of  short  arm  of  chromosome  17,  the 
minimally deleted region always involves 17p13, the locus of the TP53 gene.
Most  cases  (over  80%)  with  17p  deletion  show  loss  of  one  copy  and  mutation  of  the 
remaining copy. The sole TP53 mutation occurs in approximately 5% of patients (Zenz, 2008; 
Dicker, 2009; Rossi, 2009).
Patients affected by CLL are treated with chemotherapy drugs or with monoclonal antibodies 
against  surface  antigens  present  in  the  B-lymphocytes.  Taking  into  account  the  great 
heterogeneity, the prognosis is extremely variable, with a survival time between 2 and 20 
years  (Rodríguez-Vicente,  2013).  Unfortunately,  despite  by  combining  different  drug 
treatments it is possible to prolong the time free of disease, the CLL tends to relapse. The only 
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curative strategy is  the allogeneic transplantation,  used in very few cases (above all  with 
young patients), given the very high mortality rate (Dreger, 2007; Gribben, 2009).
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PIPELINE
Packages installation
R  is  a  free  software  environment  for  statistical  computing  and  graphics.  It  has  several 
advantages: an active user community, a constant update, an easy installation and high quality 
standards.
It  is possible to download R at  http://cran.r-project.org/. It  runs on all  common operating 
systems.
The Bioconductor project supply additional libraries to manage biological data  (Gentleman, 
2004).
To quickly install a set of the most common packages 
source("http://www.bioconductor.org/biocLite.R")
biocLite()
To install R libreries
install.packages("name_package_R”)
In the Affymetrix system, the raw image data are stored in so-called DAT files. Currently, 
Bioconductor  software  does  not  handle  the  image  data,  and  the  starting  point  for  most 
analyses are the CEL files. These are the result of processing the DAT files using Affymetrix 
software to produce estimated probe intensity values. Each CEL file contains data on the 
intensity at each probe on the GeneChip, as well as some other quantities. To import CEL file 
data into the Bioconductor system, we use the ReadAffy function contained in the library affy. 
So first it is necessary to load the library affy, and then we issue the command ReadAffy:
library(affy) 
Data <- ReadAffy()
which reads all the CEL files in the current working directory and return the probe-level data 
in an object of class AffyBatch. The function list.celfiles() can be used to show the CEL files 
that are located in the directory. 
Affymetrix  provides  probe  information  in  what  are  referred  to  as  CDF files.  These  files 
denote which probe belongs to which probeset and whether the probe is a PM or MM.
The affy package automatically load a CDF package, when the package does not exist on the 
users system, it tries to download and install it. 
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For custom arrays, makecdfenv library can be used to convert the CDF file into an R package 
that has to be installed using the R CMD INSTALL command (Dai, 2005; Ferrari, 2007).
In this case, in order to use custom CDF packages, within the AffyBatch object, the value of 
the slot cdfName has to be replaced with the custom CDF name.
Data<-ReadAffy(cdfname ="custom_CDF_name")
The pm and mm accessory functions return the PM and MM probe intensities.
The function probeNames returns a vector of probeset IDs where the ith entry corresponds to 
the ith row of the PM matrix.The functions sampleNames and geneNames access the names of 
the samples and Affymetrix probeset IDs stored in the AffyBatch object, respectively.
names_CEL<- sampleNames(Data)
names_gene<- geneNames(Data)
In order to modify and simplify sample names sub function can be used.
sampleNames(Data)<- sub("old_pattern" ,"new_pattern", 
sampleNames(Data))
Preprocessing 
Affymetrix  expression  arrays  usually  involves  three  steps:  background  adjustment, 
normalization, and summarization. 
eset <- rma(Data) 
eset <- mas5(Data)
The  expresso function provides quite general facilities for computing expression summary 
values. In particular it allows most background adjustment, normalization, and summarization 
methods to be combined. 
eset <- expresso()  
In order to record normalize data, a dataframe has to be created. The exprs function creates an 
expression matrix in which columns represent the arrays and rows the probesets.
values<- exprs(eset)
norm<-data.frame(probeid=row.names(values),values)
write.table(norm, "datix.txt",sep="\t")
Quality Assessment of Affymetrix GeneChip
Various graphical tools that can be used to facilitate the decision of whether to remove an 
array from further analysis  Exploratory data analysis has been the tool of choice for detection 
of  problematic  arrays.  The  image function can be used to  create  chip images  of  the raw 
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intensities. 
To record the image in a png file, the object has to be create before the image creation and 
than it has to be closed.
png(" ")
image(name_CELi)
dev.off()
To generate an unique image with all the arrays together, the par function can be use.
par (mfrow=c(n_row,n_column))
{for (q in 1:length(names_CEL)image(Data[,i])} 
Looking at  the distribution  of  probe intensities  across  all  arrays  at  once  can   sometimes 
demonstrate that one array is not like the others. The boxplot gives a simple summary of the 
distribution of probes. In the affy package the boxplot method is available for the AffyBatch 
class. 
Looking at histograms of the probe-level data can also reveal problems. The hist function 
creates smoothed histograms (or density estimators) of the intensities for each array. 
boxplot(Data)
hist(Data)
The RColorBrewer package is used to select a nice color palette.
install.packages("RcolorBrewer")
#Show all the colour schemes available
display.brewer.all()
scale<-colorRampPalette(brewer.pal(9,"Blues"))
(length(names_CEL))
scale<-
colorRampPalette(colors=c("color1","color2",...,"colori"))
(length(names_CEL))
To apply the color scale, input the name of your custom scale in the argument for col.
RNA degradation
3'/5' ratios for several control genes  can be used for quality assessment purposes.
We use the AffyRNAdeg function for this evaluation.
RNAdeg <- AffyRNAdeg(Data)
plotAffyRNAdeg(RNAdeg) 
A summary of the slopes can be viewed in the following way
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summaryAffyRNAdeg(RNAdeg)
Different chip types have different characteristic slopes because of the differences in probeset 
architecture.
Probe Level Model (PLM)
Numerous useful quality assessment tools can be derived from the output of the PLM fitting 
procedures.
Two different packages allow to do this evaluation.
library(oligo) 
celFiles = list.celfiles () 
raw = read.celfiles (celFiles)
plm<-fitProbeLevelModel(raw) 
show(plm)
library("affyPLM")
plm<-fitPLM(Data)
show(plm)
This library allows to obtain three different pseudo-images that highlight also subtle artifacts 
that could otherwise be missed.
image(plm,type = "weights")
image(plm,type = "resids")
image(plm,type = "sign.resids")
By using the PLM output, it is possible to use two other graphical tools.
In the RLE plot, boxes have small spread and they are centered near 0, problematic arrays 
deviate considerably from the others.
rle<-RLE(plm, las=2,cex.axis=0.6) 
The NUSE plot shows boxes centered near 1, in the case of arrays with no spatial effect.
nuse<-NUSE(plm, las=2,cex.axis=0.6) 
arrayQualityMetrics is  a  Bioconductor  package that  provides  an  exposition  of  diagnostic 
plots  for  one  or  two  colour  microarray  data  (Kauffmann,  2009). It  uses  powerful  and 
comprehensive tools and generates an automatic report, in an html format.
library(arrayQualityMetrics)
arrayQualityMetrics(expressionset = Data,outdir = "datiraw")
28
3. MATERIALS E METHODS
By inserting do.logtransform = TRUE as option, the data are log converted, before doing the 
assessment.
Filtering
The aim of the filtering step is to discard the probesets with very low expression across the 
samples (and that provide no biological information) in order to reduce noise in data and to 
avoid  wrong  interpretations  of  the  final  results.  In  differential  analysis  for  example,  the 
number of hypothesis to test is therefore reduced (which is very useful in the multiple testing 
context).
A useful library to do this is EMA (Easy Microarray data Analysis). The function used is 
expFilter.
filter<-expFilter(eset,threshold = 3.5,p=0.01,graph = TRUE) 
In this way, it keeps only probes with at least 1 sample with an expression level higher than 
3.5. 
With the functions  dim and summary it is possible to obtain information about the result of 
this step.
An alternative approach provides for the use of genefilter package.
f1<- kOverA(1, 3.5)
ffun<- filterfun(f1) 
filter<- genefilter(exprs(eset), ffun)
The result is the same.
Here  f1  is  a  function  that  implies  “expression  measure  above  3.5  in  at  least  1  sample” 
criterion, the function ffun is the filtering function that by using genefilter is applied to the 
data.
Annotating a platform
Bioconductor provides an extensive catalog of R packages that encodes annotation resources.
From the web site is possible to download a library containing all the informations about the 
probesets in the platform. This .db package has to be installed and loaded to be opened. So 
fields of interest can be chosen, after the visualization with the ls function.
library(annotate)
library("platform_name.db")
ls("platform_name.db")
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A dataframe with all the probe informations has to be prepared and recorded in a .csv file.
ID <- featureNames(eset) 
Symbol <- getSYMBOL(ID, "platform_name.db")
Name <- as.character(lookUp(ID, "platform_name.db", 
"GENENAME")) 
Ensembl <- as.character(lookUp(ID, "platform_name.db", 
"ENSEMBL")) 
df <- data.frame(ID=ID,Symbol=Symbol, Name=Name, 
Ensembl=Ensembl)
write.table(df,"Annotation.csv",sep="\t")
In the case of Exon GeneChip, we can adopt a different strategy. The CEL file has to be read 
in an alternative way in order to create a different object. 
It allows the user to obtain summaries at the probeset level and also at the transcript level. For 
Exon arrays, there are three possible options for transcript level summarization: core, full and 
extended.
library(oligoData) 
exonCELs <- list.celfiles() 
affyExonFS <- read.celfiles(exonCELs) 
data(affyExonFS)
exonPS <- rma(affyExonFS, target = "probeset") 
exonCore <- rma(affyExonFS, target = "core") 
 
Biological  annotation  can  be  obtained  with  the  getNetAffx function.  It  will  return  an 
AnnotatedDataFrame object, which contains all the information about the platform features.
featureData(exonPS) <- getNetAffx(exonPS, "probeset") 
featureData(exonCore) <- getNetAffx(exonCore, "transcript")
In order to select only few fields, we visualize all the content available through the index, 
obtained in the following way
varLabels(featureData(exonCore))
To estract all the gene symbols
x<-pData(featureData(exonCore))[1:length(exonCore), 
"geneassignment"] 
write.table(x,"geneassignmentCore.txt",sep="\t")
For Illumina platform the annotations can be directly downloaded from the web site as .bgx 
30
3. MATERIALS E METHODS
file. The illuminaio package is then needed to convert this in csv format.
library(illuminaio) 
A<-readBGX("file.bgx")
To extract the list of gene symbols
A1<-A[[1]] 
write.table(A1,"file.csv",sep="\t")
Differentially Expressed Genes (DEG) selection
The choice to use maanova package instead of the classical aov analysis, was motivated by 
the fact that it is a powerful tool to manage both small and large scale microarray data sets, 
also arising from sophisticate designed experiments.
The first step is the preparation of design file with a well-defined fields. One has to check 
order and names of samples to set up design matrix.
One must have an Array column (in the same order respect to the names_CEL object) and 
other three columns, containg Strain, Sample and Dye. Dye is reserved for the staining dye, 
and Sample  is  reserved to  identify  biological  replicates.  Usually  we have  to  assign each 
biological subject a unique sample number.
design.table <- data.frame(Array=row.names(pData(Data)), 
Strain = c(" ",...), Sample = c(1,...), Dye = c(1,...))
This object can be recorded as a table to be used several times.
read.madata function allows to connect the normalized data to the structure of the whole 
experiment. It reads microarray data from TAB delimited text file or matrix type R object (in 
this case the values object).
pdata <- read.madata(values, designfile=designfile)
Model fitting 
To  fit  model,  one  needs  to  specify  the  formula  that  includes  factors  affecting  the  gene 
expression among ones specified in designfile. The fitmaanova function adapts the ANOVA 
model to the microarray data. This is a time-consuming step.
fit.full.mix <- fitmaanova(pdata, formula = ~Strain+Sample, 
random = ~Sample)
or, in the cases of absence of experimental replicates, a more semplified formula
fit.full.mix <-fitmaanova(pdata,formula = ~Sample, random = 
~1)
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To test how significantly a given term or terms affect to the gene expression level, R/maanova 
calculates F-test or t-test. The classical ANOVA F-test is a generalization of the t-test that 
allows for the comparison of more than two samples. The F-test is designed to detect any 
pattern of differential expression among several conditions by comparing the variation among 
replicated samples within and between conditions.
In order to obtain all possible pairwise comparison we use the PairContrast function.
C = PairContrast(n)
where n is the number of levels in test term. 
If one is interested in specific pairwise comparisons, the contrast matrix has to be created. 
This is a matrix in which the number of columns corresponds to the number of levels and the 
rows to the comparisons that are going to be made. This is an example 
C = matrix(c(-1,1,0,0,-1,1,-1,0,1), ncol=3, byrow=T)
At this point, we use the  matest  function to perform the statistical evaluation. R/maanova 
provides permutation method to calculate the significance of each test statistics.
ftest.pair <- matest(pdata, fit.full.mix, Contrast = C, 
term="Strain", n.perm=100)
The final step is the data export through the summarytable function that provide summary of 
matest, such as pvalue for the classical F statistic (F1), for F statistic based on the James-Stein 
shrinkage estimates of the error variance (Fs) and fold-change.
summarytable(ftest.pair,outfile='summarytable.csv')
To select the DEGs both fold-change and pvalue have to be taken in account.
Paired samples
The  computation  of  the  significance  in  the  case  of  natural  pairing  of  experimental  units 
requires the use of paired t-test. The variable under examination is the difference between 
couple of values.
The starting point is a different table in which the two groups are clustered together.
even_indexes<-seq(2,length(names_CEL),2) 
odd_indexes<-seq(1,length(names_CEL),2) 
ct=A[even_indexes] 
tr=A[odd_indexes] 
B<-cbind(tr,ct)
pvalue<-apply(B, 1,function(x) 
{ t.test(x[1:length(even_indexes)], x[(length(odd_indexes)+1):
(length(even_indexes)*2)],paired=TRUE)$p.value } )
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The p-value correction for multiple testing must be finally applied:
pvalue_adj<-p.adjust(pvalue, method ="method_chosen")
Annotation insertion 
The creation of the summarizing table containing normalized data, annotations, anova results 
is done in two ways: in the case of files with the same order we can use  cbind function, 
otherwise we are obliged to use merge, selecting a common field as probeID.
Correlations and heatmap
In order to calculate the correlation between couple of genes, two different functions can be 
used.
R provides the cor function that allows to select the method with no correction for multiple 
testing. In the  psych library, with  corr.test it is possible to choose both the method and the 
adjustment.
The first step is the table reading and transposition
A<-read.table("Table.csv",header=TRUE,row.names = 1)
A<-t(A)
the computation of global correlation 
B<-cor(A,method="method_chosen”)
For a specific gene against all the others, we have to create two matrices
library(psych)
single_gene<-A[,gene_position]
single_gene_matrix<-as.matrix(single_gene)
all_genes<-A[,1:length(names_gene)]
B<-corr.test(single_gene_matrix, all_genes, 
method="method_chosen”, adjust="adjust_chosen”)
To extract the correlation values and the respective significance from the list just created
C=B[[1]] 
D=B[[4]] 
These  objects  have  to  be  transposed  before  being  inserted  in  a  dataframe  for  the  final 
recording
correlazione=t(C) 
pvalue_adj=t(D) 
gene_symbol=row.names(correlazione) 
results<-
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data.frame(gene_symbol,correlazione,pvalue_adj,stringsAsFactor
s=F) 
write.table(results,"corr_risp.csv",sep="\t")
To simplify the interpretation of  this  large amount  of  data  identifying genes  with similar 
correlation values, we have used hclust and agnes functions 
A<-t(A)
d <- dist(A,method="method_chosen")
fit <- hclust(d, method="method_chosen")
plot(fit)
library(cluster)
agn<-agnes(A,method="method_chosen",metric = "metric_chosen")
plot(agn)
Reducing the dimension of the data, it is possible to use the heatmap for the visualization. 
Three different functions exist.
library(gplots)
A_heatmap <- heatmap(A_matrix)
A_heatmap <- heatmap.2(A_matrix)
library(pheatmap)
A_matrix <- data.matrix(A)
A_heatmap <-pheatmap(A_matrix)
It is important to choose correctly the range of color to maximize the contrast. The classical 
scale for microarray is the red/green, but more options exist.
In order to make different images comparable, an absolute scale is created. Correlation values 
are between 1 and -1. The choice of the resolution value is arbitrary.
resolution=400 
dosata=greenred(resolution)
a=ceiling((min(A_matrix)+1)/2*resolution) 
b=ceiling((max(A_matrix)+1)/2*resolution)
A_heatmap <-pheatmap(A_matrix,col=dosata[a:b])
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Partial Least Square (PLS) regression
In the case that samples are characterized by different features important for instance for their 
classification, PLS can be performed. Among all the genes it is possible to select a subset that 
can be used to predict a specific characteristic based on the expression level only.
library(pls)
fitplsr <- plsr(B ~ A)
pred <- predict(fitplsr, ncomp = 2)
New responses or scores are predicted using a fitted model and a new matrix of observations.
cor<-cor(y,pred) 
plot(y,pred)
library(mixOmics)
plsr<-pls(A,B)
AWK
AWK is a programming language to analyze and to elaborate text files by organizing data in a 
table format.
It requires the definition of a condition and an action to be performed on the input data.
For instance, to extract the differentially expressed genes from the summarytable,  we can 
insert  in  the  awk command after  "if"  the selection criteria  that  has  to  be  applied on the 
columns containing fold-change and Pvalue (the column number has to be preceded by the 
simbol $) and print $0 as action to extract the entire row when the criteria are satisfied.
An example
awk 'BEGIN { FS = "\t"} ; {if (($ni< -1.5 &&  $nj<0.05) || ($ni> 
1.5 &&  $nj<0.05)){print $0} }' input.csv>output.csv
With BEGIN we specify the action to do before starting the input data reading. In this case, 
we indicate with  FS the separation field of the input file. The boolean operators "or" ( || ), 
"and" ( && ), and "not" ( ! ) are used to define the selection criteria.
Shell scripts
To make multiple selections in an automatic way, the Unix shell is used. Simple but very 
useful scripts are created to increase the speed of each step and to guarantee the correctness of 
the results.
Basic linux commands (cat, ls, grep, comm, sort, and so on) are used inside a while and for 
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loops to have a repetitive execution of a list of these.
The syntax is:
while/for [ condition ]; do list of commands; done
Graphics
One of the strengths of the R language is  the graphics.  Simple,  exploratory,  high quality 
graphics are easy to produce.
R provides different possibilities of exporting graphs in png, pdf, jpeg format with R base 
package and emf format using the devEMF library.
Graphical functions are
plot(),  boxplot(),  hist(),  barplot(),  stripchart(),  dotchart().  Two  or  more  graphs  can  be 
overlayed using add=TRUE as option.
We can insert title, texts , legend, extra-axis, points, marginal texts and lines, changing several 
graphical parameters, into a pre-existent graphic with appropriate functions to obtain the best 
result.
Not only 2D plots can be created but also three-dimensional ones (scatterplot3d package).
library(scatterplot3d)
scatterplot3d(x,y,z)
plot(x,y)
The  grid package allows to control the appearance and arrangement of graphical output. A 
well-defined graphic region is created through the viewport and pushViewport function.
Grid.rect and grid.text are used to insert a rectangle and a text in the image. The first function 
needs x and y coordinates, width, and height for specifying the locations and sizes of the 
rectangles to draw. The other one requires the text to draw as its first argument.
To set the margins of a graph in R, the par() function with the mar argument can be called.
par(mar=c(bottom,left,top,right))
With  grid.arrange  function in the gridExtra package it is possible to create multiple plots 
when more than one graphic has to be flanked in a single figure. This provides somewhat 
similar functionality to par(mfrow=c()).
A special graph is the Venn diagram. This allow to present logical relations between different 
sets.  In  the  case  of  comparisons  of  different  gene  lists,  the  Venn diagram highlights  the 
proportion of elements in common. Two libraries permit to do this.
library(gplots)
A<-read.table("tableA.csv")
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B<-read.table("tableB.csv")
list<-list(A,B) 
venn(list)
library(VennDiagram)
common <- intersect(A[,1],B[,1]) 
draw.pairwise.venn(length(A[,1]),length(B[,1]),length(common))
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4.1 RESULTS OF THE FIRST PART 
The manuscript published in the peer-reviewed journal PlosONE enclosed with this thesis and 
entitled  “Transcriptomic  Analysis  Unveils  Correlations  between  Regulative  Apoptotic 
Caspases  and  Genes  of  Cholesterol”  contains  the  results  of  my  thesis  work  and  all  the 
significant figures and the biological conclusions in a much extensive form. In this paragraph, 
its subject is briefly summarized.
Although caspase-2 is the subject of many studies, its role in physiology and disease in not 
well-defined because of  controversial results. Several reviews discuss the involvement of 
caspase-2  in  different  cellular  processes  (Krumschnabel,  2009;  Vakifahmetoglu-Norberg, 
2010; Fava, 2012). 
To  identify  genes  and  pathways  under  its  influence,  its  expression  was  silenced  in  a 
glioblastoma  cell  line,  U87MG,  considering  the  suggested  roles  of  caspase-2  in  brain 
development and homeostasis.  
Glioblastomas (GBM) are among the most lethal tumors, highly recalcitrant to radiotherapies 
and chemotherapies.
After silencing only a small number of genes resulted differentially expressed: choosing a 1.5 
fold  cut-off,  24  genes  were  significantly  down-regulated  and  17  were  significantly  up-
regulated. 
Despite the limited transcriptional alterations, the results were in any case interesting. Among 
the genes up-regulated after caspase-2 silencing that could mark compensatory responses, 
LIPA, CYP51A1 and CYP1B1 are linked with cholesterol metabolism, and two others are in 
some way connected with it.
Taking into account that previous studies showed that caspase-2 is involved in the regulation 
of the levels of this metabolite, we decided to further investigate the relationship between this 
cystein-protease and cholesterol genes. 
Since complex regulative networks influence cholesterol  homeostasis  in vivo,  cell  culture 
models are not the best tool to investigate correlations of gene expression. We decided to 
expand our study by retrieving all data available in public repositories about gene expression 
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profile studies in  glioblastoma and human brain. Data coming from 13 datasets including 327 
microarrays were used to assess the relation between  CASP2 and  LIPA in glioblatoma. A 
weak but significant inverse correlation was confirmed.
To  clarify  whether  the  expression  of  other  caspases  found  correlations  with  LIPA,  we 
expanded this  analysis  to  all  caspases,  as  well  as  to  elements  of  the  molecular  platform 
involved in caspase-2 activation (CRADD/RAIDD and PIDD). Furthermore, gene expression 
profile data from 12 datasets including 293 microarrays of normal brain were recovered for 
comparison.  We  found  for  CASP2/LIPA a  good  and  significant  inverse  correlation  in 
cerebellum and a positive one in hippocampus. This result could depend on the difference of 
cholesterol genes expression between different brain areas (Segatto, 2012).
Therefore, we decided to investigate with a more comprehensive approach the correlations 
between caspase-2 and the expression of genes involved in cholesterol homeostasis. In order 
to clarify whether or not these correlations are limited to caspase-2 we extended this study to 
all caspases. 
Genes involved in cholesterol  homeostasis,  including steroidogenesis were extracted from 
Gene Ontology (GO) and integrated from literature data. In total we selected 256 genes, of 
which 166 were grouped into 5 categories:  biosynthesis,  adsorption/import,  export,  steroid 
and bile acid synthesis and transcriptional regulators. 
To understand whether our discoveries were limited to CNS or could be observed also in 
other tissues, we decided to compare variations in the expression levels of caspases and of 
cholesterol  genes  in  human  liver,  an  essential  organ  for  cholesterol  homeostasis.  Gene 
expression profiles from 5 datasets including 106 microarrays of normal human liver were 
interrogated.
Since  changes  in  the  expression  of  cholesterol  genes  are  linked  to  several 
physiological/pathological  conditions.  To  understand  the  significance  of  the  describe 
correlations,  we decided  to  interrogate  more  precisely  the  public  available  datasets  form 
human brain used in our studies. We restricted our inquiries to one dataset (GSE17612) in 
which, information about the specific brain area, the anterior prefrontal cortex (Brodmann 
area 10) and subjects age were available.
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4.2 RESULTS OF THE SECOND PART 
In the last  part  of my PhD, I  worked on microarray data with the purpose to build up a 
methodological  approach  to  define  pathways  activated  after  drug treatment  through  gene 
expression profile analysis. In the specific case as a model, in order to develop a pipeline able 
to extract information concerning the cellular response to a specific compound, I used data 
coming  form  chronic  lymphocytic  leukemia  (CLL)  cells  exposed  to  two  different 
pharmacological treatments.
Given the high frequency of relapse and the difficulties in treating this disease, many efforts 
have been done to find novel effective and save treatments for chronic lymphocytic leukemia. 
In  our  work,  CLL cells  from  patients  affected  by  this  disease,  under  treatment  at  the 
Hematology  Department  of  the  University  of  Padova,  were  treated  with  two  different 
molecules both impacting on the ubiquitin-proteasome system (UPS). Due to the importance 
of the proteasome in the regulation of different cellular functions, targeting the ubiquitin-
proteasome system has been used as a strategy for developing new treatments against cancer 
(Huang, 2009; Adams, 2004).  
Several  chemotherapeutic  drugs  induce  cell  death  through  the  activation  of  apoptotic 
programs.  By  considering  the  fact  that  chemo-resistance  is  a  consequence  of  mutational 
accumulations in genes involved in apoptosis, our group in the past focused the attention in 
the  identification  of  new  compounds  able  of  inducing  cell  death  through  alternative 
mechanisms  (Henderson,  2005). Fifty-seven  small  molecules  were  tested  in  a  screening 
(Aleo, 2006) and at the end two were selected and only one underwent further investigations 
(Foti, 2009). Both isolated compounds were UPS inhibitors, which belong to the class of non-
selective isopeptidase inhibitors.  This family of compounds is,  able to act against  several 
isopeptidases, offering advantages in terms of effectiveness on different tumors. 
UPS used in our work were bortezomib and a derivative of G5 named 2cPE.
     Figure 1. Chemical structure of G5
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Bortezomib is a novel, slow-reversible, and highly specific proteasome inhibitor, which has 
been approved for the treatment  of  multiple  myeloma and mantle cell  lymphoma (Pérez-
Galán, 2006).
G5 (Figure 1) was modified in order to optimize its use in vivo. Out from this approach a new 
molecule was generated named 2c that was next conjugated to polyethylene glycol (PEG), a 
common strategy to improve drug solubility and bioavailability (see section 5.2 of this thesis 
containing  the  recently  published  manuscript).  The  new  compound  was  named  2cPE 
(Cersosimo, 2015).
Drug treatment and evaluation of cell viability
Initially, we compared the ability of the two UPS inhibitors to trigger cell death of CLL cells 
obtained from different patients. The percentages of cell survival after treatments for both 
drugs and the principal characteristics of the patients are reported in the table 1. Overall cells 
from different patients show certain variability in the cell death response and in particular to 
2cPE treatment. These experiments were performed at the University of Padova.
Table 1. Summary of the genetic profiles of the patients, which cells were object of the study. In columns 2 and 
3  are  reported  the  percentage  of  cell  survival  after  treatment  with  2cPE  and  bortezomib.  Patients  were 
categorized based on the standard classification and a set of prognostic factors. SHM =immunoglobulin receptor  
heavy chain (IGHV) hypermutation status; FISH =  more frequent genetic aberrations; CD38 expression.
Single patient evaluation
Cells  from  the  available  patients  were  evaluated  for  the  responsiveness  to  both  UPS 
inhibitors, but since the principal aim of this study was the characterization of the response to 
2cPE  treatment,  only  a  subgroup  of  cells  incubated  with  bortezomib  underwent  the 
microarray analysis. 
The RNA was extracted and a microarray analysis was performed. I processed all the CEL 
files together, by using standard tools available within the affy package. I used a UniGene ID 
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% of cell alive after 24 hours prognostic markers standard classification
patient code 2cPE BORT SHM FISH CD38 RAI BINET
LLC122 85 41 unmut 11q- POS 0 A
LLC195 98 14 unmut 11q-; 13q- POS 2 B
LLC270 83 35 unmut 11q- POS 2 B
LLC300 12 11 unmut 13q- NEG 2
LLC305 25 23 mut normale NEG 0 A
LLC351 19 8 unmut 17q-; 13q- POS 1 A
LLC366 55 33 nv 13q-; 12+; p53 mut POS 0 A
LLC37 92 62 mut 13q- NEG 2
LLC43 32 18 mut 12+ POS 1 A
LLC4 18 19 mut nd NEG 1
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centered CDF (Chip Description file) in order to have only one intensity value per gene (Dai,  
2005).
The cells obtained from different patients exhibited a different response in particular to 2cPE. 
In  order  to  unveil  the  possible  mechanisms  of  resistance  to  treatment  each  patient  was 
considered separately. In this manner it was possible to appreciate which was the magnitude 
of the response in terms of alteration of gene expression.
Table 2. Patient  response in terms of number of genes,  which expression was changed after treatments,  as 
indicated. 
Table 2 shows that in some cases, responsiveness has a direct correlation with the number of 
genes,  which  expression  is  altered  after  treatment,  whereas  in  one  case,  the  alteration  is 
remarkable but the drug is not able to induce cell death. Hence, two mechanisms of resistance 
can be hypothesized. In the first case (patients LLC122, LLC195, LLC270) the drug is not 
able to trigger the initial response that is normal converted in the activation of specific genetic 
programs  (gene  expression  changes).  In  the  second case  (patient  LLC37)  a  block  in  the 
apoptotic responsiveness should be present at  a certain level,  after  the engagement of the 
transcriptional response.
Extraction of genes differentially responsive to drug treatments
After  the  initial,  single  patient  analysis,  next  step  was  to  identify  a  list  of  genes  which 
expression is influenced by the two compounds in a significative manner among all patients. 
The idea was to define common and specific patterns of response to the two drugs.
In  order  to  obtain  these  information,  a  set  of  differentially  expressed  genes  (DEG)  was 
extracted,  after  an accurate  no conventional  quality  assessment.  Since the data  of  treated 
43 
2cPE Bortezomib
FC 1.5 FC 2.0 FC 1.5 FC 2.0
LLC122 109 17 211 25
LLC195 18 4 282 50
LLC270 49 12 162 23
LLC300 535 92 - -
LLC305 2525 783 - -
LLC351 632 169 - -
LLC366 195 34 179 12
LLC37 258 71 283 71
LLC43 120 26 111 13
LLC4 1647 457 - -
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samples are linked to their respective controls, we decided to use a paired t-test instead of the 
standard  statistical  method  previously  chosen.  Therefore,  the  analysis  was  conducted  by 
taking into account that, every single alteration in gene expression has to be referred to the 
corresponding level before treatment. In both cases, for each compound used, a list of genes 
was obtained (cut off: fold change 1.5; p value 0.05).
Figure 2 shows the result of such analysis. 
For  both  down-regulated  and  up-regulated  genes,  there  is  only  a  partial  overlapping  of 
modulated genes (common pattern). Instead, the vast majority of these genes were modulated 
independently by the two compounds.
Figure 2. Venn diagram of down and up-regulated genes after 2cPE and Bortezomib treatments
Table 3. List of common down-regulated genes (Fold change > 1.5).
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Gene symbol
Bortezomib 2cPE
pvalue FC pvalue FC
ADA 0.0477 -1.6127 0.0318 -1.6760
AKAP5 0.0116 -1.6217 0.0244 -1.6535
BTLA 0.0052 -1.5515 0.0492 -1.6378
DUSP4 0.0213 -1.9980 0.0059 -2.1808
ENC1 0.0146 -1.5824 0.0170 -1.6999
FAM111B 0.0094 -1.6207 0.0200 -1.7306
GAPT 0.0079 -1.6868 0.0283 -1.7190
IL2RA 0.0189 -1.6484 0.0228 -1.7765
LILRB2 0.0318 -1.6981 0.0296 -1.6349
MS4A7 0.0400 -1.9534 0.0291 -1.6023
PVRIG 0.0041 -2.0139 0.0262 -2.3021
PYCARD 0.0223 -1.5048 0.0224 -1.6480
RGCC 0.0256 -1.5511 0.0190 -1.5693
RNASE6 0.0142 -1.6640 0.0205 -1.9681
SOWAHD 0.0158 -1.5023 0.0286 -1.7865
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Table 3. List of common up-regulated genes (Fold change > 1.5).
DAVID analysis
In order to understand pathways and cellular functions modified by the two UPS, I performed 
an over-representation analysis on each DEG list using DAVID (Sherman, 2007). Results are 
summarized in table 4 and table 5. It is evident that the two UPS inhibitors exert profoundly 
different effects on the cellular functions, possibly indicating different intracellular targets. In 
the case of 2cPE several genes linked protein misfolding, cellular stress and cell survival 
resulted  differentially  expressed.  qRT-PCR  experiments  on  selected  genes  (SQSTM1, 
HMOX1, GCLM, LCK) of  the identified pathways confirmed the regulation operated by 
2cPE (data not shown). On the contrary, after Bortezomib treatment several genes coding for 
proteasome components showed an altered expression,  as previously observed  (Mitsiades, 
2002). 
Table 4. Results of DAVID analysis of differentially expressed genes after 2cPE treatment.
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Term Count % PValue Benjamini FDR
GO:0006986~response to unfolded protein 13 8.333 1.66013E-012 2.67113E-009 2.78174E-009
GO:0010033~response to organic substance 25 16.026 3.10830E-008 1.25031E-005 5.20837E-005
GO:0006457~protein folding 13 8.333 7.73350E-008 1.77759E-005 0.000129585
GO:0042981~regulation of apoptosis 25 16.026 2.38466E-007 4.79604E-005 0.0003995807
GO:0043066~negative regulation of apoptosis 16 10.256 8.25416E-007 0.0001106684 0.001383084
Gene symbol
Bortezomib 2cPE
pvalue FC pvalue FC
BAG3 0.0086 2.1355 0.0262 4.2462
DNAJB1 0.0068 1.7294 0.0226 3.8534
DNAJB4 0.0042 1.6538 0.0186 4.4083
E2F6 0.0068 1.8537 0.0194 1.8695
GADD45A 0.0059 1.6606 0.0302 2.0034
GCLM 0.0043 1.9413 0.0142 5.0008
HSPA1A 0.0104 3.1499 0.0155 4.6622
HSPA1B 0.0102 3.2281 0.0183 6.9492
HSPA6 0.0209 1.8104 0.0315 7.6563
HSPA8 0.0159 1.6203 0.0179 1.9407
HSPH1 0.0074 1.6869 0.0203 3.2081
KEAP1 0.0064 1.5879 0.0114 1.5506
LRP8 0.0095 1.6167 0.0231 1.5270
MAFG 0.0051 1.6000 0.0188 2.1370
MIR22HG 0.0027 2.0390 0.0203 2.7014
PSMC2 0.0038 2.1857 0.0262 1.5162
PSMD14 0.0027 2.1162 0.0318 1.5110
SRXN1 0.0142 1.7259 0.0116 2.8933
ZFAND2A 0.0106 1.7024 0.0373 2.2129
4. RESULTS and DISCUSSION
Table 5. Results of DAVID analysis of differentially expressed genes after Bortezomib treatment.
Hierarchical clustering
As subsequent analysis we decided to use the list of genes differentially expressed in response 
to the different inhibitors to investigate their  use as markers of the responsiveness to the 
compounds and of the apoptotic susceptibility. To illustrate the data in a simple manner we 
selected the hierarchical clustering.  
The initial intensities were converted into differences of expression because they are much 
more informative respect to the absolute values. 
The lists of DGE were fused and used to extract the values of single patient differences, in an 
automatic  way.  An  unsupervised  clustering  analysis  was  performed  using  bioconductor 
packages, and the results are presented as heatmap, a coloring code graph that simplify their 
interpretation.
Interestingly,  the  cluster  analysis  evidenced  that  in  the  case  of  2cPE  treatment  a  clear 
correlation between the magnitude of the expressional responses and induction of cell death is 
present. With the exclusion of patient LLC37 all patients which cells are responsive to 2cPE 
induced  apoptosis  cluster  together.  Similarly,  patients,  which  cells  are  resistant  to  2cPE 
treatment, evidence limited transcriptional changes and cluster together. As discussed above 
cells form LLC37 patient probably contain some alterations in the pro-death signaling acting 
after the initial transcriptional response elicited by 2cPE. 
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Term Count % PValue Benjamini FDR
GO:0000502~proteasome complex 14 15.730 4.31329E-018 5.26221E-016 4.96617E-015
GO:0051340~regulation of ligase activity 15 16.854 6.41469E-018 2.75832E-015 9.94011E-015
GO:0010498~proteasomal protein catabolic process 15 16.854 1.90722E-016 1.90958E-014 3.44169E-013
GO:0043085~positive regulation of catalytic activity 19 21.348 1.93518E-010 8.75925E-009 2.99873E-007
GO:0007049~cell cycle 17 19.101 2.85459E-006 7.01389E-005 0.0044233329
4. RESULTS and DISCUSSION
Figure 3. Differences of gene expression regarding the up-regulated genes (FC > 1.5) for 2cPE and bortezomib. 
The dendrograms are based on hierarchical clustering using the average linkage method.
Correlation between 2cPE treatment responses and single patient fold change
To further characterize the transcriptional response to 2cPE treatment and to identify genes, 
which  could  be  involved  in  transducing  its  anti-proliferative  signaling,  we  thought  to 
calculate the spearman correlation between the treatment response in terms of percentage of 
cell  survival  and  the  single  patient  fold  change  of  the  differentially  modulated  genes 
(Benjamini-Hockberg was chosen as multiple test correction). 
This study was done only for 2cPE given the low number of patients treated with bortezomib. 
The gene that shows the best correlation, the top of the rank, in terms of responsiveness to 
2cPE is SH3BP5 (r -0.9879 pvalue_adj 0.0017).
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Figure 4.  Plot of differences of mRNA levels for SH3BP5 versus patient responsiveness in term of % of cell 
survival after the treatment. Linear regression and Spearman correlation (Benjamini and Hochberg correction)  
are reported.
This result is particularly interesting because this gene codifies for a natural inhibitor of an 
important pathway involved in the regulation of CLL proliferation. B-cell receptor (BCR) 
signaling pathway has a central role in the CLL pathogenesis and it represents a potential 
therapeutic target (Burger, 2013; Woyach, 2012). SH3BP5 encodes for a negative regulatory 
protein that inhibits the auto and trans-phosphorylation activity of Btk, a critical component 
of this signaling pathway (Yamadori, 1999; Mohamed, 2009).
To further discover genes which differential  expression could mark the responsiveness to 
2cPE,  a  PLS  regression  (Abdi,  2013;  Boulesteix,  2007)  was  performed  over  the  global 
profile. This kind of exploratory technique allows to select variable with predictive capability. 
Among  the  measures  obtained  through  this  analysis  some  are  more  important  for  the 
determination of the best predictors (Mehmood, 2012).
The significativity of the regression will be independently assessed in the next future.
Several DEG were discovered also through this approach. 
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Figure 5.  Plot of responsiveness in terms of % of cell survival versus the response prediction using the new 
factors called latent variables which have the best predictive power, identified after pls analysis.
After literature searching, we understood that several of these prognostic genes, up-regulated 
by 2cPE treatment are involved in the NRF2 response. This result was confirmed also by the 
GSEA analysis selecting the C3 (motif gene set), downloaded form the Molecular Signature 
Database.
NRF2 is a transcription factor activated in case of oxidative stress as a response to reactive 
oxygen species accumulation. 
In normal conditions NRF2 is constantly degraded through the proteasome. When the levels 
of  ROS  increase,  it  dissociates  from  the  regulatory  protein  KEAP1  (FC  1.5506)  with 
consequent stabilization, translocation into the nucleus and transcription of the target genes 
(Itoh, 1999). Overall the bioinformatics analysis indicates that 2cPE triggers some sort of 
oxidative stress, possibly by dumping the anti-oxidant defenses (work in progress). 
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Table 6. A subset of genes up-regulated by 2cPE
Alterations in the expression of proteasomal components 
Being both the  compounds ubiquitin-proteasome system inhibitors,  we were interested to 
know how they altered the expressions of genes encoding for proteasomal components. In 
fact, it is well known that bortezomib, triggers compensatory response marked by the up-
regulation of several proteasomal components  (Mitsiades, 2002). I used Gene Ontology to 
extract a list of genes involved in proteasome formation assembly and homeostasis. Next I 
extracted the values of global (average) fold change for this gene family. 
Results are presented in Figure 6. As expected in bortezomib treated cells the mRNA levels of 
several  genes  encoding  for  protesomal  subunits  were  up-regulated.  Surprisingly  this 
adaptation, although present also in 2cPE treated cells was less noticeable.
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Gene symbol Gene name pvalue_adj FC
HMOX1 heme oxygenase (decycling) 1 0.0142 7.9015
TXN thioredoxin 0.0142 1.9739
NQO1 NAD(P)H dehydrogenase, quinone 1 0.0116 1.9085
TXNRD1 thioredoxin reductase 1 0.0114 2.2343
PRDX1 peroxiredoxin 1 0.0186 1.4725
GCLC glutamate-cysteine ligase, catalytic subunit 0.0203 1.6711
GCLM glutamate-cysteine ligase, modifier subunit 0.0142 5.0008
GSR glutathione reductase 0.0170 1.5147
SOD1 superoxide dismutase 1, soluble 0.0235 1.5399
KEAP1 kelch-like ECH-associated protein 1 0.0114 1.5506
MAFG v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog G 0.0188 2.1370
CHOP C/EBP homologous protein 0.0469 1.8440
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 0.0236 1.6544
GADD45A growth arrest and DNA-damage-inducible, alpha 0.0302 2.0034
E2F6 E2F transcription factor 6 0.0194 1.8695
SQSTM1 sequestosome 1 0.0188 1.7508
BAG3 BCL2-associated athanogene 3 0.0262 4.2462
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 0.0205 2.0938
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 0.0502 2.4430
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 0.0226 3.8534
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 0.0186 4.4083
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 0.0203 1.9334
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 0.0220 3.7442
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B member 1 0.0258 1.7337
HSPA1A heat shock 70kDa protein 1A 0.0155 4.6622
HSPA1B heat shock 70kDa protein 1B 0.0183 6.9492
HSPA1L heat shock 70kDa protein 1-like 0.0176 2.8786
HSPA6 heat shock 70kDa protein 6 0.0315 7.6563
HSPA8 heat shock 70kDa protein 8 0.0179 1.9407
HSPD1 heat shock 60kDa protein 1 (chaperonin) 0.0378 1.8462
HSPH1 heat shock 105kDa/110kDa protein 1 0.0203 3.2081
4. RESULTS and DISCUSSION
Figure 6. Fold change of the proteosomal components after 2cPE and Bortezomib treatments.
Clustering of no-treated samples
The analysis of genes differentially expressed following 2cPE treatment evidenced (with the 
exclusion of patient LLC37) a strong correlation between the magnitude of the response and 
the apoptotic susceptibility. Hence to identify putative predictors of the drug responsiveness 
we focused the analysis on the gene expression profiles characterizing CLL from different 
patients before drug-treatmet. 
We used the agnes function in the bioconductor cluster package to clusterize samples using 
the average linkage method.
Figure 7. Hierarchical clustering of whole gene expression in CLL cells from different patients before the 2cPE 
treatment. 
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Importantly,  three patients  that  showed low sensitivity  to  2cPE treatment  cluster  together 
(Figure 7). In order to have information about which genes are much strongly responsible for 
this clustering separation, a standard t-test was performed. A the top of the rank the ATM gene 
was found (pvalue 2.9306E-005 FC -1.87). 
This  result  is  of  particular  interest,  because  all  three  patients  under  consideration  are 
characterized by the 11q deletion, which affects the ATM locus (Stankovic, 2014). 
Other  two genes,  NPAT and CUL3 lie  in the same chromosome region and they score a 
significant reduction in terms of expression in the non-responsive patients (pvalue 0.0035 FC 
-1.69 and pvalue 0.0020 FC -1.64, respectively).
A subset of genes was extracted using pvalue and fold change (mean difference of expression 
between the two clusters) as selection criteria. This gene list is now under evaluation.
ATM is a protein kinase involved in DNA damage and oxidative responses. Several studies 
suggest that loss of ATM correlates with CLL resistance to chemotherapy and poor patient 
survival (Ripollés, 2006; Austen, 2007). The combined status of ATM and p53 is predictive of 
the  response  to  chemotherapeutic  treatments  (Jiang,  2009).  Preliminary  studies  have 
confirmed the activation of ATM following 2cPE treatment in the CLL cell line MEC-1 and 
further studies have been planned to evaluate the contribution of this serin-threonin kinase to 
the apoptotic response engaged by the isopeptidase inhibitor.
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5. ADDITIONAL WORK
5.1  Next-Generation  Sequencing  Analysis  of  miRNAs 
Expression in Control and FSHD Myogenesis
Previous  studies  have demonstrated the involvement  of  miRNAs in muscle  development, 
through  the  control  of  myoblast  proliferation  and differentiation.  Raffaella  Meneveri  and 
coworkers  used  next-generation  sequencing  (NGS)  to  discover  which  miRNAs  are 
specifically  expressed  during  normal  myogenesis,  in  comparison  with  a  pathological 
condition.  Specifically,  they  compared  results  obtained  from  normal  tissues  with  those 
deriving from patients affected by facioscapulohumeral muscular dystrophy (FSHD), the third 
most common myopathy, with an incidence of 1 in 14.000 in the general population.
They  obtained  two list of miRNAs modulated exclusively in the normal and in the FSHD 
muscle.  Control  myogenesis  showed the modulation of  38 miRNAs (4 down and 34 up-
regulated) whereas FSDH myogenesis dysregulated miRNAs were only 15 (4 down and 11 
up-regulated).  During  my  PhD  thesis  I  analyzed  two  different  datasets,  which  have  in 
common  the  same  differentiation  protocol  and  the  platform  to  extrapolate  a  list  of 
differentially expressed genes. TargetScan, a tool for the prediction of putative target genes, 
was used in order to define among all the differential regulated genes a set of potentially  
validated targets.
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5.2 Synthesis, Characterization, and Optimization for in Vivo  
Delivery of a Nonselective Isopeptidase Inhibitor as New 
Antineoplastic Agent
The non-selective isopeptidase inhibitor G5 has a cytotoxic activity  against different cancer 
cells. To  improve  its  activity  a  small  chemical  library  of  G5-derivatives  was  generated. 
Among all the G5-like compounds, we selected 2c, which even though less active respect to 
G5, it was selected because capable of inducing apoptosis over necrosis, and for the presence 
of  a  OH group.  This  OH  group  allowed  the  addiction  of  PEG (Polyethyleneglycole)  to 
increase 2c solubility in water. Conjugation of PEG to a low molecular weight drugs is a 
common strategy to increase the efficacy in vivo.
2c conjugated to PEG was named 2cPE and in this manner it behaves as a pro-drug. In fact 
2cPE has to be converted into an active species through the action of secreted esterases.
It was observed that not all the cancer cell lines were capable of processing the prodrug. 
Furthermore, the conditioned medium of 2cPE responsive cell lines was able to transform 
unresponsive cells into responsive ones. Hence during this thesis, I applied genes expression 
profile studies to discover the secreted esterase involved in 2cPE maturation. A list of 173 
putative esterases codified by the human genome was extracted from Gene Ontology and 
integrated through the use of HomoloGene. The enzyme capable to release the active form of 
2c must have the expression pattern reflecting the difference in term of responsiveness of the 
cell lines used to assess the efficacy of the drug: higher level in the cell line with the highest 
responsiveness and lower in the case of the cell line less responsive.
Only seven esterases satisfied the expression profile. Among these enzymes, PLA2G7 was 
taken in consideration because of the structure of the interface binding area that appeared able 
to bind molecules like 2cPE.
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6. CONCLUSIONS
The main purposes of my PhD were to get practice and skills in the analysis of data generated 
by the microarray technology and to develop a computational pipeline for this analysis. After 
a short period spent in the evaluation of freely available tools, we decided to use R to have a 
stronger  control  over  all  steps  of  the  analysis.  The applied  pipeline  has  been adapted  to 
different  special  cases  of  microarray  data,  including  in  house  generated  data  and  data 
recovered from public available databanks. When the experimental environment required it, 
the  pipeline  was  expanded  in  order  to  extract  different  information  from the  data  under 
consideration.
Several steps have been performed from the command line in order to speed up the results 
attainment and to increase their reliability and the correctness. A simple but more efficient 
script has been written to carry out many operations in sequence and AWK has been used to 
manage big files in a table format with substantial time saving. The computational tools have 
been applied  to  investigate  different  biological  questions  (the  role  of  caspase-2;  the anti-
neoplastic response elicited by UPS inhibitors and the basis of genetic diseases). 
Thanks to the analysis of different gene expression profiles I was able with this thesis:
I)  to  unveil  correlations  between cholesterol  genes,  regulative caspases and brain  
aging.
II) to propose the enzyme involved in the maturation of a pro-drug
III) to define survival pathways and resistance mechanisms engaged by a new UPS 
inhibitor.
The main goal of this thesis has been the creation of a computational service, available to all 
members  of  the  Department,  for  the  analysis  of  the  microarray data,  which is  now fully 
operative.
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7. Appendix
7. Appendix
7.1 Scripts – part 1
R
library(affy) 
library(maanova)
data<-ReadAffy()
eset <- rma(data)
design.table=data.frame(Array=row.names(pData(data)),Strain=c(
"siC2mut","siC2mut","siC2wt","siC2wt","siPGAM5","siPGAM5","
siUSP34","siUSP34"),Sample=c(1,1,2,2,3,3,4,4),Dye=c(1,1,1,1
,1,1,1,1)) 
write.table(design.table,"design.txt",sep="\t", row=F,quote=F)
datafile<-exprs(eset)
data<-data.frame(probeid=row.names(datafile),datafile)
write.table(data, "datix.txt",sep="\t",row=F,quote=F)
pdata <- read.madata(datafile, designfile="design.txt")
fit.full.mix <-fitmaanova(pdata,formula = 
~Strain+Sample,random = ~Sample) 
C = matrix(c(1,-1,0,0,1,0,-1,0,1,0,0,-1), ncol=4, byrow=T) 
ftest.pair = matest(pdata, fit.full.mix, Contrast = 
C,term="Strain", n.perm=100)
summarytable(ftest.pair,outfile='shortsummarytablepair.csv')
annot = read.delim("annot.csv") 
out= read.delim("shortsummarytablepair.csv") 
out.annot = merge(annot,out,by.x="PROBE_ID", by.y="PROBE_ID", 
all.x=T, all.y=F, sort=F) 
write.table(out.annot,"AnovaResults.txt",sep="\t", 
row=F,quote=F)
png("BoxplotNomi.png") 
boxplot(data,title="Summary of data distribution", 
col=c("2","3","4","5","6","7","8","12","20"),lwd=0.9,adj=0.
21,names=c("1","2","3","4","5","6","7","8"),cex.axis=0.8,la
s=3,cex=1)
dev.off()
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A<-read.table("datixCASP2.csv",header = TRUE, row.names = 1) 
y1 <- (A[,1] + A[,2])/2 
y2 <- (A[,3] + A[,4])/2 
s2 <- ((A[,3] - A[,4])/2)^2 
s1 <- ((A[,1] - A[,2])/2)^2 
s <- sqrt((s1 +s2)/2) 
s[s<0.08478]<-0.0847800 
summary(s) 
     Min.   1st Qu.    Median      Mean   3rd Qu.      Max. 
0.0002991 0.0476900 0.0847800 0.1091000 0.1425000 1.2220000 
d<-abs(y1-y2) 
t<-d/s 
pv<-1-pt(t,2) 
A[,5]<-pv 
colnames(A)[5]<- c("pvalue")
write.table(A,"tmp.txt",row.name=TRUE,col.name=TRUE,sep="\t")
library(affy)
data<-ReadAffy(cdfname ="HG-U133PLUS2_HS_ENTREZG")
eset <- mas5(data)
datafile<-exprs(eset) 
datax<-data.frame(probeid=row.names(datafile),datafile) 
write.table(datax, "datiBA.txt",sep="\t",row=F,quote=F)
library(devEMF) 
A<-read.table("Brain_log.csv",header=TRUE,row.names = 1) 
A<-t(A) 
B<-read.table("Gliobl_log.csv",header=TRUE,row.names = 1) 
B<-t(B) 
emf("Overlay.emf",height=7, width=16) 
boxplot(B,las = 2,outpch = NA,col="grey",at=c(2, 6, 10, 14, 
18, 22, 26, 30, 34, 38), xaxt = "n") 
ll<-data.frame(B) 
stripchart(ll,method="jitter",pch =19,cex=0.2,add = 
TRUE,vertical = TRUE,at=c(2, 6, 10, 14, 18, 22, 26, 30, 34, 
38)) 
boxplot(A,las = 2,outpch = NA,col="light blue", add=TRUE, 
at=c(1, 5, 9, 13, 17, 21, 25, 29, 33, 37)) 
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l <-data.frame(A) 
stripchart(l,method="jitter",pch =19,cex=0.2,add = 
TRUE,vertical = TRUE,at=c(1, 5, 9, 13, 17, 21, 25, 29, 33, 
37)) 
legend(2,2,c("Brain", "Glioblastoma"),pch = 21, pt.bg = 
c("light blue","grey"), pt.cex = 1.5) 
axis(1,at=c(2, 6, 10, 14, 18, 22, 26, 30, 34, 
38),labels=c("CASP1","CASP2","CASP3","CASP4","CASP5","CASP6
","CASP7","CASP8","CASP9","CASP10"), tick=FALSE) 
title(main="Caspases Expression in Brain and Glioblastoma",pch 
= 30) 
dev.off() 
A<-read.table("Brain_ages",row.names = 1) 
plot(A[,1],A[,2]) 
fit<- glm(A[,1]~A[,2]) 
co <- coef(fit) 
abline(fit)
head -1 datiBAGlioblplus2.txt >Tab_Glioblplus2.txt 
for sonda in `cat probe_geni.txt`; do 
echo $sonda 
awk -v probe=$sonda '{if ($1 == probe){print $0;}}' 
datiBAGlioblplus2.txt >>Tab_Glioblplus2.txt 
done
echo 'nome directory output?' 
read outdir 
elenco_categ_dir=categorie
mkdir $outdir 
categorie=`ls ../$elenco_categ_dir/` 
for categoria in $categorie; do 
nome_categoria=`echo $categoria | sed s/.csv//` 
echo $categoria 
for gene in `cat ../$elenco_categ_dir/$categoria`; do 
echo $gene 
59 
7. Appendix
awk -v probe=$gene '{if ($1 == probe){print $0}}' 
corr_test.csv >> output_categorie/175_"$nome_categoria".csv 
done 
done
7.2 Scripts – part 2
R
library(affy)
data<-ReadAffy(cdfname ="HG-U219_HS_ENTREZG")
eset <- rma(data)
datafile<-exprs(eset) 
datax<-data.frame(probeid=row.names(datafile),datafile) 
write.table(datax, "datix.txt",sep="\t",row=F,quote=F)
#quality control
#differentially expressed genes determination
even_indexes<-seq(2,length(names_CEL),2) 
odd_indexes<-seq(1,length(names_CEL),2) 
ct=A[even_indexes] 
tr=A[odd_indexes] 
B<-cbind(tr,ct)
pvalue<-apply(B, 1,function(x) 
{ t.test(x[1:length(even_indexes)], x[(length(odd_indexes)
+1):(length(even_indexes)*2)],paired=TRUE)$p.value } )
ddd<-p.adjust(bbb, method ="fdr”)
write.table(ddd,"fdr.csv",sep="\t")
A<-read.table("SH3BP5_rips.csv",header=TRUE,row.names = 1) 
A<-t(A) 
fit<- glm(A[,2]~A[,1]) 
co <- coef(fit) 
png("SH3BP5-survival.png") 
plot(A[,1],A[,2],pch=20,main="correlation treatment response - 
single Fold Change",xlab="% of cell survival",ylab="SH3BP5 
FC") 
text(80,0.7,"spearman correlation -0.9879", col="blue") 
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text(80,0.65,"pvalue_adj 0.0017", col="blue") 
abline(fit, col="blue",lwd=2) 
dev.off()
library(cluster) 
A<-read.table("datiBA_NT_only.csv",header=TRUE,row.names = 1) 
A<-t(A) 
agn<-agnes(A,method="average",metric = "euclidean",stand = 
FALSE) 
plot(agn)
#!/bin/csh -f 
set outdir=OUT 
mkdir $outdir 
set i=1 
set in=`(ls Bortezomib*_uniq.dat)` 
while ($i <= $#in) 
set nome_paziente1=`echo $in[$i] | sed s/_uniq.dat// | sed 
s/Bortezomib_//` 
set ii=1 
set n=`(ls 2FEP*_uniq.dat)` 
while ($ii <= $#n) 
set nome_paziente2=`echo $n[$ii] | sed s/_uniq.dat// | sed 
s/2FEP_//` 
if ($nome_paziente1 == $nome_paziente2) then 
echo $i 'contro' $ii 
comm $in[$i] $n[$ii]> $outdir/"$nome_paziente1".dat 
endif 
@ ii = $ii + 1 
end 
@ i = $i + 1 
end
#!/bin/csh 
set i=1 
set in=`(ls *.csv)` 
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while ($i <= $#in) 
set nome_paziente=`echo $in[$i] | sed s/.csv//` 
cat $in[$i] | awk '{print $2}' | grep -v NA | grep -v Symbol | 
sort | uniq > "$nome_paziente"_uniq.dat 
@ i = $i + 1 
end 
#!/bin/csh -f 
set outdir=OUT 
mkdir $outdir 
set i=1 
set in=`(ls *_uniq.dat)` 
while ($i <= $#in) 
set ii=1 
set n=`(ls *_uniq.dat)` 
while ($ii <= $#n) 
set nome_paziente=`echo $in[$i] | sed s/_uniq.dat//` 
set paziente=`echo $n[$ii] | sed s/Bortezomib_// | sed 
s/_uniq.dat//` 
echo $i 'contro' $ii 
cat $in[$i] | grep -w -o -f  $in[$i] $n[$ii]> 
$outdir/"$nome_paziente"_"$paziente".dat 
@ ii = $ii + 1 
end 
@ i = $i + 1 
end
awk '{a[$0]++}END{for(i in a){if(a[i])print i,a[i]}}'  
cat.csv>count.csv
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Transcriptomic Analysis Unveils Correlations between
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Abstract
Regulative circuits controlling expression of genes involved in the same biological processes are frequently interconnected.
These circuits operate to coordinate the expression of multiple genes and also to compensate dysfunctions in specific
elements of the network. Caspases are cysteine-proteases with key roles in the execution phase of apoptosis. Silencing of
caspase-2 expression in cultured glioblastoma cells allows the up-regulation of a limited number of genes, among which
some are related to cholesterol homeostasis. Lysosomal Acid Lipase A (LIPA) was up-regulated in two different cell lines in
response to caspase-2 down-regulation and cells silenced for caspase-2 exhibit reduced cholesterol staining in the lipid
droplets. We expanded this observation by large-scale analysis of mRNA expression. All caspases were analyzed in terms of
co-expression in comparison with 166 genes involved in cholesterol homeostasis. In the brain, hierarchical clustering has
revealed that the expression of regulative apoptotic caspases (CASP2, CASP8 CASP9, CASP10) and of the inflammatory
CASP1 is linked to several genes involved in cholesterol homeostasis. These correlations resulted in altered GBM
(Glioblastoma Multiforme), in particular for CASP1. We have also demonstrated that these correlations are tissue specific
being reduced (CASP9 and CASP10) or different (CASP2) in the liver. For some caspases (CASP1, CASP6 and CASP7) these
correlations could be related to brain aging.
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Introduction
Caspases were initially discovered as critical enzymes in the
control of apoptosis. Quite soon it was evident that, they can
supervise additional biological processes, such as inflammation
and differentiation [1,2]. This discovery has granted the dichot-
omy between apoptotic and non-apoptotic caspases. More
recently, it has been observed that caspases controlling apoptosis
can also play specific roles unrelated to cell death [3–5].
Caspases can be divided into initiator and effector caspases
depending on the presence of a long prodomain at their amino-
terminal region. Initiator caspases act at the apex of a proteolytic
cascade, whereas effector caspases act downstream and are
involved in the cleavage of specific cellular proteins [1].
Caspase-2, caspase-8, caspase-9, and caspase-10 are the long
prodomain caspases involved in the apoptotic process. Caspase-8
and caspase-10 have well-established roles in the engagement of
the extrinsic pathway, whereas caspase-9 is the critical enzyme for
the intrinsic/mitochondrial pathway. Caspase-8 can also play roles
unrelated to apoptosis, such as in NF-kB activation or in limiting
necroptosis and caspase-10 has been recently shown to control
autophagy [6].
Caspase-2 is still a mysterious caspase. It shows a peculiar
nuclear localization that is regulated by two different NLSs [7]. A
CARD domain, at the amino-terminal region is responsible for the
homotypic interaction with adaptor molecules. Although a
molecular platform controlling its activation has been described
[8,9], the contribution of caspase-2 to apoptosis is still debated.
Different, sometimes controversial results have been published and
multiple functions have been attributed to caspase-2.
Mice deficient for caspase-2 and for its adaptor protein RAIDD
have proved absent or only very limited defects in apoptosis [8,9].
Further studies with cells from caspase-2 2/2 mice have
indicated that caspase-2 could be considered a tumor suppressor,
since its absence can favor oncogene-mediated transformation
[10,11].
Difficulties in defining a gene function in specific biological
context could arise from the presence of regulative circuits that
compensate the experimental alteration. There are several
examples of genes down-regulated by siRNA approaches, or
through homologous recombination in mice, which have gener-
ated only minimal phenotypes [12–14].
The still obscure impact of caspase-2 on cell functions could be
masked by compensatory mechanisms engaged following its
inactivation. In this manuscript we have investigated the gene
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expression profile of human cells silenced for caspase-2 expression.
Our goal was to unveil whether perturbation of caspase-2 levels
could influence the expression of genes involved in specific cellular
functions, either as part of common regulative circuits or of
compensatory mechanisms.
Materials and Methods
Cell culture, siRNA, reagents and antibodies
U87MG and IMR90-E1A cells were grown in DMEM
supplemented with 10% FBS, penicillin (100 U/mL), glutamine
(2 mmol/L), and streptomycin (100 mg/mL) at 37uC in 5% CO2
atmosphere. RNA oligos for interference (RNAi) were purchased
from Dharmacon: CASP2 RNAi1, AAACAGCUGUUGUU-
GAGCGAA; Control1 (CASP2 mutated) RNAi, AAACAAUU-
GUUGUUGAGCGAA; or Qiagen: CASP2 RNAi2 CAUCUU-
CUGGAGAAGGACATT and a non-targeting siRNA UUCU-
CCGAACGUGUCACGU, Control2. Cells were transfected
24 hours after plating by adding the Opti-MEM medium
containing Lipofectamine 2000 (Invitrogen) plus RNAi oligos.
BSA and Filipin (Sigma), anti-LBPA [15], anti-transferrin receptor
(Tnf-R) (OKT9), anti-GM-130 (BD biosciences), anti-caspase-2
[16]. Secondary anti-mouse and anti-rabbit antibodies were Alexa
Fluor 488 and Alexa Fluor 546 conjugated (Invitrogen).
Western blotting
Proteins obtained after an SDS denaturating lysis and
sonication were transferred to a 0.2-mm-pore-sized nitrocellulose
membrane and incubated with the specific primary antibodies.
After several washes, blots were incubated with peroxidase-
conjugated goat anti-rabbit or (Euroclone Milano I) for 1 h at
room temperature. Finally, blots were developed with Super
Signal West Dura, as recommended by the vendor (Pierce).
RNA expression array and data analysis
Total RNA was isolated using RNeasy Mini kit (Qiagen). RNA
sample was labeled according to the standard one cycle
amplification and labeling protocol (Affymetrix). Labeled cRNA
was hybridized on Affymetrix GeneChip Human Gene 1.0 ST
Array. Robust Multi-Array Average (RMA) normalization was
applied [17]. Data analysis was performed using the t-test as
implemented in the R statistical package. A minimum standard
deviation was assumed corresponding to the median percentile of
all standard deviations in order to avoid fortuitously large t
statistics. Differentially expressed genes were selected based on.
1.5 fold change and P,0.05. The analysis of Gene Ontology terms
was performed using the DAVID server [18,19]. Microarray data
have been deposited in NCBI Gene Expression Omnibus (GEO)
and the GEO accession number is GSE61388.
RNA extraction and quantitative qRT-PCR (quantitative
reverse transcription polymerase chain reaction)
Cells were lysed using Tri-Reagent (Molecular Research
Center). A total of 1mg of total RNA was retrotranscribed by
using 100 U of Moloney murine leukemia virus reverse transcrip-
tase (Invitrogen). Quantitative reverse transcription-PCR (qRT-
PCR) analyses were performed using Bio-Rad CFX96 and SYBR
Green technology. The data were analyzed by use of a
comparative threshold cycle using HPRT (hypoxanthine phos-
phoribosyltransferase) and b-actin as normalizer genes. All
reactions were done in triplicate.
Immunofluorescence microscopy
Cells were fixed with 3% paraformaldehyde and permeabilized
with 0.5% Triton X-100 and blocked in PBS 3% BSA for 1 h RT.
After washes coverslips were incubated with Filipin (100mg/mL)
and relative primary antibodies for 2 hrs. After several washes
coverslips were incubated with secondary antibodies. Cells were
imaged with a Leica confocal scanner SP equipped with a 488 l
Ar laser and a 543 to 633 l HeNe laser. Cell images for
deconvolution were taken using the Leica AF6000 LX microscope.
Data preparation and analysis
29 human microarray datasets were included in this study,
totaling 726 arrays. Brain (11 datasets 293 microarrays) GBM (13
datasets 327 microarray) Liver (5 datasets 106 microarrays) were
used and in all cases. All datasets were downloaded manually from
GEO [20] and ArrayExpress databases [21]. We analyzed only
expression data obtained using the most comprehensive human
expression platform HG U133 Plus 2.0. For GBM (GSE11100;
GSE13041; GSE15824; GSE19728; GSE23806; GSE23935;
GSE29796; GSE30563; GSE32374; GSE4290; GSE7696;
GSE9171) for normal human brain (GSE5281; GSE7307;
GSE17612; GSE21935; GSE15824; E-MEXP-2351; GSE21354;
E-MEXP-2280; GSE15209; GSE7692; GSE4290) for human liver
(E-GEOD-40873; E-MTAB-950; E-GEOD-23343; E-AFMX-11;
E-MEXP-2128). We processed all the CEL files together by using
standard tools available within the affy package in R [22].
We use a UniGene ID centered CDF (Chip Description file) in
order to have only one intensity value per gene. CDFs were
downloaded from the Molecular and Behavioral Neuroscience
Institute Microarray Lab (URL:http://brainarray.mbni.med.umich.
edu/Brainarray/Database/CustomCDF/genomic_curated_CDF.
asp) [23]. All annotation information were downloaded from the same
website. The normalization step was done with the standard MAS5.0
algorithm, described in the Statistical Algorithms Description Docu-
ment available from Affymetrix (URL: http://www.affymetrix.com/
support/technical/whitepapers/sadd_whitepaper.pdf).
We converted all microarray data to log values. We extracted
the data regarding the genes of interest in an automatic way.
Correlations among gene expression levels were calculated using
the library psych in R choosing the Pearson correlation method. p-
values were adjusted for multiple testing using Benjamini and
Hochberg’s method [24]. Genes were clustered using hierarchical
clustering using the complete linkage method according to
similarity in correlation patterns, as measured by euclidean
distance [25]. Heat maps were generated with R with positive
correlation scores (values) colored by blue while negative ones
colored by dark green. GO (Gene Ontology) annotations and
knowledge from the literature was used to create a list of genes
involved with the cholesterol metabolism. Gene expression levels
were correlated with age using the Spearman’s correlation making
minimal assumptions about the relationship between the two
diverse variables.
Results and Discussion
Gene expression profile studies in cells with down-
regulated caspase-2 expression
To identify genes and pathways under the influence of caspase-2
we silenced its expression in the glioblastoma cell line U87MG.
We selected glioblastoma cells since important apoptotic functions
have been attributed to caspase-2 in the brain and because CASP2
deficits elicit compensatory mechanisms in this tissue [26,27].
Caspase-2 deficient cells did not display overt alterations in
terms of cell proliferation, cell cycle and apoptosis (data not
Caspases and Cholesterol Homeostasis
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shown). Next transcriptional expression profiles of cells transfected
with caspase-2 siRNA and control siRNA were compared. We
selected a 1.5 fold cut-off and globally 24 genes were significantly
down-regulated (Table S1), whereas 17 genes were significantly
up-regulated in caspase-2 silenced cells (Fig. 1A). This number is
particularly small, since in parallel experiments after silencing of
other genes, such as USP34 or PGAM5 fluctuations in the
expression of more than 200 and 800 genes, respectively were
observed (data not shown). Microarray and immunoblot analysis
proved the effective down-regulation of CASP2 mRNA (Fig. 1A)
and protein (Fig. 1B).
Figure 1. Transcriptomic variations in cells silenced for caspase-2. A. List of the top up-regulated genes (cut-off 1.5) in U87MG cells silenced
for caspase-2 expression. B. Cellular lysates from U87MG cells transfected with the indicated siRNAs against caspase-2 or the relative control siRNAs
were generated and after immunoblot were probed with an anti-caspase-2 antibody. P62, nucleoporin was used as loading control. C. mRNA
expression levels of CYP1B1, CYP51A1 and LIPA were measured using qRT-PCR in U87MG cells transfected with the indicated siRNAs against caspase-
2 or the relative control siRNAs. Data are presented as mean 6 SD; n=3. D. mRNA expression levels of CYP1B1, CYP51A1 and LIPA were measured
using qRT-PCR in IMR90-E1A cells transfected with siRNA1 against caspase-2 or the control siRNA. Data are presented as mean 6 SD; n= 3.
doi:10.1371/journal.pone.0110610.g001
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Next we focused our attention on the 17 genes up-regulated
after caspase-2 down-regulation, which could be entangled in
compensatory responses. Analysis of associated GO terms
indicated that these genes are involved in different biological
functions, including cell cycle control, inflammation and mem-
brane trafficking. Particularly, 3 of them: CYP51A1, CYP1B1 and
LIPA are linked to cholesterol metabolism. Since caspase-2
expression can be influenced by SREBPs and a previous study
proposed a role of caspase-2 in the control of cholesterol and
triacylgycerol levels [28,29], we investigated in more detail the
relationships between caspase-2 and cholesterol genes.
CYP51A1 and CYP1B1 are cytochrome P450 family members
involved respectively in cholesterol/sterol biosynthetic processes
and in the metabolism of a wide range of structurally diverse
substrates, including cholesterol [30,31]. LIPA encodes for the key
enzyme responsible for acidic hydrolysis of cholesteryl esters and
triglycerides delivered from lipoproteins to lysosomes [32].
Furthermore also PIK3R3 (phosphatidylinositol-3 kinase regu-
latory subunit p55c), LCN1 (tears lipocalin), other two caspase-2
influenced genes are in some relations with cholesterol and lipid
metabolism. The first is a target of SREBPs [33] and the second
can bind an assortment of lipids including cholesterol [34]. For all
these reasons we decided to study the relationships between
caspase-2 and CYP51A1, CYP1B1 and LIPA.
qRT-PCR analysis was performed to validate the microarray
experiments. The expression of CYP1B1 and LIPA was
augmented in U87MG cells silenced for caspase-2, whereas for
CYP51A1 the increase was minimal and not statistically significant
(Fig. 1C). To confirm these results we used a second siRNA
against caspase-2 (siRNA2) and a second control oligos, from a
different provider (Fig. 1B). The results were similar. CYP1B1 and
LIPA expression was augment in U87MG cells silenced for
caspase-2. We also investigated whether this up-regulation could
be observed in other cell lines. Figure 1D shows that only LIPA
induction can be observed in human fibroblasts expressing the
E1A oncogene after caspase-2 silencing. In this cell line CYP51A1
and CYP1B1 mRNA levels resulted unchanged. However LIPA
up-regulation was much more pronounced compared to U87MG
cells. These findings indicate that correlations between caspase-2
and cholesterol genes expression could vary in different cell types.
Figure 2. Cholesterol distribution in cells silenced for caspase-2 expression. A. U87MG cells were fixed and processed for
immunofluorescence. Epifluorescence microscopy followed by deconvolution analysis was used to visualize different subcellular compartments
and cholesterol distribution. With arrows indicate LDs and green arrows LDs encircled by lysosomes. Scale bar 40 mM. B. U87MG cells were transfected
with siRNA against caspase-2 or control siRNA as indicated. 48 h later cells fixed and stained with filipin to visualize the intracellular distribution of
cholesterol. Arrows point to LDs. Scale bar 30 mM. C. Quantitative analysis of LDs presence in U87MG and IMR90-E1A cells transfected with siRNA
against caspase-2 or control siRNA. Data are presented as mean 6 SD; n= 3.
doi:10.1371/journal.pone.0110610.g002
Figure 3. Analysis of LIPA and caspases expression in GBM and different areas of the CNS. A. Plot of CASP2 versus LIPA expression levels
in GBM. Linear regression is reported. B. Correlations in expression levels between LIPA and the indicated genes in GBM. C. Correlations in expression
levels between LIPA and the indicated genes in different CNS areas.
doi:10.1371/journal.pone.0110610.g003
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LIPA generates unesterified cholesterol, which can be used as
substrate for steroidogenesis or be re-esterified for storage in lipid
droplets by acyl-CoA:cholesterol acyl transferase [32]. The
increase of LIPA levels in cells with down-regulated caspase-2
might compensate a deficit in Srebp2-driven lipid synthesis/
accumulation in human cells, as previously suggested [29].
To understand whether mRNA levels of LIPA, CYP51A1 and
CYP1B1 are influenced by other caspases, we silenced caspase-8
expression in U87MG cells. We selected caspase-8 because, like
caspase-2, it is a regulative apoptotic caspase, and because it is
expressed in U87MG cells (Figure S1A). The designed siRNA
silenced caspase-8 expression (Figure S1B). When Caspase-8
expression was down-regulated only CYP1B1 mRNA levels were
clearly augmented. LIPA and CYP51A1 expression was not
significantly changed.
Analysis of intracellular cholesterol distribution in
caspase-2 silenced cells
Having evidences of the existence of a connection linking
caspase-2 to some genes of the cholesterol pathway, we compared
the subcellular distribution of cholesterol after labeling of IMR90-
E1A and U87MG cells with filipin. Fluorescence staining was
detectable in the plasma membrane (PM) and in intracellular
membrane structures (Fig 2A). As expected co-localization studies
using GM130, transferrin receptor and LBPA, as markers
respectively of, Golgi apparatus, late endosomal compartment
and endosomal/recycling compartment evidenced that cholesterol
can be detected in all these organelles. In addition, intense filipin
fluorescence staining was present in regular spherical structures
that do not co-localize with the used markers and that can be
identified as LDs (lipid droplets).
Next we compared filipin staining between caspase-2 silenced
and control cells. Remarkably, the number of LDs detectable in a
cell, as well as the percentage of cells holding them was reduced
after caspase-2 silencing (Fig. 2B). Quantitative analysis proved
that in both cell lines, the percentage of cells presenting LDs was
reduced after caspase-2 silencing (Fig. 2C). This observation
further indicates that down-regulation of caspase-2 could influence
in cholesterol homeostasis.
Correlation studies of LIPA and caspase-2 expression in
glioblastoma
Taking into account the complex regulative networks influenc-
ing cholesterol homeostasis in vivo, the use of the cell culture
models to investigate correlations between caspase-2 and choles-
terol genes expression is limiting. Hence, to further expand our
study we decided to interrogate public available gene expression
datasets of glioblastomas. In principle, if caspase-2 controls a
circuit that influence LIPA expression in cultured glioblastoma
cells the expression of these two genes should be inversely
correlated in tumors. Gene expression profiles from 13 datasets
including 327 microarrays of GBM were interrogated. Figure 3A
illustrates that in glioblastoma, mRNA levels for CASP2 and LIPA
evidence a weak, but significant inverse Pearson correlation (r -
0.2593; p-value 2.00E-00.6).
Since also caspase-8 down-regulation can influence the expres-
sion of certain cholesterol genes (Figure S1), we extended this study
to all caspases. as well as, to elements of the molecular platform
involved in caspase-2 activation (CRADD/RAIDD and PIDD)
[8,9]. With the exclusion of CASP1 mRNA, which level weakly
but positively correlates with LIPA, all the other caspases do not
evidence significant correlations with LIPA expression (Fig. 3B).
Concerning PIDD, its expression negatively correlates with LIPA
mRNA levels (r -0.3497; p-value 3.38E-014) in GBM.
Expression correlations between CASP2/LIPA and PIDD/
LIPA were also evaluated in normal tissues. A good and significant
inverse correlation was scored for both genes in cerebellum. On
the contrary, in the hippocampus and with lowest score in the
brain, a significant positive correlation only for CASP2/LIPA was
observed (Fig. 3C). Interestingly, differences in terms of expression
of cholesterol genes between different brain areas are known [35].
Expression correlations among caspases and cholesterol
genes in normal brain and in glioblastoma
Although in cultured cell lines we noted an inverse correlation
in terms of expression between CASP2 and LIPA, in vivo the
situation is heterogeneous, as suggested by the analysis of different
CNS (Central Nervous System) areas. Moreover, since silencing of
caspase-2 affects also other cholesterol genes, it is evident that
these correlations cannot be simply analyzed without taking into
account other genes involved in cholesterol homeostasis. For
example down-regulation of LIPA provoked the up-regulation of
several genes implicated in cholesterol biosynthesis, as compensa-
tory mechanism [36]. Therefore, we decided to investigate with a
more comprehensive approach the correlations between expres-
sion of caspase-2 and the expression of genes involved in
cholesterol homeostasis. We extended this study to all caspases
and we also included the normal tissues. Gene expression profile
data from 11 datasets including 293 microarrays of normal brain
were recovered from public available databases.
We first evaluated changes in the mRNA levels for the different
caspases between normal brain and GBM. Surprisingly the
mRNA levels of several caspases, both inflammatory (CASP1
and CASP4) and apoptotic (CASP3, CASP6, CASP7 and CASP8)
were significantly augmented in tumor samples (Fig. 4A).
Next, genes involved in cholesterol homeostasis, including
steroidogenesis were extracted from Gene Ontology (GO) and
integrated from literature data. In total we selected 256 genes, of
which 166 were grouped into 5 categories: biosynthesis, adsorption/
import, export, steroid and bile acid synthesis and transcriptional
regulators. The category export was subdivided into HDL (High
Density Lipoproteins), LDL (Low Density Lipoproteins) and
VLDL (Very Low Density Lipoproteins). At this point we
exploited microarray datasets to evaluate correlations in the
expression levels between caspases and cholesterol genes. Pearson
correlation between the expression level of each caspase and each
cholesterol gene was computed for human brain samples. Based
on the similarity in correlation patterns caspases and cholesterol
genes were hierarchically clustered using the complete linkage
method.
Figure 4. Co-expression analysis of caspases and cholesterol genes in human brain and GBM. A. Expression levels of the different
caspases in GBM and in the normal brains. Box plots depicted in red mark tumors whereas blue was used for normal brain. mRNA levels of CASP1,
CASP3, CASP4, CASP6, CASP7 and CASP8 were significantly augmented in tumor samples. p-value ,2.2e-16. B. Correlations of expression levels
between caspases and cholesterol genes in different brain and GBM samples in Cholesterol export, lipoproteins category. Data obtained were used to
calculate the correlation values with the Pearson method. In the heat map positive values are displayed in blue and negative in dark green. The
dendrograms displayed on the top are based on hierarchical clustering using the complete linkage method.
doi:10.1371/journal.pone.0110610.g004
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Cholesterol export, lipoproteins. The CNS produces its
own lipoprotein transport system that is distinct from the plasma
[37]. CASP1, 2, 8, 9, and 10 share correlations in terms of changes
in the mRNA levels with several genes involved in HDL
biogenesis. In particular expression of CASP2, 9 and 10 show
the highest correlations with APOD, APOM, APOE, APOA5,
PON1, CAV1, CAV3, ABCA1 and ABCG1 (Fig. 4B and Table
S2).
APOD and APOM are apolipoprotein belonging to the
lipocalin protein superfamily [38]. APOM expression is under
the influence of hormones and cytokines [39]. In apoM-deficient
mice plasma HDL are reduced by approximately 17–21% [40].
Moreover, APOM is an important carrier of shingosine-1-
phosphate (S1P), a signaling molecule controlling several processes
including inflammation [41]. APOD not only contributes to HDL
formation but can also act as antioxidant [42]. This function could
explain the up-regulation of APOD expression with aging in
human prefrontal cortex, as part of a protective circuit [38,43].
APOE is the major apolipoprotein for CNS HDL and is mainly
synthetized by astrocytes [37,44]. It is possible that ApoE-
containing lipoproteins are involved in delivering cholesterol to
neurons for growth, repair and synaptogenesis [37,45]. Fluctua-
tions in APOE mRNA could be related to repair. In fact, in
astrocytes ApoE synthesis increases dramatically after nerve injury
[46,47]. APOE and in particular the e4 allele is the major known
genetic risk factor for late-onset Alzheimer’s disease [48].
PON1 belongs to paraoxonase genes family and is secreted into
the extracellular environment where it binds HDL. This
antioxidant enzyme confers to HDL some of the anti-atherogenic
properties, such as HDL-mediated cholesterol efflux from
macrophages, and the inhibition of LDL oxidation [49].
Although in the brain their activities are less characterized,
ATP-binding cassette (ABC) transporters ABCA1 and ABCG1,
but also CAV1 and CAV3 mediate cholesterol efflux and play
important roles in the transfer of phospholipids and cholesterol to
apolipoproteins such as ApoE and ApoM [37,50].
In GBM expression correlations among constituents of HDL
and pro-apoptotic regulative CASP2, 8, 9, and 10 are still present
but reduced. In particular CASP2, 9 and 10 do not show
significant correlations with APOD, ABAC1 and CAV1 and also
in the case of ABCG1 the correlation is diminished. Instead,
another transporter, ABCG4 exhibits correlations.
In GBM, CASP1 reveals profound different correlations with
HDL genes and clusters together with CASP4, another inflam-
matory caspase, and the effector caspases. HDL genes showing
strongest correlations with CASP1 are APOL1, SOAT1, CAV1,
ABCA1 and PCTP. Interestingly, cholesterol efflux associates
more strongly with the expression of ABCG1 than of ABCA1 [51].
Cholesterol biosynthesis. Almost all the cholesterol found
in the CNS is produced from local biosynthesis [52]. Also in the
case of the category ‘‘cholesterol biosynthesis’’, correlation analysis
revealed that the regulative apoptotic caspases, with the addition
of CASP1 cluster together. In particular strong positive correla-
tions (Fig. 5 and Table S3) with mRNA levels of a group of genes
involved in cholesterol biosynthesis (LSS, CYB5R3, DHCR7,
MVK) emerged. By contrast, HMGCR the gene encoding for the
enzyme converting the 3-hydroxyl-3-methyl-glutarylCoA (HMG-
CoA) into mevalonate scores a good but negative correlation.
Since it represents the limiting step in cholesterol biosynthesis, the
implications of the correlations between certain enzymes of
cholesterol biosynthesis and regulative apoptotic caspases are
unclear at the moment. Significant correlations were not observed
for all the other caspases. Expression of CYP51A1 in the brain
achieves a strong inverse correlation compared to CASP2, CASP9
and CASP10. CYP51A1 encodes for lanosterol 14a-demethylase,
which in addition to being a key enzyme of the cholesterol
biosynthetic pathway [31] is also involved in the steroidogenesis
[53].
In GBM correlations among regulative apoptotic caspases and
genes involved in cholesterol biosynthesis are less evident. Again
CASP1 clustered with effector caspases in the absence of
significant correlation scores. Interestingly, CASP3 shows good
correlations with some genes involved in cholesterol biosynthesis
including HMGCR.
Cholesterol absorption/import. Lipoproteins produced by
astrocytes can be internalized, after binding to LDL receptor
superfamily by neurons and glia cells [37]. Also in the category of
absorption/import, analysis of the correlations at mRNA levels
resulted in two clusters where the regulative apoptotic caspases
plus CASP1 segregate from all the others. CASP2 CASP9 and
CASP10 show the strongest correlations with APLP2, LRP1,
LDLR, LRP2, LRP5, MSR1, LIPG, SCARF1, GPIHBP1, NPC2,
LAMTOR1 and LDLRAP1 (Fig. 5 and Table S4).
LDLR, LRP1, LRP2, LRP5 are all members of the low-density
lipoprotein receptors family [54]. These receptors can bind a large
number of extracellular ligands but a common ligand for all is the
ApoE protein, which mediates internalization and catabolism of
lipoprotein particles [55]. The LDLR is highest expressed in glial
cells than in neurons, on the opposite LRP1 is highest expressed in
neurons than in glia [56,57]. These observations suggest that
correlations with regulative apoptotic caspases are not limited to a
specific cell type. APLP2 an APP homologous can influence LRP1
expression and the toxicity mediated by beta-amyloid oligomers
[58]. LDLRAP1 encodes for an adaptor cytosolic protein that
interacts with and is involved in the endocytosis of LDLR. MSR1,
SCARF1 and SCARB1 are involved in the uptake of lipoproteins.
Endothelial lipase (LIPG) regulates the circulating level of HDL
[59]. It is expressed in different areas of the CNS including CA3
pyramidal cells of the hippocampus, ependymal cells in the ventral
part of the third ventricle [60]. LIPG is also expressed in brain
capillary endothelial cells, major constituents of the blood brain
barrier [61]. GPIHBP1, (glycosylphosphatidylinositol-anchored
high-density lipoprotein binding) can be considered a platform
for lipolysis [62] and it is also involved in the transport of
lipoprotein lipase (LPL) [63]. LAMTOR1 and NPC2 work
downstream to the internalization of lipoproteins. The first as
key regulator of endosome dynamics and lysosome biogenesis, the
second by removing unesterified cholesterol from late endosomes/
lysosomes [64,65].
It is evident that several genes involved in cholesterol and lipids
up-take show a coordinate expression with regulative apoptotic
caspases. High positive scores in terms of correlation among pro-
apoptotic regulative caspases and genes involved in cholesterol
internalization are in agreement with the negative score observed
in the case HMGCR [66]. In GBM, as above observed for other
categories, these correlations are less robust and CASP1 distinctly
Figure 5. Co-expression analysis of caspases and cholesterol genes in human brain and GBM. Correlations in terms of expression levels
between caspases and cholesterol genes in different brain and GBM samples, for the indicated categories. Data obtained were used to calculate the
correlation values with the Pearson method. In the heat map positive values are displayed in blue and negative in dark green. The dendrograms
displayed on the top are based on hierarchical clustering using the complete linkage method.
doi:10.1371/journal.pone.0110610.g005
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changes relationships with cholesterol genes, thus clustering with
the effector caspases.
Steroid and bile acid synthesis. This category collects
heterogeneous gene families. Nevertheless, the apoptotic regulative
caspases cluster again together, whereas CASP1 is here found
together with other inflammatory caspases and with the effector
caspases. TSPO, CYP7B1, CYP8B1 and CYP19A1 show the
highest positive correlation scores (Fig. 6 and Table S5).
Steroid biosynthesis begins with the transfer of free cholesterol
from intracellular stores into mitochondria [67]. TSPO encodes
for a translocator located on the outer mitochondrial membrane,
which binds cholesterol with high affinity and transfers it in the
inner mitochondrial membrane. TSPO activity is the rate-limiting
step in the synthesis of all steroids [68]. Interestingly, alterations in
TSPO expression has been found in various psychiatric disorders,
including social phobia, post-traumatic stress disorder, adult
separation anxiety and schizophrenia [69].
CYP7B1 catalyzes 7-hydroxylation of C19 and C21 steroids and
in the brain it is involved in the metabolism of neurosteroids and
oxysterols [70]. Defects of CYP7B1 in humans have been linked to
spastic paraplegia [71,72].
CYP8B1 is a sterol 12a–hydroxylase. In mice expression of
CYP7A1 and of CYP8B1 is integrated [73]. In the liver, circadian
signals can influence CYP7A, CYP8B, and CYP51A1 expression
[74].
CYP19A1 encodes for the cytochrome P450 aromatase an
enzyme responsible for the synthesis of all oestrogens from
androgen precursors [75]. Oestradiol synthesis in the brain
regulates several functions of the adult CNS, from neural plasticity
to injury responses [76]. Increased expression of CYP19A1 during
neurodegeneration could interfere with apoptotic pathways and to
decrease the extent of brain damage [77].
In glioblastoma the correlations affect other genes and are in
general attenuated. TSPO expression is not longer linked to
regulative caspases, whereas it shows positive correlations with
effectors and inflammatory caspases.
Transcriptional regulators. Finally, we investigated the
correlations among caspases and the expression of TFs (Tram-
scription Factors) involved in the control of cholesterol genes
expression. Figure 6 documents the results, which photocopy those
previously obtained with the other categories. Apoptotic regulative
caspases and CASP1 share similar relationships, in terms of
expression correlations, with transcriptional regulators of choles-
terol genes. SREBF1, SREBF2, PPARA and NR1H2 display the
highest score with CASP2, CASP9 and CASP10 (Figure 6 and
Table S6). In the case of SREBF2, Pearson correlation coefficients
with caspases were similar to those described for cholesterol genes
[78].
SREBF1 and SREBF2 (sterol regulatory element binding
proteins) are TFs that control cellular lipid homeostasis. SREBF1
encodes for two proteins Srebp1a and Srebp1c produced via
alternative transcription start sites. Srebp1c preferentially influ-
ences expression of fatty acid biosynthesis genes, whereas Srebp2 is
devoted to transcribe genes involved in cholesterol homeostasis,
lipoproteins import and lipids trafficking. Serbp1a can support
transcription of both SREBF1 and SREBF2 genes [79]. In this
respect it is interesting to note that only SREBF2 accomplishes a
good correlation with CASP2 in GBM.
PPARA belongs to the family of peroxisome proliferator-
activated receptors, which includes (PPARa, PPARb/d and
PPARc). These TFs function as obligate heterodimers with
retinoid-X receptors (RXRs). PPARa supervises energy homeo-
stasis by stimulating fatty acids and cholesterol breakdown and
gluconeogenesis [80–82]. PPARb/d is mainly engaged in fatty
acid oxidation. PPARc principal activity is to drive storage of
lipids, in particular by controlling adipocyte differentiation [83]. In
the brain PPARD is the most abundant and quite ubiquitously
expressed member, whereas PPARA and PPARG are expressed in
more restricted areas and cell types [84,85]. In addition to their
metabolic role, PPARs in the CNS have been implicated in the
control of neuronal differentiation, death, inflammation and
neurodegeneration [83]. In GBM expression correlation between
PPARA and regulative caspases are abrogated. On the other side a
good correlation between PPARG and CASP1 appears (Fig. 6).
NR1H2 (liver X receptor-beta) is another master TF orches-
trating the expression of genes of the cholesterol homeostasis [86].
Similarly to SREBF1, SREBF2 and PPARA correlations between
NR1H2 and CASP2, CASP9 and CASP10 are abrogated in
GBM. Interestingly, in GBM new correlations emerged between
the second nuclear hormone receptors liver X receptor alpha
(LXRalpha/NR1H3) and inflammatory caspases CASP1 and
CASP4.
In summary, the correlation among regulative apoptotic
caspases and certain cholesterol genes observed in this study
could be orchestrated by selected TFs, well-known master
regulators of cholesterol metabolism such as SREBF1, SREBF2,
PPARA and NR1H2.
Expression correlations among caspases and cholesterol
genes in the liver
To understand whether our discoveries are limited to CNS or
can be observed also in other tissues, we decided to compare
variations in the expression levels of caspases and of cholesterol
genes in human liver, an essential organ for cholesterol homeo-
stasis. Gene expression profiles from 5 datasets including 106
microarrays of normal human liver were interrogated. Figure 7
shows that correlations among cholesterol genes and expression of
regulative apoptotic caspases are less pronounced and only in
some categories: transcriptional regulators, cholesterol biosynthesis,
steroid and bile acid synthesis, these genes cluster together. In the
liver CASP7 reaches the highest scores both for positive and
negative correlations. For example CASP7 expression is strongly
inversely correlated with those of several apolipoprotein genes, but
it positively correlates with NPC1, VLDLR, SOAT1, SNX17 and
VPS4B (Table S7); which are genes involved in cholesterol up-take
and storage. It is important to note that similarly to caspase-2,
caspase-7 expression is under the influence of Srebp1/2 and of
statins [87].
CASP9 and CASP10 in terms of correlations with cholesterol
genes maintain in the liver a pattern resembling that remarked in
the brain and they cluster in almost all categories. By contrast
CASP2 exhibits a correlation pattern rather different from the
brain and it frequently clusters with CASP5. This observation
suggests that the correlations between caspase-2 and cholesterol
genes are related to a specific brain endeavor [88,89]. Remark-
Figure 6. Co-expression analysis of caspases and cholesterol genes in human brain and GBM. Correlations of expression levels between
caspases and cholesterol genes in different brain and GBM samples, for the indicated categories. Data obtained were used to calculate the correlation
values with the Pearson method. In the heat map positive values are displayed in blue and negative in dark green. The dendrograms displayed on the
top are based on hierarchical clustering using the complete linkage method.
doi:10.1371/journal.pone.0110610.g006
Caspases and Cholesterol Homeostasis
PLOS ONE | www.plosone.org 11 October 2014 | Volume 9 | Issue 10 | e110610
Caspases and Cholesterol Homeostasis
PLOS ONE | www.plosone.org 12 October 2014 | Volume 9 | Issue 10 | e110610
ably, several reports have proposed specific biological activities for
caspase-2 in the CNS [26,89–91].
Caspases, cholesterol genes and aging
Changes in the expression of cholesterol genes in the brain are
linked to several physiological/pathological conditions including,
regeneration, plasticity, circadian rhythms, diet, degeneration,
social behavior and also the presence of several different cell
linages [37,38,43,58,69,74,77,83,92]. To understand the signifi-
cance of the described correlations, we decided to interrogate
more precisely the public available datasets used in our studies. We
restricted our inquiries to one dataset (GSE 17612) in which,
information about the specific brain area (the anterior prefrontal
cortex/Brodmann area 10) and subjects age were available. 23
microarray of normal brain met these requirements. Age
distribution is shown in figure 8A. Cholesterol and caspase genes
were ranked accordingly to the Spearman method, respect to the
age of the subjects. Figure 8B illustrates that the expression of a set
of cholesterol genes shows a good inverse correlation respect to age
(green dots) and on the opposite, the expression of a different set of
genes increases with aging (blue dots).
Among genes, which mRNAs levels are down-regulated with
aging, we have found CYP46A1 and HMGCR (Fig. 8B and 8C).
CYP46A1 encodes for the hydroxylase, which converts cholesterol
to 24S-hydroxycholesterol and provides the major route in
cholesterol excretion from the brain [93]. In the case of HMGCR
our observations are in agreement with previous results pointing to
a decline in brain cholesterol synthesis with age [43,94,95]. On the
opposite previous study reported an up-regulation of cholesterol-
24-hydroxylase mRNA in mouse brain with aging [96]. Indeed in
their studies the authors analyzed the hippocampus from day 10
up to 21 months. After an up-regulation at 3 months, a trend to
decrease in both mRNA and protein levels of CYP46A1 can be
appreciated. In humans 24S-hydroxycholesterol levels are highest
in the first decade of life and then decline with age [97].
Furthermore, also in human brain, analysis of cholesterol 24-
hydroxylase protein evidenced some reduction during aging [98].
Undoubtedly, further studies are necessary to clarify this point.
Taking into account that mice lacking 24-hydroxylase exhibit
severe learning and memory defects [99], clarification of
CYP46A1 expression during aging is of particular interest.
We have included in this analysis also the different caspases.
Figure 8C reveals that expression of inflammatory CASP1 and
also of the effector caspases CASP6 and CASP7 positively
correlates with aging.
Several studies have indicated a contribution of caspase-6 to
neurodegeneration including Alzheimer and Huntington diseases
[100–104]. A more recent report has proposed that caspase-6
activity can predict lower episodic memory ability in aged
individuals [105]. CASP1 is a key regulator of inflammation, via
the generation of IL-1b and involved in the regulation of age-
related cognitive-dysfunctions. CASP1 genetic variations have
been associated with cognitive function [106] and several data
have linked caspase-1 to brain aging [107,108]. Deficiency in
Nlrp3 inflammasome-mediated caspase-1 activity improved cog-
nitive function and motor performance in aged mice [109].
Furthermore, caspase-1 also influences in a still undetermined
manner lipid metabolism [110].
Conclusions
Our initial aim, of discovering compensatory pathways to solve
the caspase-2 mystery has led us to unveil large and shared
correlations among different caspases and cholesterol genes.
Expression correlations studies have attracted attention to uncover
new biological circuits [111,112] and dedicated methodological
tools have been developed [113,114]. We have applied hierarchi-
cal clustering of gene expression correlations to hypothesize new
functions for caspases and caspase-2 in particular. An unexpected
finding was that the regulative apoptotic caspases (CASP9 and
CASP10 in particular) share a correlation pattern with cholesterol
genes, similarly to CASP2. The reported strong correlations
among these caspases and certain cholesterol genes in a
heterogeneous tissue, such as the human brain and in a
heterogeneous population, suggest that expression of these genes
is influenced by common signaling networks linked to specific
biological processes. Hence, expression of certain cholesterol genes
and of regulative apoptotic caspases in the brain should be under
the control of the same regulative circuits. Since in GBM these
correlations are in general less prominent, it is possible that genetic
lesions, altering proliferation also impact on cholesterol homeo-
stasis. Although the contribution of cholesterol genes to GBM
development is largely unexplored, recently a survival pathway
engaged by the LDL receptor, through the EGFRvIII/PI3K/
SREBP-1 axis has been discovered [115]. This observation
suggests that oncogenic driven changes in gene expression could
revise the harmonic co-regulation of caspases and cholesterol
genes.
This scenario is well exemplified by CASP1, which evidences
the most overt changes in terms of correlations with cholesterol
genes between brain and GBM. Taking into account that its
expression is augmented in GBM, these changes could reflect the
establishment of an inflammatory microenvironment.
When the same analysis were performed using microarray data
obtained from cultured glioblastoma cells, correlations were in
general weaker and apoptotic regulative caspases clustered
separately (data not shown). This observation indicates that
complex networks of environmental signals control the expression
of these genes. Networks that cannot be easily replaced under in
vitro culture conditions. A consideration that could explain the low
number of genes, which expression is influenced by caspase-2
siRNA in cultured glioblastoma cells.
It is evident that, correlations in terms of expression could
have different biological origins/implications: from the presence
of different cell lineages in the sample, up to different neuronal
activities, different inflammatory/degenerative states, different
cognitive functions and different hormonal signaling. We are
consciousness that this complexity deserves further experimental
work. Here we have discovered that for some caspases, in a
specific brain’s area, the correlations with certain cholesterol
genes could be related to aging. In this case the correlation
could be linked to the induction of degenerative processes. In
fact, caspase signaling engaged by the ordered activation of
caspase-8 and caspase-3/7 controls microglia activation and
neurotoxicity with implications in Parkinson’s and Alzheimer’s
diseases [116].
For other caspases, including caspase-2 the reason for this
correlation is unclear at the moment. Taking into account that
Figure 7. Co-expression analysis of caspases and cholesterol genes in human liver. Correlations of expression levels between caspases and
cholesterol genes in different liver samples, for the indicated categories. Data obtained were used to calculate the correlation values with the Pearson
method. In the heat map positive values are displayed in blue and negative in dark green. The dendrograms displayed on the top are based on
hierarchical clustering using the complete linkage method.
doi:10.1371/journal.pone.0110610.g007
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evidences sustaining non-apoptotic roles of caspases in the CNS
are accumulating [117] several hypothesis concerning caspase-2
could be formulated. Previous studies [28], here confirmed, linking
SREBFs levels to CASP2 expression suggest a direct involvement
of this enzyme in cholesterol homeostasis. Although the mecha-
nisms need to be elucidated, our data further encourage
investigating towards this direction.
Figure 8. Analysis of cholesterol and caspase genes expression with aging in anterior prefrontal cortex. A. Bar plot displaying the age
frequencies of the samples used in the analysis. B. Dot plot of ranked correlations of the 129 genes involved in cholesterol homeostasis/
steroidogenesis and caspases respect to age. C. Dot plot of ranked correlations of genes involved in cholesterol homeostasis/steroidogenesis and
caspases that scored significant expression correlation with respect to age. We applied the Spearman method (Benjamini and Hockberg correction).
P,0.05.
doi:10.1371/journal.pone.0110610.g008
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Supporting Information
Figure S1 A. Expression profiles in U87MG cells of the
different caspases. Microarray expression data were obtained
from GSE14889 [118]. B. mRNA expression levels of CASP8
were measured using qRT-PCR in U87MG cells transfected with
siRNA against Caspase-8 or a control siRNA. Data are presented
as mean 6 SD; n=3. C. mRNA expression levels of CYP1B1,
CYP51A1 and LIPA were measured using qRT-PCR in U87MG
cells transfected with siRNA against Caspase-8 or a control
siRNA. Data are presented as mean 6 SD; n=3.
(JPG)
Table S1 Genes down-regulated.1.5 fold in U87MG
cells silenced for Caspase-2.
(XLS)
Table S2 Top score cholesterol genes of the subclass
cholesterol export in terms of correlations of expression
levels with regulative apoptotic caspases in human
brain. Values are shown for all caspases.
(XLS)
Table S3 Top score cholesterol genes of the subclass
cholesterol biosynthesis in terms of correlations of
expression levels with regulative apoptotic caspases in
human brain. Values are shown for all caspases.
(XLS)
Table S4 Top score cholesterol genes of the subclass
cholesterol adsorption/import in terms of correlations
of expression levels with regulative apoptotic caspases
in human brain. Values are shown for all caspases.
(XLS)
Table S5 Top score cholesterol genes of the subclass
steroid and bile acid synthesis in terms of correlations of
expression levels with regulative apoptotic caspases in
human brain. Values are shown for all caspases.
(XLS)
Table S6 Top score cholesterol genes of the subclass
transcriptional regulators in terms of correlations of
expression levels with regulative apoptotic caspases in
human brain. Values are shown for all caspases.
(XLS)
Table S7 Top score cholesterol genes in terms of
correlations of expression levels with caspase-7 in
human liver. Values are shown for all caspases.
(XLS)
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Abstract
Emerging evidence has demonstrated that miRNA sequences can regulate skeletal myogenesis by controlling the process of
myoblast proliferation and differentiation. However, at present a deep analysis of miRNA expression in control and FSHD
myoblasts during differentiation has not yet been derived. To close this gap, we used a next-generation sequencing (NGS)
approach applied to in vitro myogenesis. Furthermore, to minimize sample genetic heterogeneity and muscle-type specific
patterns of gene expression, miRNA profiling from NGS data was filtered with FC$4 (log2FC$2) and p-value,0.05, and its
validation was derived by qRT-PCR on myoblasts from seven muscle districts. In particular, control myogenesis showed the
modulation of 38 miRNAs, the majority of which (34 out 38) were up-regulated, including myomiRs (miR-1, -133a, -133b and
-206). Approximately one third of the modulated miRNAs were not previously reported to be involved in muscle
differentiation, and interestingly some of these (i.e. miR-874, -1290, -95 and -146a) were previously shown to regulate cell
proliferation and differentiation. FSHD myogenesis evidenced a reduced number of modulated miRNAs than healthy muscle
cells. The two processes shared nine miRNAs, including myomiRs, although with FC values lower in FSHD than in control
cells. In addition, FSHD cells showed the modulation of six miRNAs (miR-1268, -1268b, -1908, 4258, -4508- and -4516) not
evidenced in control cells and that therefore could be considered FSHD-specific, likewise three novel miRNAs that seem to
be specifically expressed in FSHD myotubes. These data further clarify the impact of miRNA regulation during control
myogenesis and strongly suggest that a complex dysregulation of miRNA expression characterizes FSHD, impairing two
important features of myogenesis: cell cycle and muscle development. The derived miRNA profiling could represent a novel
molecular signature for FSHD that includes diagnostic biomarkers and possibly therapeutic targets.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is the third
most common myopathy, with an incidence of 1 in 14.000 in the
general population. Signs of FSHD become visible in an
individual’s 20’s (men) or 30’s (women) and include loss of muscle
strength in the face, shoulders, and upper arms before eventually
attaining the abdomen, legs and feet. FSHD is transmitted as an
autosomal dominant trait and it is thought to be mainly associated
to an epigenetic alteration leading to transcriptional imbalance of
the responsible genes [1,2]. Almost all FSHD patients carry
rearrangements reducing the copy number of a 3.3 kb tandemly
repeated sequence (D4Z4) located at 4q35, and containing a
conserved open reading frame for a double homeobox gene
(DUX4). D4Z4 copy number is highly polymorphic in healthy
individuals ranging between 11 and .100copies while FSHD
patients carry fewer than 11 repeats [3]. Notably, although the
number of D4Z4 repeats seems to be a critical determinant of the
age of onset and clinical severity of FSHD, patients without D4Z4
contraction (phenotypic FSHD or FSHD2) as well as healthy
individuals with D4Z4 contraction (carrier) have been also
identified [4,5]. All these observations strongly suggests that
FSHD derives from the interplay of more complex genetic and
epigenetic events than those already described; these additional
events might take place at either 4q35 or elsewhere in the human
genome.
Recently a unifying genetic model [6] that provides the
expression of D4Z4 as a major cause of FSHD has been proposed.
Another recent paper [7] defining the epigenetic regulation of
4q35 gene expression, demonstrated that D4Z4 deletion is
associated to reduced epigenetic repression by Polycomb silencing
in FSHD patients. Furthermore, DBE-T, a chromatin associated
non-coding RNA is produced selectively in FSHD patients and it
coordinates the de-repression of 4q35 genes. However, another
study evaluating a large-scale population analysis of healthy and
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Figure 1. Study design and data analysis. A) Study design: Next-generation Sequencing (NGS) on three control and three FSHD myoblast cell
lines before and after in vitro myogenic differentiation was used in order to derive miRNA modulation in: a) control myogenesis (CN myotubes vs CN
myoblasts; arrow a); b) FSHD myogenesis (FSHD myotubes vs FSHD myoblasts; arrow b); c) FSHD myoblasts versus control myoblast (arrow c), and d)
FSHD myotubes vs control myotubes (arrow d). B) Flow chart of filtering and analysis of NGS data. NGS generated a total of 1536106 high quality
reads, that were filtered for rRNA, tRNA, snRNA, snoRNA, repeat associated RNAs and intron/exon. The filtered reads (approx. 996106 reads, an
average of 86106/sample) were analyzed to derive known miRNAs (R/Bioconductor) and novel miRNAs (mireap). Differentially expressed miRNAs
between samples were derived by log2FC§2 and p-value,0.05 parameters. The homogeneity of miRNA modulation among samples was evaluated
by cluster analysis (dChip). miRNAs were then validated by qRT-PCR. Finally, target genes were predicted for modulated miRNAs and functionally
annotated by DAVID.
doi:10.1371/journal.pone.0108411.g001
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unrelated FSHD patients reports that the genetic criteria in order
to manifest FSHD (D4Z4 contraction associated with a specific
chromosomal background 4A-161-p(A)- pathogenic haplotype)
occur in 63.7% of the analyzed FSHD patients and in 1.3% of
healthy subjects [8]. Although these data certainly represent a
major advance toward the definition of the molecular basis of
FSHD, many questions on the disease etiology remain unex-
plained. Also the reported high degree of variability of the disease,
in term of onset, progression and severity strongly suggests that
other mechanism(s) linked to the 4q subtelomere and/or to other
regions of the human genome may play a role in the disease
pathogenesis.
Various recent studies have demonstrated that both FSHD
myoblasts and myotubes are characterized by an extensive gene
expression dysregulation mainly affecting the myogenesis and
including genes linked to cell cycle control, particularly G1/S and
G2/M transitions, muscle structure, mitochondrial function,
oxidative stress response, and cholesterol biosynthesis [9,10,11].
The deciphering of the molecular basis of FSHD has been
further complicated by the finding that microRNAs (miRNAs) are
involved in both control and pathological myogenesis [12,13,14].
MiRNAs are evolutionarily conserved short non-coding RNAs
(,22 nts) that regulate the stability and/or the translational
efficiency of target mRNAs. They have a very pervasive role since
it is estimated that a single miRNA has the potential to regulate
hundreds of target genes, and therefore,.90% of all human genes
could be under miRNAs regulation [15]. MiRNAs are essential for
normal mammalian development and are involved in fine-tuning
of many biological processes, such as differentiation, proliferation
and apoptosis [16,17]. Emerging evidence has demonstrated that
miRNA sequences can regulate skeletal myogenesis by controlling
the process of myoblast proliferation and differentiation, in
particular, microRNA-1, -206 and -133a/b were defined as
myomiRNAs to emphasize their crucial role in myogenesis
[18,19]. More recently, a simultaneous microRNA/mRNA
expression profiling of healthy myogenic cells during differentia-
tion allowed to identify the involvement of miRNAs in the
regulation of various biological processes such as cell cycle,
transcription, transport, apoptosis and DNA damage [20]. Given
these assumptions it was not surprising that miRNAs dysregulation
was found to be involved in muscle dysfunctions [9,12,21].
To date, miRNA studies reported for FSHD were essentially
based on the analysis of a restricted number of known miRNA
sequences, thus not allowing the derivation of the full miRNA-
based dysregulation network. To close this gap, here we report
miRNAs expression analysis, derived by next-generation sequenc-
ing (NGS), in primary muscle cells from healthy and FSHD
subjects during differentiation.
Results
Study design and NGS general results
In order to determine the entire small non coding RNAs (,
35 nts) transcriptome in control (CN) and FSHD primary
myoblast cell lines, before and after in vitro myogenic differen-
tiation, we used next-generation sequencing (NGS). Study design
was organized to allow the comparison of small non-coding RNA
expression profiles between FSHD and CN myoblasts and
myotubes (Fig. 1A, arrows c and d respectively) and of the two
differentiation processes (Fig. 1A, arrows a and b, respectively). In
order to derive biological markers (i.e. miRNA dysregulation)
commonly manifested by different affected muscle districts, we
used two FSHD primary myoblasts cell lines deriving from
rhomboid and one from ilio-psoas muscles, and three control
myoblasts from tensor fascia lata, quadriceps and vastus interme-
dius (Table S1).
As shown in the flow chart reported in Fig. 1B, small RNA
sequencing generated a total of 1536106 high quality reads.
Mature miRNAs make up the majority of sequences in the 18 to
25 nts size range (65% average), with a clear peak at 22 nts in all
samples. The average of known miRNAs per sample was of 556,
whereas un-annotated small RNAs (new miRNA candidates) per
sample were 28.
The differential expression of known miRNAs was analyzed in
the different stages of muscle differentiation by DEseq analysis.
Furthermore, in order to assess the robustness of our approach,
some of the miRNAs identified as differentially expressed were
validated by qRT-PCR using specific TaqMan miRNA assays in
primary FSHD and healthy myoblasts. For these experiments we
employed the same cell lines used for NGS and additional ones
from different muscles, including biceps and deltoid (Table S1). As
reported in Materials and Methods, the nine control and the seven
FSHD cell lines showed a highly comparable extent of Desmin-
positive cells and of myogenic markers modulation upon
differentiation (Fig. S1). Gene targets of differentially expressed
miRNAs were predicted in both control and FSHD cellular
systems by using the TargetScan algorithm. Derived gene targets
were filtered on two independent transcriptome profiling exper-
iments carried out on control and FSHD myogenesis [9,10], and
shared targets were then functionally annotated by DAVID. Novel
miRNAs were predicted by mireap and considered as novel
candidates only if detected with a mean reads of ten in at least two
out of three samples of one or more experimental groups (CN and
FSHD myoblasts; CN and FSHD myotubes).
Modulation of miRNA expression during physiological
and FSHD myoblast differentiation
We first analyzed the data regarding physiological myogenesis
(control myotubes vs control myoblasts; Fig. 1A, arrow a). Filtered
miRNA reads (mapping to miRBase v20) from the three control
myoblasts samples and the corresponding myotubes were analyzed
for differential expression by DEseq analysis, setting the log2 Fold
Change (log2FC) at $2 and p-value,0.05. From this analysis we
evidenced that during the control myogenesis 38 miRNAs showed
a modulation in their expression, and that the great majority of
them (34 out of 38) were up-regulated (Fig. 2A and B).
The hierarchical clustering analysis clearly separated prolifer-
ating from differentiated cells independently of the muscle district
used (tensor fascia lata, quadriceps and vastus intermedius). As
expected, the muscle specific miRNAs (myomiRs) hsa-miR-1,
-133a, -133b and -206, were among the most up-regulated
(Fig. 2B and Table S3). Twenty-six miRNAs were already
reported to be involved in muscle differentiation either in human
or in mouse cells, whereas 12 miRNAs, ten up-regulated (hsa-miR-
95, -146a, -874, -1246, -1290, -3164, -4488, -208a, -944 and
-3144) and two down-regulated (hsa-miR-3934 and -3165), were
not previously known to be involved in muscle differentiation. The
full list of the miRNAs modulated during control myoblasts
differentiation with corresponding FC and p-value is reported in
Table S3.
The same analysis was carried out on FSHD myogenesis
(Fig. 1A, arrow b). As shown in Fig. 3A, the DEseq analysis
evidenced the modulation of only 15 miRNAs during pathological
muscle differentiation. Even in this case the hierarchical clustering
analysis clearly separated proliferating from differentiated cells,
independently of the muscle district (Fig. 3B). The majority of
miRNAs was up-regulated (11 out of 15), including myomiR-1 and
-206, although with a FC lower than that showed in control
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myogenesis (Table S4). MyomiR-133a and -133b showed up-
regulation trend (log2FC.5) without reaching significance (p-
value = 0.33). The full list of the miRNAs modulated in FSHD
myogenesis, with corresponding FC and p-value, is reported in
Table S4. Scatter plots of the reads of modulated miRNAs (for
each control and FSHD proliferating and differentiated cell line)
are reported in Fig. S2. To further support the results obtained by
the sequencing approach, the same control and FSHD myoblast
and myotube RNAs were used to analyze the expression of
myomiRs (miR-1, miR-133a and miR-206) by qRT-PCR (Fig.
S3). In both control and FSHD myotubes, we confirmed the
general trend of myomiRs up-regulation derived by sequencing,
with the pathological samples showing a lower extent of up-
regulation than the normal ones.
Dysregulation of miRNA expression in FSHD myoblasts
and myotubes
We next performed DEseq analysis of miRNAs differentially
expressed in FSHD myoblasts and myotubes vs controls (Fig. 1,
arrows c and d). No miRNAs were found significantly dysregulated
(log2FC$2 and p-value,0.05) in FSHD versus control myoblasts
(Fig. 1, arrows c); this result was probably due to the high
variability of miRNA expression observed in myoblasts. Con-
versely, 21 miRNAs were found dysregulated in FSHD myotubes
(Table S5 and Fig. 4A), among these 12 miRNAs were up-
regulated. The hierarchical clustering analysis clearly separated
the pathological samples from the control ones and the three
analyzed samples of each group resulted homogeneous in miRNAs
dysregulation (Fig. 4B).
Figure 2. MiRNA modulation in control myogenesis. A) DEseq analysis of miRNAs differentially expressed in control myotubes vs control
myoblasts (control differentiation). MiRNAs showing a modulation with log2FC$2 and a p-value,0.05 are shown as red dots. B) Hierarchical
clustering of the 38 modulated miRNAs (34 up-regulated and 4 down-regulated) in regard to the analyzed samples. C1:MX01010MBS; C2:
MX03609MBS; C3: MX01110MBS, Control cell lines (see Table S1).
doi:10.1371/journal.pone.0108411.g002
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qRT-PCR Validation
The effective validation of deep sequencing results was
performed by the TaqMan miRNA assay on all the cell lines
listed in Table S1, including those already used for the NGS
experiment. Particularly, for myomiR-1, -133a and -206 the assay
was carried out at different time points during myogenic
differentiation (0, 3 and 7 days of differentiation) (Fig. 5A). In
control cells, the myomiRs progressively increased their expression
with the proceeding of time of differentiation, reaching the
maximum of expression at seven days, with FC values ranging
from approximately 350 folds (miR-1) to 28 folds (miR-206). In
FSHD cells myomiRs showed an up-regulation significantly lower
than that observed in controls, reaching at day seven an expression
value similar to or slightly lower than that showed by control cells
at day three. Comparable fusion indexes and expression values of
myogenic markers in healthy and FSHD myoblasts and myotubes
(see Fig. S1) support that the obtained results are not related to a
Figure 3. MiRNA modulation in FSHD myogenesis. A) DEseq analysis of miRNAs differentially expressed in FSHD myotubes vs FSHD myoblasts
(FSHD differentiation). MiRNAs showing a modulation with log2FC$2 and a p-value,0.05 are shown as red dots. B) Hierarchical clustering of the 15
modulated miRNAs (11 up-regulated and 4 down-regulated) in regard to the analyzed samples. F1:MX00409MBS; F2: MX03010MBS; F3:MX04309MBS,
FSHD cell lines (see Table S1).
doi:10.1371/journal.pone.0108411.g003
Figure 4. MiRNA dysregulation in FSHD myotubes. A) DEseq analysis of miRNAs differentially expressed in FSHD myotubes vs control
myotubes. MiRNAs showing a differential expression of log2FC$2 and a p-value,0.05 are shown as red dots. B) Hierarchical clustering of the 21
modulated miRNAs (12 up-regulated and 9 down-regulated) in regard to the analyzed samples. C1:MX01010MBS; C2: MX03609MBS; C3:
MX01110MBS, Control cell lines; F1:MX00409MBS; F2: MX03010MBS; F3:MX04309MBS, FSHD cell lines (see Table S1).
doi:10.1371/journal.pone.0108411.g004
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different extent of differentiation between control and pathological
samples.
Six additional miRNAs were evaluated for their expression by
qRT-PCR (Fig. 5B). As shown in Fig. 5 and summarized in
Table 1, the qRT-PCR assays validated about the 70% of the
analyzed NGS data. Particularly, the up-regulation of hsa-miR-
139 and hsa-miR-146b during, respectively, FSHD and control
myogenesis, and the down-regulation of hsa-miR-206 in FSHD vs
CN myotubes did not reach the statistical significance showed by
NGS results, while maintaining the same trend. On the contrary,
the up-regulation of miR-133a in FSHD myogenesis, the down-
regulation of hsa-miR-1 and hsa-miR-133a in FSHD vs CN
myotubes, and the down-regulation of hsa-miR-155 in FSHD
myogenesis already observed in the NGS analysis became
significant in the qRT-PCR analysis.
Comparison of FSHD and control myogenesis
The comparison of miRNA modulation between control and
FSHD differentiation processes is reported in Fig. 6A, where black
and striped bars identify the Fold Change of miRNAs up- and
down-regulated, respectively, in control and FSHD myogenesis.
From this comparison it was possible to derive that FSHD
differentiation lacks the modulation of 29 miRNAs, the majority of
which (27/29) was up-regulated in control differentiation (black
bars in Fig. 6A, and Fig. 6B); while six miRNAs (4 up- and 2
down-regulated) were modulated only during the FSHD differen-
tiation process (striped bars in Fig. 6A and Fig. 6B). Nine miRNAs
showed the same trend in both processes (Fig. 6A and B), but with
differences in Fold Change values. Among these, miRNAs pivotal
for the myogenic process, such as hsa-miR-1, -206 and -222, were
included. Thus, FSHD myogenesis differs from control myogenesis
for the complete (35) or partial (9) dysregulation of a total of 44
miRNAs.
Figure 5. Validation of NGS data. A) qRT-PCR analysis of myomiRs (miR-1, miR-133a and miR-206) during control and FSHD myogenesis at 0, 3
and 7 days of differentiation. B) qRT-PCR analysis of six microRNAs modulated in control and/or FSHD myogenesis. GM: growth medium; 3D: 3 days of
differentiation; 7D: 7 days of differentiation. * p-value,0.05; ** p-value,0.01; *** p-value,0.001.
doi:10.1371/journal.pone.0108411.g005
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Prediction of miRNA target genes
To understand the functional impact of miRNA dysregulation
during FSHD myogenesis we used TargetScan prediction software
to derive potentially affected targets. In order to improve target
prediction accuracy, a common approach is to combine the output
of two or more prediction algorithms, however this strategy has
been proved inefficient [20]. Therefore, we have used a single
algorithm, TargetScan, which uses many parameters to predict
target scoring without omitting miRNAs with multiple target sites
[22]. Since the binding of a miRNA to the 39 UTR of its mRNA
target predominantly act to decrease target mRNA levels [23] we
decide to essentially focalize our attention on mRNA targets
showing an opposite expression value compared to the analyzed
miRNA. Normally, this approach has been carried out on mRNA
expression profile derived by using the same cells from which the
miRNA expression profile has been derived [11,20,21]. However,
the comparison of mRNA expression profiles derived by myoblast
cell lines or biopsies from different FSHD patients and controls
clearly evidenced a certain variability in the obtained results
[5,9,10,11,24,25]. In addition, mRNA expression differences were
also found by analyzing different muscles, such as biceps and
deltoids [11]. To reduce sample variability, we filtered the
predicted mRNA targets on two chip expression data
(GSE26061 [9]; GSE26145 [10]), sharing in vitro myogenic
differentiation protocol and platform although using primary
FSHD and control cell lines different from those analyzed in this
work. Functional classes corresponding to the filtered mRNAs
were assigned by DAVID Gene Ontology Database (Table 2). As
shown in Fig. 6, control myogenesis showed the modulation of 38
miRNAs (4 down- and 34 up-regulated), whereas FSHD
myogenesis was characterized by 15 dysregulated miRNAs (4
down- and 11 up-regulated) and the lack of modulation of 29
miRNAs. Applying the rationale described above, we derived a
total of 139 and 78 down- and up-modulated mRNAs in control
myogenesis (potentially ‘‘validated’’ target, Table S6), and a total
of 37 down- and 18 up-regulated transcripts in FSHD myogenesis
(potentially ‘‘validated’’ target, Table S7). In control myogenic
differentiation, the majority of down-regulated genes belonged to
cell cycle (27 entries), DNA metabolic process (17 entries),
cytoskeleton organization (11 entries), angiogenesis (8 entries)
and signal transduction (19 entries); genes involved in cell adhesion
(9 entries), regulation of cell migration (5 entries), muscle
development (7 entries), lipid biosynthetic process (6 entries) and
response to insulin (4 entries) were found up-regulated (Table 2).
Conversely, in FSHD myogenesis genes belonging to muscle
development (3 entries) and cell adhesion (5 entries) were down-
regulated, whereas those involved in regulation of signal trans-
duction (3 entries) were up-regulated. All the identified biological
processes, except the down-regulation of cell adhesion in FSHD
samples, showed a significant p-value ranging from 3.4E-10 to
3.2E-02 (see Table 2). It is noteworthy that target genes involved
in two important biological processes of myogenesis (i.e. cell cycle
and striated muscle development) subjected to miRNA control
were, as expected, down- and up-regulated, respectively, in control
cells. In FSHD myogenesis, on the contrary, the cell cycle was not
down-regulated, and control of striated muscle development was
down-regulated. It is important to notice that this analysis did not
take into account the different FC showed by the nine miRNAs
shared by control and FSHD myogenesis.
Identification of novel miRNAs
To identify novel potential miRNAs involved in human muscle
system, the unclassified tags were further processed by mireap
(http://sourceforge.net/projects/mireap). We considered only
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tags meeting the default parameters, expressed in all experimental
groups or preferentially expressed in one or more sample groups
(i.e. proliferating vs differentiated cells, or FSHD vs control cells)
and with mean read counts per group greater than ten. By using
these criteria we identified a total of 13 novel candidate miRNA
genes. In Table S8 are reported the main features of these novel
miRNA genes, including chromosome location and genomic
organization, mfe (minimum free energy), sequence and structure
of hairpin precursor, and sequence of 5p or 3p. A summary of
these data is reported in Table 3: six miRNAs showed a
preferential expression in myoblasts (both in FSHD and control)
and four miRNAs seemed to be specific for myotubes. The
remaining three miRNAs characterized all the considered groups
(both control and FSHD myoblasts and myotubes). Among the 13
Figure 6. Comparison of miRNA modulation in control and FSHD myogenesis. A) Black and striped bars identify the Fold Change of
miRNAs modulated respectively, in control and FSHD myogenesis. Bars on the left and on the right represent, respectively, down- and up-regulated
miRNAs. *hsa-mir-208a showed infinite FC value (see Table S3). B) Venn diagram showing the number of miRNAs unique to FSHD (white) or control
(grey), and shared (light grey) by FSHD and control differentiation processes.
doi:10.1371/journal.pone.0108411.g006
MiRNA Expression in Control and FSHD Myogenesis
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e108411
novel miRNAs, two miRNAs (namely hsa-miR-m1-3p and hsa-
miR-m13-5p) had already been detected by analyzing prostate and
breast tumor cells [26,27] and the mature hsa-mir-m9-3p showed
100% sequence similarity with hsa-mir-574 whose gene however
differs in genomic location [28].
Furthermore, it is interesting to note that no sample showed
reads generated from the D4Z4 region. This observation, derived
either by the analysis of the filtered out repeats or by the re-
mapping NGS raw data to specific D4Z4-bearing chromosome
regions such as 4q and 10q, suggests that short transcribed
sequences from D4Z4 array may have a length greater than
35 nts, the threshold used to build our libraries.
Discussion
The paper reports the first complete analysis of miRNA
modulation during in vitro differentiation in both control and
FSHD-derived myogenic cells. Myogenesis is a complex process
that includes proliferation, differentiation, and formation of
myotubes and myofibers. These molecular events are regulated
by myogenic factors and miRNAs. MiRNAs specifically expressed
in skeletal and cardiac muscles are called myomiRs, to imply their
important roles in the regulation of muscle development and
differentiation [13,19,29]. Recently miRNA dysregulation has
been reported in FSHD [9,12,21]. However, due to the
approaches used, these studies were limited for the number and
type of miRNAs that could be simultaneously investigated; in
addition they would not detect miRNAs expressed at low level and
excluded discovery of novel miRNAs. Thus, to get the whole
pattern of miRNA dysregulation in FSHD we used a next-
generation sequencing (NGS) approach. Previous work aimed at
identifying biomarkers in FSHD by the transcriptional profiling
found muscle-type specific patterns of gene expression [11].
Similarly, DUX4-fl expression was found to vary between
myotubes derived from different muscle groups [30]. Therefore,
we tailored the experimental protocol to derive FSHD and control
miRNA profiles common to different muscles. To this aim, due to
inter-individual genetic heterogeneity, from deep sequencing data
we considered only miRNA modulation with FC$4 (log2FC$2)
and p-value,0.05. Then the derived miRNA expression in both
FSHD and control myogenesis was validated by qRT-PCR in all
the available FSHD and control cell lines.
Control myogenesis showed the modulation of 38 miRNAs, the
majority of which (34 out 38) were up-regulated. The up-regulated
miRNAs included those previously identified as key regulators of
both proliferation and differentiation of myogenic cells and for this
reason called myomiRs: hsa-miR-1, -133a, -133b and -206
[19,31,32]. The obtained results are in agreement but also expand
what is known about miRNA modulation during in vitro human
myogenic differentiation. Among the modulated miRNAs, 27
were in fact already reported to be involved in muscle
differentiation either in human or in mouse cells [20,33].
Conversely, 12 miRNAs, ten up-regulated (hsa-miR-95, -146a, -
874, -1246, -1290, -3164, -4488, -208a, -944 and -3144) and two
down-regulated (hsa-miR-3934 and -3165), were not previously
detected to be differentially expressed during control myogenesis.
In comparison with a previous work [20], the reduced number of
modulated miRNAs during control myogenesis that we derived is
probably due to the choice of higher FC value (FC$4).
Furthermore, the observed up-regulation of myomiRs strongly
supports the validity of used cell lines and differentiation protocol.
Interestingly, some up-regulated miRNAs not previously reported
to be involved in muscle differentiation, were previously shown to
affect cell proliferation by targeting HDAC1 (hsa-miR-874),
impairing cytokinesis (hsa-miR-1290), inhibiting cell growth (hsa-
miR-95) and regulating differentiation of smooth muscle cells (hsa-
miR-146a) [34,35,36,37].
Control myogenesis also showed the possible involvement of
some of the novel miRNAs we derived by NGS. In this regard, six
out of the 13 identified novel miRNAs (see Table 3) seem to
characterize the proliferating status of muscle cells (myoblasts,
miR-m2-3p, -m3-3p, -m4-5p, -m7-5p, -m12-3p, and –m13-5p)
and one the differentiated status (myotubes, miR-m6-3p). Two,
hsa-miR-m1-3p, and hsa-miR-m13-5p, have been previously
identified by the NGS approach and validated in breast and
prostate cancer cells (identified respectively as hsa-miR-B19 and
hsa-novel-miR-08) [26,27]. Further experiments are thus neces-
sary to validate and determine the possible involvement in muscle
cells differentiation of these novel miRNAs.
The comparison of control and FSHD myogenesis clearly
evidenced a reduced number of modulated miRNAs in FSHD
than in control muscle cells, thus suggesting that a complex
dysregulation of miRNA expression characterizes the dystrophy.
In total, nine miRNAs were shared between the two processes and
Table 2. Functional classification of predicted target genes in control and FSHD myogenesis.
Biological processes CONTROL MYOGENESIS FSHD MYOGENESIS
Down (p-value) Up (p-value) Down (p-value) Up (p-value)
Cell cycle +(3.4E-10)
DNA metabolic process +(2.8E-06)
Cytoskeleton organization +(2.7E-03)
Angiogenesis +(1.2E-03)
Signal transduction +(8.2E-03) +(3.2E-02)
Cell migration +(6.0E-03)
Cell adhesion +(1.2E-02) +(7.4E-02)
Striated muscle development +(1.6E-02) +(5.8E-03)
Sterol biosynthetic process +(1.0E-02) +(5.0E-04)
Response to insulin +(3.4E-03)
Functional classification of predicted target genes of modulated miRNAs in control and FSHD myogenesis, filtered on GSE26061 [9] and GSE26145 [10]. For full lists of
considered miRNAs and predicted target genes refer to Tables S3, S4 and S6, S7, respectively.
doi:10.1371/journal.pone.0108411.t002
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these included myomiR-1 and -206, with FC values of up-
regulation during differentiation lower than those derived for
control cells. Moreover, qRT-PCR analysis proved that in control
cells the up-regulation of myomiRs is higher than in FSHD ones
by a FC ranging from 2.4–5.56 for hsa-miR-206 and 133a to 136
for hsa-miR-1. Furthermore, the kinetic of myomiRs up-regulation
during FSHD myogenesis strongly suggests a defect in late stages
of the differentiation process. Other differences between control
and FSHD differentiation are represented by six miRNAs (i.e. hsa-
miR-1268, -1268b, -1908, 4258, -4508- and -4516) not modulated
in control cells and that therefore could be considered FSHD-
specific, likewise three novel miRNAs (hsa-miR-m5-5p, hsa-miR-
m10-5p and hsa-miR-m11-5p) that seem to be specifically
expressed in FSHD myotubes (see Table 3). Of interest, hsa-
miR-1268 exhibited a significant differential expression during the
differentiation of pluripotent human embryonic stem cells into
embryoid bodies [38]. In summary, FSHD myogenesis differed
from control myogenesis by the loss of modulation of 29 miRNAs
(black bars in Fig. 6A, and Fig. 6B) and the acquisition of
modulation of six miRNAs, two down-regulated and four up-
regulated (striped bars in Fig. 6A, and Fig. 6B). Among the nine
miRNAs shared by the two differentiation processes (black and
striped double bars in Fig. 6A), the myomiRs showed a significant
deficit of expression in late phases of FSHD differentiation.
Moreover, the comparison of miRNA expression between control
and FSHD myoblasts or myotubes detected 21 dysregulated
miRNAs only in myotubes (12 up-regulated and 9 down-
regulated). The lack of differentially expressed miRNAs in FSHD
myoblasts may be explained both by a high variance of miRNA
expression showed by myoblasts and by the high FC used.
Some discrepancies between the data we derived and those
recently reported in a similar cellular system [21] require several
considerations. First, the methodological approach (NGS against
transcriptome profiling), and consequently the cut-off used make
the results obtained not comparable; second, both healthy and
FSHD myoblast cell lines characterized by a high percentage of
DES+ cells were induced to differentiate for three days [20] and
for seven days (herein). Lastly, our study design was set up in order
to derive a FSHD miRNA profiling possibly shared by different
muscle districts and including all the microRNAs present in
miRBase (release 20), as well as novel miRNAs. In this regard, it is
noteworthy that if we had used the microRNA panel version 1.0 (a
TaqMan low density array containing 365 miRNAs) instead of the
NGS approach, we would have only detected the modulation of
five miRNAs during differentiation of FSHD myoblasts (namely
hsa-miR-1-1, 1-2, -206, -222 and -139), instead of the fifteen
effectively found (see Table S4). Thus, as previously shown in
other cellular systems [26,27,39,40] the deep sequencing approach
allowed us to derive a more complete view of miRNA
dysregulation in FSHD.
Our data strongly suggest that, in addition to the recently
reported up-regulation in proliferating FSHD vs control cells,
which however did not result in a complete down-regulation of the
corresponding target genes [21], a defect of myomiRs expression
also characterize late stages of FSHD differentiation. In fact, the
extent of myomiRs expression in FSHD cells after seven days of
differentiation was similar to or lower than that found at three days
in control cells. Thus, besides the reported up-regulation of
myomiRs in FSHD myoblasts due to the early euchromatization
of their promoters [21] other defects could be responsible of their
down-regulation during late stages of differentiation. In this regard
it is possible to hypothesize a defect in FSHD myotubes at the
myomiRs transcriptional or post-transcriptional levels, such as a
decrease of myogenic differentiation factors controlling their
transcription (i.e. MEF2) [41], or of factors controlling their
processing. The latter hypothesis agrees with previous results
showing that FSHD myotubes are characterized by the down-
Table 3. Novel miRNAs predicted by mireap.
Name Chromosome location Mature miRNA sequence Length
Genomic
context
Expression
n.samples Other evidence
hsa-miR-m1-3p chr11:122022800–122022877 AAAAGGGGGCTGAGGTGGAGG 21 intronic 12/12 (higher
expression in
myoblasts)
PMID:21346806
hsa-miR-m2-3p chr11:125757935–125758025 AGGGGCGCGGCCCAGGAGCTCAGA 24 intronic 5/6 myoblasts no
hsa-miR-m3-3p chr13:111102986–111103008 AGCTGGGGATGGAAGCTGAAGCC 23 intronic 4/6 myoblasts no
hsa-miR-m4-5p chr14:74998697–74998789 CTGCTCTGATGTCTGGCTGAGC 22 intronic 5/6 myoblasts No
hsa-miR-m5-5p chr15:41592311–41592403 ATCATTTGGCAGGGGGTAGAGTA 23 intergenic 3/3 FSHD
myotubes
No
hsa-miR-m6-3p chr15:45493361–45493452 TTGTGGAAACAATGGTACGGCA 22 overlaps repeat/tRNA 4/6 myotubes No
hsa-miR-m7-5p chr17:8042708–8042779 GAGTTAGCGGGGAGTGATATATT 23 overlaps repeat/tRNA 4/6 myoblasts No
hsa-miR-m8-3p chr:6:28918819–28918903 TCGGGCGGGAGTGGTGGCTTTT 22 overlaps repeat/tRNA 12/12 No
hsa-miR-m9-3p chr8:79679467–79679541 TGAGTGTGTGTGTGTGAGTGTGA 23 intronic 9/12 (all groups) mature miRNA identical
to hsa-mir-574, different
genomic location
PMID:17604727
hsa-miR-m10-5p chrX:18651329–18651427 AACTTTGGAATGTGGTAGGGTA 22 intronic 3/3 FSHD
myotubes
No
hsa-miR-m11-5p chrX:40478974–40479066 ATCATTTGGCAGGGGGTAGAGTA 23 intergenic 3/3 FSHD
myotubes
No
hsa-miR-m12-3p chr13:111102941–111103018 AGCTGGGGATGGAAGCTGAAGCC 23 intronic 4/6 myoblasts No
hsa-miR-m13-5p chr20:3194751–3194835 CAAAATGATGAGGTACCTGATA 22 Intronic 6/6 myoblasts PMID:21152091
doi:10.1371/journal.pone.0108411.t003
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regulation of a gene (Dicer1) controlling the cytoplasmic matura-
tion of pre-miRNAs [10].
Our data allowed us to confirm a few miRNAs previously found
dysregulated by independent analysis of ten major skeletal muscle
disorders, including FSHD [12,42]. Among the miRNAs we
derived to be deregulated during FSHD muscle differentiation,
four miRNAs (miR-146a, -146b, -155, -222) were consistently
found up-regulated in six or more muscular disorders, including
FSHD, whereas miR-501 was found dysregulated in five muscle
diseases, but not in FSHD. Furthermore miRNA-486, a muscle
enriched miRNA, previously found significantly reduced in
patients with DMD [12], was found up-regulated in the present
study. Interestingly overexpression of this miRNA in mouse
primary myoblasts resulted in increased proliferation and thus in
altered cell-cycle kinetics [43].
In order to understand the functional outcome of miRNA
dysregulation in FSHD, the derived up- and down-regulated
target genes were functionally clustered into biological processes.
This approach when applied to healthy muscle differentiation
evidenced two important features of myogenesis: cell cycle and
muscle development. Effectively, as muscle differentiation pro-
ceeds, sustained by the up-regulation of myogenic markers (due to
the down-regulation of the corresponding miRNA regulators), the
cell proliferation program must slow down due to the up-
regulation of miRNA controlling genes involved in this process.
An opposite trend of the two biological processes was found to
characterize FSHD myogenesis. In fact, down-regulated genes
were essentially involved in the regulation of striated muscle tissue
development, and no regulation of cell cycle was observed. Thus in
FSHD cells miRNA dysregulation affects two important aspects of
differentiation leading to a defect in myogenesis. These data are in
agreement with previously reported studies [9,10,20].
By the NGS approach we derived that FSHD myogenesis is
characterized by a profound dysregulation of miRNA expression
showing the involvement of at least 38 known miRNAs, including
the myomiRs and possibly three novel miRNAs, but excluding
small RNAs previously reported to derive from the D4Z4 array
[14]. This and previous works have clearly demonstrated that
FSHD cells are characterized by a global dysregulation of mRNA,
miRNA and protein expression essentially affecting the myogenic
process [9,10,11,21,24,44].
The up-regulation of the last DUX4 gene in individual showing
a reduced numbers (#8) of D4Z4 repeats at 4q35 combined with a
specific molecular signature (4A(159/161/168) DUX4 polyade-
nylation signal (PA) haplotype) is supposed to underlie FSHD
pathophysiology [6]. However, it has been recently reported that
1.3% of healthy individuals carry the same molecular signature
and 19% of subjects affected by FSHD do not carry alleles with
eight or fewer D4Z4 repeats [8]. Furthermore, a dysregulation of
genes involved in myogenesis has been recently observed in FSHD
fetuses; importantly, the DUX4-fl pathogenic transcript was
detected in both FSHD and control samples [45], as well as in
unaffected individuals, but not in all FSHD cases [8]. These data
suggest that the molecular basis of FSHD might not be simply
based on the overexpression of the single DUX4 gene, but rather
from a cascade of dysregulation mediated by the D4Z4 array
contraction. This structural alteration, as previously shown, might
induce conformational changes in the 4q35 region itself, and
perhaps elsewhere in the human genome [46,47]. Furthermore, in
the dysregulation cascade could also play a role lncRNAs, such as
DBE-T [7].
Conclusions
By using the NGS approach, we derived the complete pattern of
miRNAs regulating in vitro control and FSHD myogenesis. In
addition to confirming previously reported FSHD-related miR-
NAs, we identified additional known and novel miRNAs that are
differentially expressed between FSHD and control myogenesis
and thus potentially contributing to the FSHD pathogenic
mechanism. In general, the comparison of control and FSHD
myogenesis reveals that the dystrophy is characterized by a
complex alteration of miRNA expression, which also includes the
significant down-regulation of myomiRs at late stages of differen-
tiation, thus essentially affecting muscle differentiation and
development.
Thus, the full range of molecular alteration(s) at the basis of
FSHD is not yet fully deciphered and the miRNA profiling we
derive could represent a novel molecular signature for FSHD that
includes diagnostic biomarkers and possibly therapeutic targets.
Materials and Methods
Cell lines
Primary FSHD and control cell lines were obtained from
Myobank-AFM (Institut de Myologie-Groupe Hospitalier Pitie´-
Salpetrie`re, Paris) and Boston Biomedical Research Institute
(BBRI, Senator Paul D. Wellstone Muscular Dystrophy Cooper-
ative, Research Center for FSHD). Six cell lines derived from
biopsies of different healthy and FSHD muscles including vastus,
tensor fascia lata, quadriceps femoris (controls) and ilio-psoas and
rhomboid (FSHD) (Table S1) were used for deep small RNA
sequencing. In addition, to these cell lines, five control and four
FSHD cell lines from deltoid and biceps [48] (Table S1) were used
to validate deep sequencing data by qRT-PCR. FSHD primary
cell lines were derived from biopsies of mild or not affected
muscles and showed a D4Z4 array contraction ranging from 5.9 to
28 kb as determined by Southern Blot after EcoRI/BnlI digestion.
The results reported below were derived by the analysis of all the
cell lines listed in Table S1, comprising nine controls and seven
FSHD and thus including also the cells used for NGS. Control and
FSHD myoblasts were at low population doubling (from 2 to 7)
and highly comparable for the expression of the muscular marker
Desmin (96–97%) and the proliferation marker Ki67 (62–65%), as
determined by immunofluorescence (Fig. S1). Furthermore,
control and FSHD cell lines showed a comparable extent of
differentiation as demonstrated by the down-regulation of the
proliferation marker Ki67 (by immunofluorescence) and of MYF5
(by qRT-PCR), and by the up-regulation of MYOG (by qRT-
PCR), MYOD (by Western blot) and MHC (by qRT-PCR and
Western blot), as well as a comparable extent of fusion index (40–
45%) (Fig. S1). In addition, FSHD and control myoblasts and
myotubes appeared similar when analyzed by immunofluores-
cence. The cell lines used for NGS originated results in the average
comparable to those shown in Fig. S1. Cells were cultured as
described in guidelines of BBRI and Cheli et al [9].
Immunofluorescence, image acquisition and analysis
Cell immunofluorescence was performed as described [49], with
antibodies specific for Desmin (rAb, Sigma Aldrich), ki67 (rAb,
Vector) and sarcomeric myosin MHC (MF20, from Developmen-
tal Studies Hybridoma Bank). Appropriate secondary antibodies
conjugated with Alexa 488 (green, Cell Signalling) or Alexa 568
(red; Cell Signalling) were used for fluorescence detection, Nuclei
were stained with Hoechst Stain Solution (H6024, SIGMA).
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Fluorescent images were taken on confocal laser scanning
microscope (Zeiss Lsm 01, Biorad mrc 600, Biorad 1024) using
126magnification. Images showing double or triple fluorescence
were separately acquired using appropriate filters, and the
different layers were merged with ImageJ software.
For all control and FSHD cell lines used in this study, the
quantification of Desmin and ki67 positive cells has been
performed on myoblasts and myotubes. Furthermore, for all
control and FSHD cell lines, the absolute fusion index has been
calculated as the percentage of MHC-positive nuclei over total
number of nuclei after 7 days in differentiation medium.
An average value was determined by counting cells (200–300
cells/field) in at least 5 microscopic fields per sample at 126
magnification.
RNA isolation and deep sequencing
Total RNA was isolated with the mirVana miRNA isolation kit
(cat.# AM1560, Life Technologies) from myoblast cell lines
derived from 3 FSHD patients and 3 control subjects, before and
after in vitro differentiation. RNA was quantified by Nanodrop
spectrophotometer (Thermo Scientific) and its integrity was
evaluated on an Experion automated electrophoresis system
(Bio-Rad); all samples had a RNA Quality Indicator (RQI) value
$9.
20 micrograms of total RNA were used for PAGE purification
of small RNA molecules shorter than 35 nucleotides, adaptor
ligation, and small RNA library preparation. The obtained
libraries were sequenced on a HiSeq 2000 platform (Illumina) at
BGI, Hong Kong, giving approximately 12 million high quality
reads per sample (submitted to SRA database under acc. number
SRP034654).
Sequencing data analysis
MicroRNA differential expression analysis was performed using
R/Bioconductor, by following the workflow implemented in the
oneChannelGUI interface [50,51]. Briefly, adaptor sequences
were trimmed from fastq files using a specific perl script, and then
sequences were aligned to the reference human miRBase v.20
precursor dataset (www.mirbase.org) using bowtie 1.0.0. Data
were filtered for count threshold (.8 reads in 50% of samples
analyzed) and pairwise comparisons of differential miRNA
expression were performed using DEseq (log2FC§2; p-value,
0.05). Hierarchical clustering of differentially expressed miRNA
was performed with dChip (version 2010.01; https://sites.google.
com/site/dchipsoft/).
Identification of novel miRNAs
After excluding all reads that matched known small RNA classes
annotated in miRBase v.20 (known miRNAs) and Rfam (e.g.
tRNA, snRNA, snoRNA), putative novel miRNAs were predicted
using mireap (http://sourceforge.net/projects/mireap/). The
program predicts novel miRNAs from deep sequenced small
RNA libraries by taking into consideration miRNA biogenesis,
sequencing depth, and structural features (hairpin structure and
stability) to improve the sensitivity and specificity of miRNA
identification. Among predicted novel miRNAs, we considered as
plausible candidates those matching the following criteria: 1) the
detection in several samples (at least 2 out of 3 samples of one or
more experimental groups); 2) the mature miRNA had sufficient
sequence support (at least a mean of 10 reads for each
experimental group); 3) the sequence did not match to known
miRNAs in miRBase v.20.
Quantitative Real-time PCR
Quantitative RT-PCR (qRT-PCR) analysis was performed on
7900 HT Fast Real-Time PCR System (Applied Biosystems) by
TaqMan small RNA Assays to validate the miRNA sequencing
data. The miRNA specific probes were from Applied Biosystems.
150 ng RNA was reverse transcribed by TaqMan MicroRNA
Reverse Transcription Kit (cat.# 4366596; Applied Biosystems) at
16uC for 30 min, 42uC for 30 min and 85uC for 5 min. Each
amplicon was analyzed in duplicate in 96-well plates. TaqMan
small RNA Assays reactions were performed following manufac-
turer’s protocol (cat.# 4440048; Applied Biosystems). RNU48 was
used for normalization. Thermal cycling conditions for real time
PCR were 2 min at 95uC, followed by 40 cycles at 95uC for 10 s
and 60uC for 30 s. Results were analyzed using the comparative
22DDCt method. qRT-PCR experiments for MYF5, MYOG,
MHC and GAPDH gene expression analysis were performed as
described [9]. The statistical analysis was performed using a two-
tail unpaired t-test and the error bars on the graphs are referred to
standard deviation. qRT-PCR probes and primers are listed in
Table S2.
Derivation of target genes
The putative miRNAs target genes were predicted by
TargetScan Human (http://www.targetscan.org/) [52]. The
prediction tool is based on different parameters such as
complementarity to the seed region, 39 complementarity, local
AU content, position contribution and conservation in different
species [22]. Predicted target genes were then filtered on the basis
of their inverse correlation with the expression of mRNAs of two
different chip analysis on Affymetrix human exon 1.0 ST array
[9,10], using a FC$1.5 and a p-value,0.05.
Pathway and functional annotation analysis
The derived predicted target genes, inversely correlated to the
miRNAs expression, were subjected to the analysis of Gene
Ontology terms (biological processes) by DAVID (Database for
Annotation, Visualization and Integrated Discovery, v6.7) [53,54].
The target genes were mapped to the GO annotation dataset, and
the enriched biological processes were extracted using the EASE
score, a modified Fisher exact p-value.
Protein extracts and Immunoblot analysis
Cells were collected in RIPA Buffer (50 mM TrisHCl pH=7,4,
150 mM NaCl, 0,1% SDS, 0,5% Deoxycholate Sodium, 1% NP-
40 and protease inhibitor cocktail 1X-cat.# P2714-1BTL, Sigma
MO, USA), and centrifuged 15 minutes at 13000 rpm at 4uC to
discard cellular debris. Sample preparation and Western blot
analyses were performed as described in Pisconti et al [55]. After
electrophoresis, polypeptides were electrophoretically transferred
to nitrocellulose filters (Thermo Scientific) and antigens revealed
by the respective primary Abs and the appropriate secondary Abs,
through autoradiography using enhanced chemiluminescence
(LiteAblot Plus, cat.# EMP011005, Euroclone). In Western blot
analyses, primary antibodies against MHC (MF20, from Devel-
opmental Studies Hybridoma Bank), MYOD (cat.# sc-31942,
Santa Cruz) and housekeeping gene GAPDH (cat.# G8795;
Sigma) were used.
Supporting Information
Figure S1 Characterization of control and FSHD myoblasts cell
lines. A) Example of immunostaining experiment on proliferating
and differentiated primary myoblasts (control: MX01010MBS;
FSHD: MX04309MBS). Images have been taken at confocal laser
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scanning microscope at 126 magnification. Nuclei were stained
with Hoescht (blue). Panels I–IV show localization of Desmin and
Ki67 in proliferating myoblasts; panels I–II show immunostaining
experiment using the polyclonal anti-Desmin (red); panels II–IV
show immunostaining experiment using the polyclonal anti-Ki67
(red). Panels V–VIII show co-localization of Desmin or Ki67 and
MHC on differentiated primary myoblasts: panels V–VI show
immunostaining with polyclonal anti-Desmin and monoclonal
anti-MHC (Ab-Desmin-red and Ab-MHC-green); panels VII–
VIII show immunostaining with polyclonal anti-Ki67 and
monoclonal anti-MHC (Ab-Ki67-red and Ab-MHC-green). Scale
bar = 100 mm. B) Percentage of Desmin and Ki67 positive cells in
myoblasts and myotubes after 7 days of differentiation derived
from immunostaining with appropriate antibodies (Ab-Desmin
and Ab-Ki67). Results are expressed as mean6SD of independent
experiments performed on all cell lines described in Table S1. C)
Absolute fusion index was determined at day 7 of differentiation
(D7), counting the percentage of MHC- positive nuclei over the
total number of nuclei. An average value was determined by
counting cells in at least 5 microscopic fields (200–300 cells/field).
Results are expressed as mean6SD of independent experiments
performed on all cell lines (see Table S1). *p,0.05. D) Myogenic
differentiation was evaluated by qRT-PCR analysis for MYF5,
MYOG, MHC expression. All data points were calculated in
triplicate as gene expression relative to endogenous GAPDH
expression. Data are represented as the mean6SD of independent
experiments performed on all cell lines described in Table S1.
GM: growth medium; 7D: seven days of differentiation. *p,0.05,
**p,0.01. E) Example of Western blot analysis with specific
antibodies against MYOD and MHC in control and FSHD
myoblasts at different time points during myogenic differentiation
(GM: growth medium; 3D: three days of differentiation; 7D: seven
days of differentiation). GAPDH protein level was used as an
internal loading control. Graphs show mean values 6SD obtained
from the ratio of densitometric values of protein/GAPDH bands.
Data are representative of independent experiments performed on
all cell lines described in Table S1. The Western blot in E shows a
representative experiment (control: MX01010MBS; FSHD:
MX04309MBS). *p,0.05, **p,0.01.
(TIF)
Figure S2 Scatter plots of the reads of miRNAs modulated in
control and FSHD myogenesis. C1: MX01010MBS; C2:
MX03609MBS; C3: MX01110MBS, Control cell lines;
F1:MX00409MBS; F2: MX03010MBS; F3:MX04309MBS,
FSHD cell lines (see Table S1).
(PDF)
Figure S3 Authentication of NGS data by qRT-PCR. qRT-
PCR analysis of myomiRs (miR-1, miR-133a and miR-206)
during control and FSHD myogenesis at 0 and 7 days of
differentiation on the three control and three FSHD cell lines used
in the NGS experiment (MX01010MBS; MX03609MBS;
MX01110MBS, MX00409MBS; MX03010MBS;
MX04309MBS). GM: growth medium; 7D: seven days of
differentiation. *p,0.05; **p,0.01.
(TIF)
Table S1 Primary myoblasts cell lines used in this study. Cell
lines have been obtained from Myobank-AFM Istitut de Myologie
(Paris)*and Boston Biomedical Research Institute (BBRI, Boston).
(XLSX)
Table S2 Taqman probes and primers used in qRT-PCR
experiments.
(XLSX)
Table S3 List of microRNAs modulated in control myogenesis
resulting by DEseq analysis.
(XLSX)
Table S4 List of microRNAs modulated in FSHD myogenesis
resulting by DEseq analysis.
(XLSX)
Table S5 List of microRNAs modulated in FSHD vs control
myotubes resulting by DEseq analysis.
(XLSX)
Table S6 Potentially ‘‘validated’’ targets. List of predicted target
genes of miRNAs modulated in control myogenesis, filtered on
GSE26061 [9] and GSE26145 [10].
(XLSX)
Table S7 Potentially ‘‘validated’’ targets. List of predicted target
genes of miRNAs modulated in FSHD myogenesis, filtered on
GSE26061 [9] and GSE26145 [10].
(XLSX)
Table S8 Novel miRNAs predicted by mireap.
(XLSX)
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ABSTRACT: Bis-arylidenecycloalkanones structurally related to the nonselective isopeptidase inhibitor G5 were synthesized
and tested for cytotoxic activity against glioblastoma cells. Cytotoxicities correlate well with Hammett σ constants for substituted
arylidene groups, confirming the proposed inhibition mechanism. A new inhibitor (2c) based on the 4-hydroxycyclohexanone
scaffold, which favors apoptosis over necrosis, was selected for further development. 2c inhibited representative deubiquitinases
with micromolar IC50, and its proapoptotic activity was studied on several cancer cell lines. Inhibitor 2c was conjugated to PEG
via dicarbamate and diester linkers. While the dicarbamate was inactive, the diester (2cPE) behaves like a prodrug and is
converted into the active species 2c by secreted esterase activities. Finally, 2cPE was also tested in vivo on A549 lung carcinoma
xenografts generated in mice. Intravenous treatment with 2cPE led to a significant reduction in primary tumor growth, without
appreciable toxicity to mice.
■ INTRODUCTION
Protein modification by the addition of the 8 kDa ubiquitin or
Ub-like (Ubl) proteins is a well-known and widespread post-
translation modification not limited to influencing protein
destruction but also their subcellular localization or the
assembling into multiprotein complexes.1−3 Ub and Ubl
peptides are generally ligated to proteins by the sequential
action of three enzymes: a ubiquitin-activating enzyme (E1), a
Ub-carrier enzyme (E2), and a Ub-protein ligase (E3). E3
enzymes show specificity in substrate choice and represent
critical players in several signaling pathways.3,4
Ub and Ubl linkages are reversible, and their cleavage entails
the involvement of a large family of enzymes, known as
isopeptidases. Although isopeptidases can be viewed as E3-
ligase antagonists, additional functions, such as maturation of
Ub or Ubl peptides, are under their supervision. The
isopeptidase family includes deubiquitinating enzymes
(DUBs), which in principle should be specifically devoted to
the rupture of Ub linkages, and other proteolytic enzymes,
which target additional Ubl proteins.5,6
The discovery of bortezomib7 and its approval for the
treatment of relapsed multiple myeloma and mantle cell
lymphoma has opened the field to new inhibitors targeting,
more specifically, critical enzymes of the ubiquitin−proteasome
system (UPS) and showing less adverse side effects.8,9 In this
scenario E3 ligases and DUBs/isopeptidases have gained
increasing attention as targets for drug development. These
enzymes represent good candidates to influence the function of
proteins controlling the transformed phenotype or to induce
cellular stresses, which can kill cancer cells.9−12
In the past decade several reports have described the
discovery, synthesis, and characterization of isopeptidase
inhibitors.13−23 On the basis of the specific target selectivity,
they can be divided into two classes: selective inhibitors, acting
on a specific enzyme or on a limited number of enzymes, and
nonselective isopeptidase inhibitors (N-SIIs), which in principle
can affect the activity of several isopeptidases. The two classes
offer different and complementary advantages for the develop-
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ment of new anticancer treatments. The first class guarantees
advantages in terms of selectivity when growth/survival of a
specific tumor depends on a specific isopeptidase. On the other
hand, the second class, affecting more enzymes and multiple
pathways, may offer advantages in terms of effectiveness on
different tumors. Hence, further studies to improve the
antineoplastic activities of inhibitors of both classes are of
primary importance.
A subclass of N-SIIs includes molecules characterized by the
presence of a cross-conjugated α,β-unsaturated dienone with
two sterically accessible electrophilic β-carbons13 that can act as
Michael acceptors to target nucleophiles, like the catalytic
cysteine of several isopeptidases.13−17 Recently, a molecule of
this family, RA190, has been engineered to exert specificity
against proteasome ubiquitin receptor RPN13 (Figure 1).23
Optimization of these inhibitors in terms of in vivo efficacy is
a fundamental step toward their possible use in the clinic. In
this work, starting from G5, a N-SII previously identified by us
(Figure 1),14 we performed structure−activity studies that lend
support to the proposed mechanism of inhibition and allowed
us to develop a G5 derivative optimized for in vivo
antineoplastic activity.
■ RESULTS AND DISCUSSION
Structure−Activity Studies. The effect on tumor cell
survival of two series of dienones was investigated in
glioblastoma U87MG cells, which in response to G5 enter
both apoptosis and necrosis.24 The first series (Table 1) is
based on the bis(arylidene)tetrahydrothiapyran-4-one 1,1-
dioxide scaffold of G5 with variations in the substituents on
the aromatic rings. In the second series (Table 2), the sulfone
group of the G5 scaffold is replaced by other groups, while the
4-nitro substituents on the aromatic rings are fixed.
With the exception of the fluoro derivative 1f, symmetrical
compounds 1a−i and G5 were obtained by the acid catalyzed
Knoevenagel condensation of tetrahydrothiapyran-4-one 1,1-
dioxide (Scheme 1, X = SO2) with aromatic aldehydes.
25,26 An
alternative approach was adopted for the synthesis of 1f
(Scheme 1), consisting of the condensation between the
corresponding aldehyde and tetrahydrothiapyran-4-one fol-
lowed by mCPBA oxidation of the resulting sulfide 3. The
oxidation of the p-fluoro derivative 3 to the desired sulfone 1f
was accompanied by the formation of the Baeyer−Villiger
Figure 1. Cross-conjugated dienone N-SIIs RA190 and G5.
Table 1. Cytotoxicity of Bis(arylidene)tetrahydrothiapyran-
4-one 1,1-Dioxides against U87MG Glioblastoma Cells
compd R1 R1′ R2 R2′ IC50 [μM]a,b sdb
1a H H H H 5.11 1.67
1b CH3 CH3 H H 4.74 0.21
1c OH OH H H 6.73 0.15
1d OCH3 OCH3 H H 3.57 0.72
1e OPh OPh H H 2.94 0.57
1f F F H H 2.21 0.23
1g CN CN H H 1.35 0.15
1h OCH3 OCH3 NO2 NO2 1.14 0.18
1i H H NO2 NO2 0.76 0.07
1j NO2 OH H H 2.17 0.27
1k NO2 OCH3 H H 2.09 0.42
1l NO2 CH3 H H 1.39 0.34
G5 NO2 NO2 H H 0.77 0.21
aFrom cell viabilities measured with a resazurin assay, 48 h after
treatments. bExperiments were carried out in triplicate and are
presented as mean values and standard deviations (sd).
Table 2. Cytotoxicity of Nitrobenzylidene Dienones against
U87MG Glioblastoma Cells
compd X IC50 [μM]
a,b sdb
2a CH2 27.5 2.0
2b CH(OCH2CH2O) 15.33 0.71
2c CHOH 4.62 1.96
2d CHCOOC2H5 2.47 0.25
2e NH 7.15 2.90
2f O 50.1 14.3
2g S 11.6 2.01
2h SO 1.79 0.81
G5 SO2 0.77 0.21
aFrom cell viabilities measured with a resazurin assay, 48 h after
treatments. bExperiments were carried out in triplicate and are
presented as mean values and standard deviations (sd).
Scheme 1. Synthesis of Symmetrical Derivatives of Series 1
and 2a
aReagents and conditions: (a) ArCHO, EtOH, aq HCl, 15−78%; (b)
ArCHO, EtOH, Ba(OH)2, 52% (for 2b); (c) mCPBA, CH2Cl2, 41−
63%.
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byproduct 4 (Scheme 1). The two products, in ratio 3:1, were
easily separated by crystallization from acetone/hexane.
Unsymmetrical compounds 1j−l were obtained as shown in
Scheme 2. Tetrahydrothiapyran-4-one was initially converted
into the monoalkylidene derivative 5 by an aldol reaction with
4-nitrobenzaldehyde followed by dehydration of the aldol.
Acid-catalyzed Knoevenagel reaction of 5 with the appropriate
aromatic aldehyde was then followed by mCPBA oxidation of
the sulfides 6j−l.
All compounds of series 2 (Table 2) are symmetrical and,
with the exception of 2h, were obtained by the Knoevenagel
condensation of the appropriate ketone and 4-nitrobenzalde-
hyde (Scheme 1). For compound 2b, containing an acid-labile
acetal group, the condensation was carried out in basic
conditions.27 Sulfoxide 2h (Table 2) was obtained by
mCPBA oxidation of the corresponding sulfide 2g. Even
under controlled conditions (1 equiv of mCPBA, 0 °C) the
reaction gave a 1:1 mixture of sulfoxide 2h and sulfone G5, but
the desired product 2h was readily purified by flash
chromatography on silica gel.
1H and 13C NMR spectroscopy showed that all compounds
of series 1 and 2 were single stereoisomers with the aryl groups
trans with respect to the carbonyl.
Data in Table 1 indicate that all the sulfones of series 1 are
active against U87MG glioblastoma cells with IC50 values in the
range 0.8−7 μM, the dinitroderivatives G5 and 1i being the
most active compounds of the series. Variations of hydro-
phobicity (log P values) and solvent accessible area are small in
this series, reflecting the limited structural changes, and no
general correlation is observed between these parameters and
citotoxicity. However, a clear correlation can be observed
between cytotoxicity and the electronic effect of the
substituents on the aromatic ring. A plot of the logarithm of
the observed IC50 against the sum of the Hammett σ constants
for the substituents on the aromatic rings28 (Figure 2) reveals
that cytotoxicity depends on the electron-withdrawing ability of
the substituents, suggesting that the cytotoxic activity is directly
related to the electrophilicity of the enone β-carbon. This is
consistent with the observation that alcohol 7, obtained by
NaBH4 reduction of G5, is devoid of cytotoxic activity and
strongly suggests that cytotoxicity may indeed result from the
alkylation of cysteine residues present in the catalytic site of
isopeptidases by the dienone moiety.13,29 Similar correlations
have been observed also for cytotoxic N-acyl-bis(arylidene)-4-
piperidones,30 and arylidenecyclohexanones,31,32 which have
been postulated to selectively react as Michael acceptors with
cellular thiols.29
Finally, the contribution of the X group was investigated in a
series of dinitro derivatives 2 (Table 2). While all compounds
in this series are cytotoxic, the presence of a polar, electron
withdrawing group in the six-membered ring appears in general
to be beneficial to achieve strong activity.
Assessment of the Dienone-Induced Apoptotic and
Necrotic Responses. In cells resistant to apoptosis, such as
mouse fibroblasts defective for Bax and Bak (Bax/Bak DKO) or
glioblastoma U87MG cells, G5 can also activate a caspase-
independent death.24,33 Although caspase-independent death
can engage different mechanisms, previous studies have
excluded the involvement of autophagy and have demonstrated
that G5 triggers a necrotic cell death.33,34 Hence, we decided to
study, on a small set of dienones and using G5 as a reference,
whether variations in the structure affect the pronecrotic and
proapoptotic activities. To this purpose, we selected derivatives
1b, 2c, and 2h and also used T98G glioblastoma cells, which
preferentially die by apoptosis in response to G5 (Figure
3).24,34
As illustrated in Figure 3A,B, the sulfoxide 2h behaves
similarly to G5 while compounds 1b and 2c show a higher
propensity to trigger apoptosis compared to G5 and 2h. In fact,
unlike the latter compounds, 1b and 2c are more effective in
killing T98G than U87MG cells, as proved by trypan blue
staining and caspase activities. Cell death in T98G cells,
induced by 1b and 2c, is characterized by a robust caspase
engagement. On the other side in U87MG cells, during cell
death induced by G5 and 2h, caspases are much less involved,
thus testifying to the existence of two different types of cell
death. The differential induction of necrosis and apoptosis in
the two cell lines was confirmed, for 2c, by using the caspase
inhibitor zVAD-fmk (Figure 3C), which was effective in
counteracting cell death only in T98G cells; similar results
were obtained with the other compounds (Supporting
Information Figure S1).
In summary, the simultaneous presence of the sulfone/
sulfoxide and nitro groups in 2h and G5 appears to promote a
necrotic response; replacement of either group, as in 2c and 1b,
lowers the necrotic activity of the N-SII and favors the
induction of apoptosis.
The ability of the compound 2c to kill preferentially through
apoptosis suggests that it could represent a better choice for in
Scheme 2. Synthesis of Unsymmetrical Derivatives of Series
1a
aReagents and conditions: (a) (i) ArCHO, NaOH, MgSO4, H2O, (ii)
HCl, EtOH 56%; (b) ArCHO, EtOH, aq HCl, 44−95%; (c) mCPBA,
CH2Cl2, 21−90%.
Figure 2. Linear correlation between U87MG glioblastoma cells
cytotoxicity (log IC50) and Hammett σ constants for compounds of
series 1 (slope of −0.39 ± 0.04; r2 = 0.8808).∑σRi is the sum of the σp
and/or σm for all the substituents on both rings.
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vivo applications, with respect to G5. Moreover, compound 2c,
possessing a reactive OH group, appears to be a good
compromise between cytotoxicity and the possibility to
introduce modifications on the core to improve the inhibitor’s
druglike properties. For these reasons 2c was selected for
further development.
Deubiquitinase Inhibition by G5 and 2c. We evaluated
the inhibitory profile of the two compounds against purified
isopeptidases using ubiquitin−AMC as a substrate. Previous
studies demonstrated that dienones are broad inhibitors,
capable of inhibiting deubiquitinases but also deSUMOylase
activities.35 Thus, we investigated G5 and 2c activities against
ubiquitin carboxy-terminal hydrolases UCHL1, UCHL5 and
the ubiquitin-specific protease USP2.
UCHL5/UCH37 is a proteasome-associated UCH, which, in
conjunction with POH1/PSMD14 and USP14, provides the
proteasome the deubiquitinase activity.3 Unlike UCHL1 and
UCHL3, UCHL5 can also process poly-ubiquitin chains, and
previous studies identified UCHL5 as a target of dienone-based
N-SIIs.16
Both G5 and 2c weakly inhibit UCHL1 (Figure 4A) but are
much less effective than other small-molecule inhibitors.36
Conversely, both compounds exhibit a more pronounced
inhibitory activity against UCHL5. G5 is considerably more
potent than 2c, as shown by the IC50 values of 13.58 μM and
42.99 μM, respectively. Thus, UCHL5 inhibition may play an
important role in eliciting the accumulation of poly-
ubiquitinated proteins in cells treated with these compounds.
When USP2 activity was analyzed, again G5 showed some
inhibitory activity (IC50 = 32.56 μM) whereas 2c was almost
inactive. This IC50 value is in agreement with previous studies
where a compound related to G5 was used.14,35
Finally, we also tested G5 and 2c inhibitory potency against
the isopeptidase USP18, which processes the Ub-like ISG15
protein and is a key regulator of the interferon response.37 Both
compounds inhibit USP18 activity, and 2c appears to be
slightly more active than G5, with IC50 of 21.20 and 33,23 μM,
respectively. The ability of 2c to inhibit USP18 was also verified
in cells by coexpressing USP18 and a fusion between ISG15
and GFP.38 When ISG15-GFP was coexpressed with USP18,
accumulation of free GFP is predominant (Figure 4B). By
contrast, in the presence of increasing concentrations of G5 or
2c, accumulation of the uncleaved ISG15-GFP chimera can be
appreciated. In the same assay, bortezomib failed in influencing
USP18-dependent cleavage of ISG15-GFP.
Analysis of 2c Proapoptotic Activity. Next, to evaluate
whether 2c shows a strong and broad spectrum of
antiproliferative activities, we measured its IC50 against several
other cancer cell lines. Data in Table 3 indicate that 2c
antiproliferative activity is indeed wide and mainly in the low
micromolar range, as already observed for U87MG and T98G
cell lines.
We then evaluated in more detail the effect of 2c on the lung
cancer cell line A549 that was later chosen for in vivo
experimentation (vide infra). Initially, we compared the
apoptotic response elicited by 2c, G5, and bortezomib to
identify the concentration ranges of the three inhibitors that
induce comparable extents of cell death (Figure 5A). We then
used these concentrations to compare the effects of the three
inhibitors on the activity of the UPS and on the accumulation
of the BH3-only protein Noxa, a sensor of endoplasmic
reticulum stress and key element of the death pathway elicited
by UPS inhibitors.14 Immunoblot analysis (Figure 5B)
demonstrated that at low concentrations bortezomib is more
effective in eliciting accumulation of poly-ubiquitinated proteins
and in stabilizing p53 with respect to 2c or G5. Interestingly,
when cell death is induced with similar intensity, accumulation
of Noxa is comparable in bortezomib and 2c treatments, thus
suggesting that ER stress is similarly evoked by the two
compounds. By contrast, high doses of G5 less efficiently
promote Noxa up-regulation, consistent with the possible
engagement of a necrotic response (Figure 5B).
Synthesis and Activity of a 2c Derivative Optimized
for in Vivo Studies. 2c, like many anticancer compounds, is
Figure 3. Apoptotic and necrotic responses induced by different
dienones in U87MG (A) and T98G cells (B). Cells were treated with
the indicated concentrations of the different compounds for 24 h.
Upper: cell death as measured by percent of trypan-blue-positive cells.
Lower: caspase activity measured with rhodamine 110 bis-(N-Z-L-
aspartyl-L-glutamyl-L-valyl-aspartic acid amide) fluorogenic substrate
(relative fluorescence units) (black, G5; gray, 2h; light gray, 1b; white,
2c). (C) Effect of caspase inhibitor zVAD-fmk on cell death induced
by 2c (percent of trypan-blue-positive cells).
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poorly soluble in aqueous solutions. A common strategy for
improving drug solubility and bioavailability consists in the
conjugation of the compound with polyethylene glycol (PEG).
Despite the intrinsic limitation of a low drug/carrier mass ratio
when used with low molecular weight drugs, polyethylene
glycol offers some advantages as a water-soluble carrier for
anticancer compounds.39−41 We thus synthesized two soluble
derivatives by conjugating 2c to monomethoxy PEG (5000 Da)
via the OH group and suitable linkers (Scheme 3).
For the synthesis of the first conjugate (9), with a
dicarbamate linker (2cPC, 2c-PEG-carbamate), 2c was
converted into the mixed carbonate 8 and then coupled with
mono-PEGylated 1,3-diaminopropane (41% overall yield).
When tested on the panel of cancer cell lines, however, this
conjugate was inactive, incapable of triggering cell death and
reducing cell proliferation (data not shown). We thus
synthesized a second derivative (11), in 57% overall yield, by
conjugating 2c with PEG through a succinate linker (Scheme
3). We reasoned that this conjugate (2cPE, 2c-PEG-ester),
containing a more reactive diester linker, could act as a prodrug,
releasing the active species 2c upon the action of cellular
hydrolases,42 and indeed, we found that 11 was active on three
of the four cell lines tested (Table 3).
In melanoma A375 and glioblastoma U87MG cells the
antiproliferative activity of 2cPE (11) is identical to that of the
parent molecule 2c (Table 3). By contrast, in A549 and, even
more so, in HT29, respectively lung and colon cancer derived
cell lines, the PEGylated molecule is less effective in
suppressing proliferation. To verify this observation, we
compared the response of A549 cells to 2cPE (11) and 2c
by scoring cell death with trypan-blue assay. Dose dependent
studies (Figure 6A) and time course analysis (Figure 6C)
confirm that 2cPE is less effective than 2c in triggering cell
death in A549 cells, an observation further corroborated by the
analysis of poly-ubiquitin accumulation, p53 stabilization, and
Noxa induction (Supporting Information Figure S2). Similar
results were obtained in HT29 cells (Supporting Information
Figure S3).
On the opposite, in A375 cells, which show similar sensitivity
to 2c and 2cPE in resazurin assay (Table 3), cell death (Figure
6B), accumulation of poly-ubiquitinated proteins, p53 stabiliza-
tion, and Noxa up-regulation (Supporting Information Figure
S2) confirm that 2cPE behaves like the active compound 2c. In
summary, in A375 cells 2c and the PEGylated derivative 2cPE
are undistinguishable as UPS inhibitors and inducers of cell
death, while A549 and HT29 cells show some resistance to the
PEGylated derivative 2cPE (11).
Activation of the 2cPE Prodrug by Secreted Esterases.
A different pattern of expression of enzymes capable of
hydrolytically releasing the active species 2c from the PEG
conjugate might explain the differential responsiveness of the
Figure 4. (A) Inhibition of ubiquitin-specific hydrolases UCHL1, UCHL5, USP2, and USP18 by G5 and 2c. (B) Immunoblot analysis showing
inhibition of USP18 in A549 cells coexpressing USP18 and the ISG15-GFP chimera. p53 levels were used to monitor the inhibition of the UPS.
Inhibitor concentrations were the following: 2c (2.5, 5, 10 μM); G5 (1, 2.5, 5 μM); bortezomib (25, 50, 100 nM). Cellular lysates were generated
after 24 h of treatment. Under these concentrations comparable % of death in A549 lung cancer cells can be observed 48 h later. (C) Quantitative
densitometric analysis of immunoblots. Data are presented as the mean of two experiments.
Table 3. Antiproliferative Activity of 2c and PEGylated
Derivative 2cPC (11) in Different Cell Lines
IC50 (μM)
a
cell line 2c 11
U87MG glioblastoma 4.62 6.9
A375 melanoma 6.1 5.7
A549 lung cancer 16 22
HT29 colorectal adenocarcinoma 7.6 >100
Hep3B hepatocellular carcinoma 8.5
Mia PaCa-2 pancreatic cancer 35.2
aFrom cell viabilities measured with a resazurin assay, 48 h after
treatments.
Figure 5. (A) Inhibitor concentrations eliciting comparable death
percentage in A549 lung cancer cells after 48 h of treatment. (B)
Immunoblot analysis of extracts from A549 cells treated as in (A) and
monitored for UPS inhibition, (poly-ubiquitin and p53 accumulation)
and induction of ER stress (Noxa induction) after 24 h of treatment.
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four cell lines to 2cPE (Table 3). This hypothesis is supported
by the observation that unresponsive A549 cells become fully
responsive to 2cPE when they are grown in the presence of
A375 conditioned medium (Figure 6D), while A375 cells retain
their responsiveness to 2cPE also in the presence of A549
conditioned medium (Figure 6E). Similar results were obtained
with HT29 cells (Supporting Information Figure S3).
Accumulation of poly-ubiquitin chains, stabilization of p53,
and Noxa induction (Figure 6F) confirm that in the presence of
conditioned medium from A375 cells, the activities of 2c and
2cPE are indistinguishable, thus indicating that the prodrug is
readily converted into the active molecule by this medium.
These results indicate that the response to 2cPE (Table 3) of
different cell lines depends on their ability to secrete an esterase
Scheme 3. PEGylation of 2ca
aReagents and conditions: (a) N,N′-disuccinimidyl carbonate (75%); (b) succinic anhydride, DMAP (82%); (c) MPEG-OH, EDC, HOBT, TEA
(70%).
Figure 6. Cell death, after 48 h, as a function of concentration in A549 (A) and A375 (B) cells treated with 2.5−10 μM 2c (black bars) and 2cPE
(11) (gray bars). (C) Cell death as a function of time in A549 cells treated with 10 μM 2c (black bars) and 11 (gray bars) for 24−72 h. (D)
Response to 10 μM 2c and 2cPE (11) of A549 cells grown in normal and A375 conditioned medium. (E) Response to 10 μM 2c and 2cPE (11) of
A375 cells grown in normal and A549 conditioned medium. (F) Immunoblot analysis showing poly-ubiquitin accumulation, p53 stabilization, and
Noxa induction in A549 cells treated with 10 μM 2c (second lane) and 2cPE (11) in normal and A375 conditioned medium (third and fourth lane,
respectively). DMSO is the negative control throughout.
Journal of Medicinal Chemistry Article
DOI: 10.1021/jm501336h
J. Med. Chem. XXXX, XXX, XXX−XXX
F
activity capable of releasing 2c from the prodrug. To gain
insight into the enzymes that might be responsible for such
processing, we applied a bioinformatics analysis.
Initially, the different esterases encoded by the human
genome were extracted using GEO categories and Homo-
loGene.43 In this manner we generated a list of 173 putative
esterases. Next, to understand which secreted esterase exhibited
an expression profile compatible with the responsiveness to
2cPE, we interrogated gene expression profiles available for
A375, A549, and HT29 cells44 with our list. The expression of
the candidate esterase is expected to be high in A375, reduced
in A549 cells, and even more reduced in HT29 cells. Seven
esterases satisfied this expression profile, as illustrated in Figure
7A. Among these potential candidates, we have focused our
attention on the phospholipase A2 group 7 (encoded by the
PLA2G7 gene). This enzyme, also known as PAF-AH (platelet
activating factor acetylhydrolase), has been extensively
characterized,45 and the crystal structures of both the ligand-
free and of the paraoxon covalently inhibited enzyme are
reported.46 PLA2G7, which hydrolyzes the ester bond at the sn-
2 position of phospholipid substrates shows a canonical σ/β
hydrolase fold, and it has an interface binding area that makes it
capable of binding to the hydrophobic portions of lipoproteins
or to the internal hydrophobic region of cell membranes. The
interface is located at the end of a long hydrophobic channel
that leads to the catalytic serine and to the oxyanion hole.
Polyethylene glycol is known to activate the phospholipase
activity of the enzyme, probably by stabilizing the interface
complex between the lipase and the hydrophobic inner regions
of cell membranes.47 To verify that PLA2G7 can accept 2cPE as
a substrate, we have built a model of the tetrahedral covalent
intermediate for the hydrolysis of 2c conjugated to an ethylene
glycol dodecamer through the same succinate linker present in
2cPE. The crystal structure of the paraoxon covalently inhibited
enzyme was used as a starting point and stepwise mutated and
optimized to build the model (see Supporting Information).
The unique conformation corresponding to a stable and
productive intermediate according to the stereoelectronic
theory of Deslongchamps48,49 is reported in Figure 7B. In
this conformation, the first five units of the PEG chain lie inside
the hydrophobic channel of the enzyme, and 2c is partially
buried inside the catalytic site, which appears to be broad and
flexible enough to host this rather large structure. The two nitro
groups have a key role in stabilizing this intermediate: one of
them is found at hydrogen bond distance with the hydroxy
groups of serines 319 and 349, while the aromatic ring
establishes π-stacking interactions with phenylalanine 322 and
further hydrophobic contacts with histidine 351 (omitted for
clarity in the figure). The other nitro group is in contact with
the side chain of arginine 218. Interactions of arginine and
serine with the nitro groups of a ligand, such as those found in
this model, are well-known in antibodies and receptor
complexes.50
The model confirms that 2cPE could be a substrate for
phospholipase A2 secreted by A375 cells and thus supports the
hypothesis that lack of this enzyme, or of other esterases that
can activate the prodrug, might explain the different low
response of A549 and HT29 cell lines (Table 3). To prove the
involvement of PLA2G7 in prodrug maturation, we generated
by retroviral infection A549 cells expressing PLA2G7 isolated
from A375 cells. As control we used A549 cells expressing only
the resistance gene PURO. In the presence of PLA2G7, A549
cells dramatically increase responsiveness to the prodrug in
terms of cell death (Figure 7C). Further evidence was obtained
by incubating 2cPE in the presence of a commercially available
preparation of PLA2G7; the enzyme was able to fully hydrolyze
2cPE in phosphate buffer at room temperature, yielding 2c and
PEG5000, as indicated by mass spectrometry (see Supporting
Information p S31). Conversely, no hydrolysis was observed in
the absence of the enzyme upon the same incubation times.
2cPE Inhibits Tumor Growth in Mice. With convincing
evidence in hand that the prodrug 2cPE (11) is converted into
the active form 2c by secreted hydrolases and PLA2G7 in
Figure 7. (A) Expression profiles in A375, A549, and HT29 cells of
seven candidate esterases for the hydrolysis of 2cPE. (B) Optimized
model of the rate determining tetrahedral intermediate for hydrolysis
of 2cPE catalyzed by phospholipase A (PLA2G7). The model was
built from the crystal structure of PLA2G7 covalently inhibited by
paraoxon (PDB code 3D5E). (C) Response to 10 μM 2c and 2cPE of
A549 cells engineered to express PLA2G7 or the control gene PURO.
Trypan blue analysis was performed 48 h after treatment.
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particular, we set to analyzing whether the PEG conjugate
displays antitumor activity in vivo. To this end we selected
A549 lung cancer cells, even if these cells showed a low
response to the prodrug in culture. However, we expected that,
in animals, the prodrug should be efficiently processed by
mouse secreted 2cPE activator PLA2G7 and, possibly, other
secreted esterases.
Initial toxicity tests indicated that 2cPE is well tolerated with
transient minimal effect on the animal’s body weight up to 800
mg/kg. All treated groups showed slight (2%) body weight loss
over the course of the first week, independent from the doses.
Subsequently, the body weight of all animals steadily increased
until the end of the study with final 6−8% gain in body weight
(Supporting Information Figure S4). No gross toxicity was
observed throughout the treatment, and 2cPE did not induce
any behavioral change or grossly visible pathological changes.
A549 lung carcinoma xenografts were generated in immune-
compromised mice, and when the tumors reached the size of
0.1 cm3, 2cPE (170 mg/kg) was administered three times with
four days intervals. After 1 week from the last injection (day
15) the percentage of tumor volume inhibition (TGI) was 72%
and 78%, respectively, for subcutaneous and intravenous
treatments (Figure 8A). At the end of the experiment, the
reduction of primary tumor growth was particularly marked
(TGI = 79%) in the intravenously treated group. No significant
adverse effects were observed correlated to drug administration.
To further characterize the in vivo antitumor activity of 2cPE,
we evaluated the cellular responses in normal mouse tissues
(liver, kidney, and spleen) and in the tumor. Immunoblot
analysis of tissue extracts also confirms in vivo the up-regulation
of p53 and Noxa following 2cPE treatment (Figure 8B). This
up-regulation was much more evident in the tumor compared
to normal tissue. To exclude species-specific enrichment of the
antibody against p53, we used, in addition to DO-1 antibody,
the 421 antibody, which recognizes with similar affinity the
human and murine proteins.
■ CONCLUSIONS
Several studies have established that compounds characterized
by the presence of the 1,5-diaryl-3-oxo-1,4-pentadienyl
pharmacophore exhibit cytotoxic activities in vitro against
multiple cancer cell lines.29 While different cellular thiols may
in principle react with these Michael acceptors, isopeptidases, a
heterogeneous family of cysteine proteases, are important
targets for their antineoplastic activity. These inhibitors, also
called N-SIIs, can trigger both necrosis and apoptosis,
depending on the cellular context.24,33,34 In this work we
have shown that the cytotoxicity of a family of dienones
structurally related to sulfone G5 is directly correlated with the
electrophilicity of the dienone system. This provides indirect
evidence that the biological activity of these compounds is due
to their ability to act as mechanism-based inhibitors of cysteine
proteases. We have also demonstrated that by varying the
substituents on the aromatic rings and the structure of the
cyclic scaffold, it is possible to limit necrosis and to favor cell
death by apoptosis. This has led to the identification of
compound 2c, based on a 4-hydroxycyclohexanone scaffold, as
a good candidate for further development.
Analysis of the inhibitor activities has indicated that G5 is in
general a more potent inhibitor of DUBs such as UCHL1,
UCHL5, and USP2 compared to 2c. By contrast, 2c functions,
to some extent, as a better inhibitor for the deISGylase USP18.
In this scenario the dichotomy apoptosis/necrosis might reflect
different patterns of cysteine protease inhibition. Certainly, in
view of the existence of additional cellular targets, alternative
hypothesis are possible and further studies will be necessary to
clarify this point.
It has been suggested that similar N-SIIs, although
characterized by a broad spectrum of activity, can nevertheless
exhibit different preferences for certain targets.15−17,35 In this
view, the lower IC50 for proteasome-associated deubiquitinase
UCHL5 compared to other USPs, displayed by both G5 and
2c, can explain their action as UPS inhibitors,13,14,16 even if
additional mechanisms must also be taken into account.23
In this study we have also designed and synthesized the first
N-SII prodrug (2cPE) by conjugating compound 2c with PEG,
through a cleavable diester linker. This strategy has overcome
the solubility issue and has provided effective antitumoral
activity in vivo, after administration of the prodrug by
intravenous injections. From the diverse response in vitro of
different cell lines to the prodrug and by applying
bioinformatics analysis and molecular modeling, we have
identified in PLA2G7/PAF-AH a key esterase involved in
prodrug maturation. This esterase has been proposed as an
activating factor for anticancer prodrugs and delivery systems
due to its overexpression in breast, stomach, colorectal,
pancreatic, prostate, and liver cancers. Anticancer lipids have
been included in liposomes to be hydrolyzed by phospholipase
A2,51 and designed phospholipids containing PEG350 or
Figure 8. (A) Variations of A549 lung carcinoma xenografts volume in
mice following subcutaneous (sc) and intravenous (iv) treatments with
2cPE (170 mg/kg). (B) Immunoblot analysis showing up-regulation of
p53 and Noxa proteins in tissues of mice treated with 2cPE. Mice in
which the tumor mass reached the size of at least 0.5 cm3 were treated
for the first time with 170 mg/kg 2cPE, and 48 h later they were
sacrificed for the generation of tissue extracts. p53 was detected with
DO-1 and 421 antibodies, showing no significant difference.
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PEG2000 chains linked to phosphatidylethanolamine by a
carbamate linkage have proven to be substrates for the
enzyme.52 PLA2G7 is primarily produced by macrophages
and circulates in plasma in active form as a complex with LDL
and HDL.53 This pattern of expression explains why A549 cells,
which are unresponsive to 2cPE in vitro, become fully
responsive when evaluated in vivo.
The antineoplastic activity of 2cPE in vivo was accompanied
by the up-regulation of p53 and of the proapoptotic protein
Noxa. This up-regulation was more marked in tumor cells
compared to liver, spleen, and kidney. Importantly, although
proapoptotic genes were up-regulated also in normal tissues at
some extent, the animals did not show any effect of toxicity.
Both the reduced up-regulation of the apoptotic program, in
normal cells and their higher intrinsic resistance to stress, can
explain the absence of evident toxicity.
Isopeptidase inhibitors represent interesting tools in antineo-
plastic therapy. Understanding mechanisms of actions,
improving the delivery, for instance by the generation of
prodrugs through a cleavable PEGylation as described here for
the first time, and further medicinal chemistry approaches to
improve activity are efforts that need pursuing to provide
additional anticancer therapeutics.
■ EXPERIMENTAL SECTION
All biologically evaluated compounds had a purity >95% as determined
by HPLC analyses (see Supporting Information).
Chemistry: General Protocols. Melting points are uncorrected
and are given in Celsius degrees. 1H NMR and 13C NMR spectra were
recorded in CDCl3, unless otherwise stated, on Jeol EX400 (400
MHz) and Varian X500 (500 MHz) spectrometers. Chemical shifts are
given in ppm relative to tetramethylsilane. IR spectra were obtained as
Nujol mulls with a Thermo-Nicolet AVATAR 320 FT instrument.
Electron impact mass spectra were obtained on a Varian Saturn 2200
spectrometer equipped with a direct insertion probe. Electrospray
mass spectra were obtained with a Bruker Daltonics Esquire 4000
spectrometer. Flash chromatography was performed on silica gel 60
(Merck, 230−400 mesh). 4H-Thiopyran-4-one 1,1-dioxide,25 and
compounds 1a,26 2a,27 2b,27 2e30 were synthesized according to the
literature. Polyethylene glycol methyl ether (Sigma-Aldrich) and all the
PEGylated derivatives were coevaporated twice with dry dichloro-
methane and dried under vacuum immediately prior to use.
(3Z)-3-[(4-Nitrophenyl)methylene]-4H-tetrahydrothiapyran-
4-one (5). A suspension of tetrahydrothiapyran-4-one (23.2 g, 0.2
mol) and 4-nitrobenzaldehyde (15.1 g, 0.1 mol) in 100 mL of water
containing MgSO4·7H2O (14.8 g, 0.06 mol) and NaOH (5 g, 0.125
mol) was stirred at room temperature for 20 h. The solid was
collected, dried, and washed repeatedly with diethyl ether to remove
the excess tetrahydrothiapyran-4-one. The product, containing
approximately equal amounts of the aldol diastereoisomers, was
dehydrated for 1 h in refluxing ethanol (100 mL) containing conc HCl
(10 mL). The mixture was cooled to 25 °C and filtered, giving the
crude enone 5 (13.9 g, 56%); mp 105−106 °C (from ethanol). 1H
NMR: δ = 2.05 (t, 2H), 2.96 (t, 2H), 3.76 (s, 2H), 7.48 (s, 1H), 7.51
(d, 2H), 8.27 ppm (d, 2H). 13C NMR: δ = 26.0, 28.5, 41.5, 123.8,
130.3, 132.4, 137.2, 141.3, 147.6, 198.5 ppm. IR: ν = 1672 (CO),
1515 and 1344 cm−1 (NO2). MS: m/z 249 (M
+ 45%), 232 (100%).
Elemental analysis calculated (%) for C12H11NO3S: C 57.8, H 4.45, N
5.62. Found: C 57.8, H 4.34, N 5.30.
General Procedure for the Synthesis of Dienones 1, 2, and 6
by the Acid-Catalyzed Knoevenagel Condensation. A solution,
or mixture, of the appropriate arylaldehyde (0.1 mol) and cyclic ketone
(0.05 mol) in 30 mL of ethanol containing 3 mL of 37% HCl was
heated at gentle reflux for 1−2 h.26 Alternatively, the reaction mixture,
in a stoppered vial, was heated at 120 °C for 20 min in a microwave
reactor. The solution was cooled in an ice bath, and the product was
collected by filtration, washed with ethanol, and dried.
(3Z,5Z)-3,5-Bis[(4-nitrophenyl)methylene]tetrahydro-4H-thi-
opyran-4-one 1,1-Dioxide (G5). 45% from tetrahydro-4H-thiopyr-
an-4-one 1,1-dioxide and 4-nitrobenzaldehyde; mp 226−230 °C (lit.54
233.5−234.5 °C). 1H NMR (DMSO-d6): δ = 4.70 (s, 4H, CH2), 7.70
(d, 4H, ArH), 7.95 (s, 2H, CH) 8.3 ppm (d, 4H, ArH). 13C NMR
(DMSO-d6): δ = 52.5, 123.8, 131.8, 130.7, 139.9, 140.8, 147.6, 184.4
ppm. IR: ν = 1677 (CO), 1513 and 1350 (NO2), 1320 and 1136
cm−1 (SO2). MS: m/z 414 (M
+ 5%), 333 (100%).
(3Z,5Z)-3,5-Bis[(4-methyphenyl)methylene]tetrahydro-4H-
thiopyran-4-one 1,1-Dioxide (1b). 69% from tetrahydro-4H-
thiopyran-4-one 1,1-dioxide and p-tolualdehyde; mp 186−188 °C.
1H NMR: δ = 2.40 (s, 6H), 4.46 (s, 4H), 7.25 (d, 4H), 7.31 (d, 4H),
7.98 ppm (s, 2H). 13C NMR: δ = 21.6, 53.2, 129.8, 129.9, 125.9, 130.8,
140.7, 144.3, 186.1 ppm. IR: ν = 1664 (CO), 1333 and 1127 cm−1
(SO2). MS: m/z 352 (M
+ 20%), 273 (100%).
(3Z,5Z)-3,5-Bis[(4-hydroxyphenyl)methylene]tetrahydro-4H-
thiopyran-4-one 1,1-Dioxide (1c). 23% from tetrahydro-4H-
thiopyran-4-one 1,1-dioxide and 4-hydroxybenzaldehyde; mp 244−
246 °C. 1H NMR ((CD3)2CO): δ = 3.0 (s, 2H), 4.57 (s, 4H), 6.94 (d,
4H), 7.41 (d, 4H), 7.87 ppm (s, 2H). 13C NMR ((CD3)2CO): δ =
52.8, 116.1, 132.6, 125.6, 125.8, 142.3, 159.5, 184.2 ppm. IR: ν = 3388
(OH), 1659 (CO), 1304 and 1128 cm−1 (SO2). MS: m/z 356 ([M-
2H]+ 58%).
(3Z,5Z)-3,5-Bis[(4-methoxyphenyl)methylene]tetrahydro-
4H-thiopyran-4-one 1,1-Dioxide (1d). 50% from tetrahydro-4H-
thiopyran-4-one 1,1-dioxide and p-anisaldehyde; mp 175−177 °C. 1H
NMR: δ = 3.83 (s, 6H), 4.46 (s, 4H), 6.96 (d, 4H), 7.40 (d, 4H), 7.97
ppm (s, 2H). 13C NMR: δ = 53.3, 55.5, 114.6, 131.9, 124.6, 126.2,
143.9, 161.2, 185.8 ppm. IR: ν = 1659 (CO), 1318 and 1125 cm−1
(SO2). MS: m/z 384 (M
+ 75%), 88 (100%).
(3Z,5Z)-3,5-Bis[(4-phenoxyphenyl)methylene]tetrahydro-
4H-thiopyran-4-one 1,1-Dioxide (1e). 50% from tetrahydro-4H-
thiopyran-4-one 1,1-dioxide and 4-phenoxybenzaldehyde; mp 165−
168 °C. 1H NMR: δ = 4.40 (s, 4H), 7.00−7.08 (m, 8H), 7.17 (t, 2H),
7.35−7.41 (m, 8H), 7.96 ppm (s, 2H). 13C NMR: δ = 53.2, 118.3,
120.0, 124.5, 125.5, 130.1, 131.8, 128.0, 143.6, 155.8, 159.5, 186.0
ppm. IR: ν = 1666 (CO), 1308 and 1133 cm−1 (SO2). MS: m/z 443
([M − SO2]+ 100%).
(3Z,5Z)-3,5-Bis[(4-cyanophenyl)methylene]tetrahydro-4H-
thiopyran-4-one 1,1-Dioxide (1g). 20% from tetrahydro-4H-
thiopyran-4-one 1,1-dioxide and 4-cyanobenzaldehyde; mp 260−262
°C. 1H NMR (DMSO-d6): δ = 4.69 (s, 4H), 7.93 (s, 2H), 7.72 (d,
4H), 8.00 ppm (d, 4H). 13C NMR (DMSO-d6): δ = 52.1, 111.9, 118.6,
130.2, 140.0, 130.7, 132.6, 138.1, 184.6 ppm. IR: ν = 2232 (CN), 1692
(CO), 1327 and 1123 cm−1 (SO2). MS: m/z 374 (M+ 30%), 309
(100%). Elemental analysis calculated (%) for C21H14N2O3S: C 67.4,
H 3.77, N 7.48. Found: C 67.0, H 3.81, N, 7.37.
(3Z,5Z)-3,5-Bis[(3-nitro-4-methoxyphenyl)methylene]-
tetrahydro-4H-thiopyran-4-one 1,1-Dioxide (1h). 54% from
tetrahydro-4H-thiopyran-4-one 1,1-dioxide and 3-nitro-4-methoxyben-
zaldehyde; mp 259−260 °C. 1H NMR (DMSO-d6): δ = 4.00 (s, 6H),
4.74 (s, 4H), 7.45 (s, 2H), 7.85 (s, 2H), 7.88 (d, 2H), 8.09 ppm (d,
2H). 13C NMR (DMSO-d6): δ = 51.9, 57.0, 114.7, 126.6, 136.4, 125.9,
128.1, 139.5, 152.7, 184.2 ppm. IR: ν = 1696 (CO), 1531 and 1340
(NO2), 1311 and 1131 cm
−1 (SO2). MS: m/z 474 (M
+ 1%), 393
(100%). Elemental analysis calculated (%) for C21H18N2O9S: C 53.16,
H 3.82, N 5.90. Found: C 52.77, H 3.80, N 5.54.
(3Z,5Z)-3,5-Bis[(3-nitrophenyl)methylene]tetrahydro-4H-thi-
opyran-4-one 1,1-Dioxide (1i). 21% from tetrahydro-4H-thiopyran-
4-one 1,1-dioxide and 3-nitrobenzaldehyde; mp 230−231 °C. 1H
NMR (DMSO-d6): δ = 4.78 (s, 4H), 7.78 (t, 2H), 7.97 (s, 2H), 7.99
(s, 2H), 8.29 (d, 2H), 8.34 ppm (d, 2H). 13C NMR (DMSO-d6): δ =
52.5, 124.7, 125.1, 130.6, 130.9, 135.6, 136.7, 140.3, 148.6, 185.5 ppm.
IR: ν = 1690 (CO), 1530 and 1350 (NO2), 1320 and 1123 cm−1
(SO2). MS: m/z 414 (M
+ 10%), 333 (100%). Elemental analysis
calculated (%) for C19H14N2O7S: C 55.1, H 3.41, N 6.76, S 7.74.
Found: C 54.7, H 3.38, N 6.44, S 7.55.
(2E,6E)-2,6-Bis[(4-nitrophenyl)methylene]-4-hydroxycyclo-
hexanone (2c). 78% from 4-hydroxycyclohexanone and 4-nitro-
benzaldehyde; mp 210−213 °C. 1H NMR (DMSO-d6): δ = 2.98 (dd,
2H), 3.09 (dd, 2H)), 4.07−4.13 (m, 1H), 5.04 (d, 1H), 7.7 (s, 2H),
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7.8 (d, 4H), 8.3 ppm (d, 4H). 13C NMR (DMSO-d6): δ = 36.0, 63.0,
123.8, 131.4, 134.0, 137.1, 142.2, 147.2, 188.9 ppm. IR: ν = 3539
(OH), 1668 (CO), 1508 and 1342 cm−1 (NO2). ESI-MS: m/z 403
(MNa+), 381 (MH+). Elemental analysis calculated (%) for
C20H16N2O6: C 63.2, H 4.24, N 7.37. Found: C 62.9, H 4.19, N 7.32.
Ethyl (3E ,5E)-3,5-Bis[(4-nitrophenyl)methylene]-4-
oxocyclohexanecarboxylate (2d). 36% from ethyl 4-
oxocyclohexanecarboxylate and 4-nitrobenzaldehyde; mp 172−174
°C. 1H NMR: δ = 1.16 (t, 3H), 2.76−2.84 (m, 1H), 3.06−3.24 (m,
4H), 4.12 (q, 2H), 7.56 (d, 4H), 7.85 (s, 2H), 8.27 ppm (d, 4H). 13C
NMR: δ = 14.2, 30.5, 3961.4, 123.8, 130.9, 135.9, 136.4, 141.7, 147.5,
173.2, 187.7 ppm. IR: ν = 1723 (CO), 1673 (CO), 1512 and
1340 cm−1 (NO2). MS: m/z 436 (M
+ 50%), 419 (100%).
(3E,5E)-Tetrahydro-3,5-bis[(4-nitrophenyl)methylene]-4H-
pyran-4-one (2f). 24% from tetrahydro-4H-pyran-4-one and 4-
nitrobenzaldehyde; mp 263−265 °C (lit.54 272−273 °C). 1H NMR
(DMSO-d6): δ = 4.96 (s, 4H), 7.73 (d, 4H), 7.77 (s, 2H), 8.28 ppm
(d, 4H). 13C NMR (DMSO-d6): δ = 68.2, 124.2, 132.1, 133.5, 136.8,
140.9, 148.0 ppm. IR: ν = 1682 (CO), 1514 and 1347 cm−1 (NO2).
MS: m/z 366 (M+ 10%), 349 (100%).
(3Z,5Z)-Tetrahydro-3,5-bis[(4-nitrophenyl)methylene]-4H-
thiopyran-4-one (2g). 41% from tetrahydro-4H-thiopyran-4-one
and 4-nitrobenzaldehyde; mp 220−223 °C (lit.54 224−225 °C). 1H
NMR: δ = 3.87 (s, 4H), 7.55 (d, 4H), 7.77 (s, 2H), 8.29 ppm (d, 4H).
13C NMR: δ = 30.1, 124.0, 130.6, 134.6, 136.2, 141.3, 147.7, 188.0
ppm. IR: ν = 1667 (CO), 1509 and 1342 cm−1 (NO2). MS: m/z
382 (M+, 20%).
(3Z,5Z)-Tetrahydro-3,5-bis[(4-fluorophenyl)methylene)]-4H-
tetrahydrothiapyran-4-one (3). 54% from tetrahydro-4H-thiapyr-
an-4-one and 4-fluorobenzaldehyde; mp 122−124 °C. 1H NMR: δ =
3.88 (s, 4H), 7.11−7.38 (m, 4H), 7.73 ppm (s, 2H). 13C NMR: δ =
30.0, 115.4 (d, JC−F = 22 Hz), 130.8 (d, JC−F = 3 Hz), 131.6 (d, JC−F =
8 Hz), 133.2 (d, JC−F = 1 Hz), 135.4, 162.5, (d, JC−F = 251 Hz), 188.4
ppm. IR: ν = 1662 (CO), 1510 and 1330 cm−1 (NO2). MS: m/z
328 (M+ 100%). Elemental analysis calculated (%) for C19H14F2OS: C
69.5, H 4.30. Found: C 69.3, H 4.41%.
(3Z,5Z)-3-[(4-Hydroxyphenyl)methylene]-5-[(4-nitrophenyl)-
methylene]-4H-tetrahydrothiapyran-4-one (6j). 44% from 5 and
p-hydroxybenzaldehyde; mp 178−180 °C. 1H NMR (DMSO-d6): δ =
3.93 (s, 2H), 3.98 (s, 2H), 6.85 (d, 2H), 7.42 (d, 2H), 7.56 (s, 1H),
7.61 (s, 1H), 7.73 (d, 2H), 8.25 (d, 2H), 10.0 ppm (broad, 1H). 13C
NMR (DMSO-d6): δ = 29.0, 29.6, 115.7, 123.6, 125.4, 130.8, 131.2,
131.8, 132.8, 136.9, 137.3, 141.6, 146.9, 158.9, 187.7 ppm. IR: ν =
3451 (OH), 1660 (CO), 1519 and 1347 cm−1 (NO2). MS: m/z 353
(M+ 100%).
(3Z,5Z)-3-[(4-Methoxyphenyl)methylene]-5-[(4-nitrophenyl)-
methylene]-4H-tetrahydrothiapyran-4-one (6k). 95% from 5 and
p-methoxybenzaldehyde; mp 152−154 °C. 1H NMR: δ = 3.74 (s, 2H),
3.84 (s, 3H), 3.96 (s, 2H), 6.96 (d, 2H), 7.39 (d, 2H), 7.51 (d, 2H),
7.73 (s, 1H), 7.77 (s, 1H), 8.27 ppm (d, 2H). 13C NMR: δ = 29.9,
30.4, 55.5, 114.3, 123.9, 127.5, 130.6, 131.3, 132.4, 133.1, 136.9, 138.4,,
142.0, 147.5, 160.7, 188.4 ppm. IR: ν = 1653 (CO), 1514 and 1344
(NO2). MS: m/z 367 (M
+ 100%). Elemental analysis calculated (%)
for C20H17NO4S: C 65.38, H 4.66, N 3.81. Found: C 65.01, H 4.64, N
3.72.
(3Z,5Z)-3-[(4-Methylphenyl)methylene]-5-[(4-nitrophenyl)-
methylene]-4H-tetrahydrothiapyran-4-one (6l). 73% from 5 and
p-tolualdehyde; mp 139−142 °C. 1H NMR (DMSO-d6): δ = 2.32 (s,
3H), 3.95 (s, 2H), 3.98 (s, 2H), 7.26 (d, 2H), 7.42 (d, 2H), 7.58 (s,
1H) 7.61 (s, 1H), 7.75 (d, 2H), 8.25 ppm (d, 2H). 13C NMR (DMSO-
d6): δ = 21.0, 29.2, 29.5, 123.7, 129.4, 130.5, 131.3, 131.7, 132.3, 133.2,
136.1, 137.2, 138.0, 141.4, 147.0, 188.0 ppm. IR: ν = 1662 (CO),
1517 and 1344 cm−1 (NO2). MS: m/z 351 (M
+ 30%), 336 (100%).
General Procedure for mCBPA Oxidations. A solution of
mCPBA (1 mmol for oxidations to sulfoxides; 2.5 mmol for oxidations
to sulfones) in CH2Cl2 (5 or 12.5 mL, respectively) was added
dropwise, at 0 °C, to a suspension of the sulfide (1 mmol) in
dichloromethane (5 mL) and stirred at 25 °C for 16 h. The mixture
was diluted with 20 mL of dichloromethane and extracted with 10%
aqueous Na2S2O5, saturated NaHCO3, and brine. The organic layer
was dried over Na2SO4, and the solvent was removed in vacuo to give
the crude product that was crystallized from ethanol.
(3Z,5Z)-Tetrahydro-3,5-bis[(4-fluorophenyl)methylene)-4H-
tetrahydrothiapyran-4-one 1,1-Dioxide (1f). Oxidation of sulfide
3 with 2 equiv of mCPBA gave a mixture of sulfone 1f and the
Baeyer−Villiger product 4 which were separated by crystallization
from acetone/hexane. 1f (41%) had mp 179−180 °C. 1H NMR: δ =
4.43 (s, 4H), 7.12−7.45 (m, 4H), 7.96 ppm (s, 2H). 13C NMR: δ =
53.1, 116.6 (d, JC−F = 22 Hz), 126.7 (d, JC−F = 1 Hz), 129.8 (d, JC−F =
3 Hz), 132.0 (d, JC−F = 9 Hz), 143.4, 163.9 (d, JC−F = 252 Hz), 186.4
ppm. IR: ν = 1664 (CO), 1333 and 1128 cm−1 (SO2). MS: m/z 360
(M+ 20%), 294 (100%). Elemental analysis calculated (%) for
C19H14F2O3S: C 63.3, H 3.92, S 8.90. Found: C 63.2, H 3.81, S
8.74. 4 (10%) had mp 176−178 °C. 1H NMR: δ = 4.27 (s, 4H), 6.89
(s, 1H), 7.07−7.14 (m, 4H), 7.53−7.72 (m, 4H), 8.05 ppm (s, 1H).
13C NMR: δ = 53.1, 55.7, 115.8, 116.13, 116.16, 116.5, 119.9, 128.0,
128.8, 137.4, 126.1, 130.5, 130.6, 131.8, 131.9, 149.7, 162.4, 165.5
ppm. IR: ν = 1721 (CO), 1315 and 1120 cm−1 (SO2). MS: m/z 376
(M+ 43%), 312 (100%). Elemental analysis calculated (%) for
C19H14F2O4S: C 60.6, H 3.72. Found: C 60.2, H 3.72.
(3Z,5Z)-3-[(4-Hydroxyphenyl)methylene]-5-[(4-nitrophenyl)-
methylene]-4H-tetrahydrothiapyran-4-one 1,1-Dioxide (1j).
60% from sulfide 7j; mp 221−224 °C. 1H NMR (DMSO-d6): δ =
4.68 (s, 4H), 6.87 (d, 2H), 7.46 (d, 2H), 7.70 (s, 1H), 7.77 (d, 2H),
7.84 (s, 1H), 8.29 (d, 2H), 10.22 ppm (broad, 1H). 13C NMR
(DMSO-d6): δ = 51.9, 52.5, 116.0, 123.8, 131.0, 133.0, 138.7, 142.9,
123.7, 124.2, 124.4, 140.4, 147.4, 159.7, 184.0 ppm. IR: ν = 3450
(OH), 1511 and 1349 (NO2), 1308 and 1121 cm
−1 (SO2). MS: m/z
385 (M+ 5%), 320 (100%).
(3Z,5Z)-3-[(4-Methoxyphenyl)methylene]-5-[(4-nitrophenyl)-
methylene]-4H-tetrahydrothiapyran-4-one 1,1-Dioxide (1k).
60% from sulfide 7k; mp 158−160 °C (from acetone−hexane). 1H
NMR: δ = 3.88 (s, 3H), 4.35 (s, 2H), 4.51 (s, 2H), 6.99 (d, 2H), 7.42
(d, 2H), 7.58 (d, 2H), 7.98 (s, 1H), 8.02 (s, 1H) 8.32 ppm (d, 2H).
13C NMR: δ = 52.7, 53.7, 55.5, 114.7, 124.2, 130.2, 132.2, 140.6, 145.2,
123.5, 126.0, 130.0, 140.0, 147.0, 161.6, 185.7 ppm. IR: ν = 1663 (C
O), 1510 and 1346 (NO2), 1319 and 1126 cm
−1 (SO2). MS: m/z 399
(M+ 10%), 304 (100%).
(3Z,5Z)-3-[(4-Methylphenyl)methylene]-5-[(4-nitrophenyl)-
methylene]-4H-tetrahydrothiapyran-4-one 1,1-Dioxide (1l).
90% from sulfide 7l; mp 155−158 °C. 1H NMR: δ = 2.44 (s, 3H),
4.35 (s, 2H), 4.49 (s, 2H), 7.27 (d, 2H), 7.32 (d, 2H), 7.58 (d, 2H),
7.97 (s, 1H), 8.01 (s, 1H) 8.30 ppm (d, 2H). 13C NMR: δ = 21.6, 52.8,
53.6, 124.2, 125.0, 129.9, 130.0, 130.2, 140.0, 140.8, 141.3, 145.4,
148.2, 185.8 ppm. IR: ν = 1663 (CO), 1519 and 1346 (NO2), 1326
and 1133 cm−1 (SO2). MS: m/z 383 (M
+ 20%), 304 (100%).
(3Z,5Z)-Tetrahydro-3,5-bis[(4-nitrophenyl)methylene]-4H-
thiopyran-4-one 1-Oxide (2h). Oxidation of the sulfide 2g with 1
equiv of mCPBA gave a 1:1 mixture of sulfone 2G and sulfoxide 2h
that were separated by flash chromatography on silica gel with 8:2
dichloromethane/ethyl acetate as eluent, giving pure 2h (34%); mp
185−190 °C. 1H NMR: δ = 3.93 (d, 2H, J = 12 Hz), 4.21 (d, 2H, J =
12 Hz), 7.58 (d, 4H), 8.03 (s, 2H), 8.3 ppm (d, 4H). 13C NMR
(DMSO-d6): δ = 48.7, 124.3, 131.0, 131.6, 140.8, 141.4, 147.9, 187.0
ppm. IR: ν = 1676 (CO), 1506 and 1349 cm−1 (NO2). MS: m/z
398 (M+, 10%), 365 (100%). Elemental analysis calculated (%) for
C19H14N2O6S: C 57.3, H 3.54, N 7.03, S 8.05. Found: C 57.2, H 3.75,
N 7.11, S 7.92.
(3Z,5Z)-3,5-Bis[(4-nitrophenyl)methylene]-4-hydroxy-tetra-
hydro-4H-thiopyran 1,1-Dioxide (7). NaBH4 (0.016 g, 0.44 mmol)
was added in small portions at 0 °C with constant stirring to a solution
of G5 (0.15 g, 0.4 mmol) in 25 mL of a 10:1 (v/v) THF/MeOH
mixture. After 20 min the reaction was quenched by the addition of
ice-cold, saturated brine (25 mL) and the product was extracted with
diethyl ether (4 × 25 mL). The combined organic layers were washed
with brine, dried over MgSO4 and the solvent was removed under
reduced pressure, giving the alcohol 7 (90%): mp 216−220 °C. 1H
NMR ((CD3)2CO): δ = 2.84 (s, 1H), 4.24 (d, 2H), 4.26 (d, 2H), 5.22
(d, 1H), 7.21 (s, 1H), 7.69 (d, 2H), 8.28 ppm (d, 2H). 13C NMR
((CD3)2CO): δ = 51.7, 76.7, 123.8, 130.1, 128.5, 134.5, 142.4, 147.3
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ppm. IR: ν = 3399 (OH), 1517 and 1351 (NO2), 1329 and 1130 cm
−1
(SO2). Elemental analysis calculated (%) for C19H16N2O7S: C 54.80,
H 3.87, N 6.73. Found: C 55.02, H 3.99, N 6.67.
(3E,5E)-3,5-Bis[(4-nitrophenyl)methylene]-4-oxocyclohexyl
2,5-dioxo-1-pyrrolidinyl Carbonate (8). N,N′-Disuccinimidyl
carbonate (1.0 g, 3.89 mmol) was added to a solution of 2c (0.74 g,
1.95 mmol) in 20 mL of 1:1 dichloromethane/acetonitrile. Pyridine
was added until the solution became clear (1 mL), and the mixture was
stirred at 25 °C for 18 h. The solution was cooled in an ice bath, and
the mixed carbonate 8 was precipitated with diethyl ether, filtered, and
dried (75%). Mp: 172−175 °C. 1H NMR (DMSO-d6): δ = 2.71 (s,
4H), 3.30−3.40 (m, 4H), 5.31−5.38 (m, 1H), 7.79 (d, 4H), 7.85 (s,
2H), 8.27 ppm (d, 4H). 13C NMR (DMSO-d6): δ = 25.3, 32.5, 74.5,
123.6, 131.2, 133.9, 136.7, 141.3, 147.1, 151.0, 169.6, 187.1 ppm. IR: ν
= 1810 (CO), 1788 (CO), 1740 (CO), 1670 (CO), 1518
and 1347 cm−1 (NO2).
2cPC (9). N,N′-Disuccinimidyl carbonate (205 mg, 0.8 mmol) was
added to mPEG5000-OH (1.0 g, 0.2 mmol) in a mixture of dry
dichloromethane (3.5 mL), acetonitrile (1 mL), and pyridine (0.5
mL), and the solution was stirred for 18 h at 25 °C under an argon
atmosphere, cooled in an ice bath, and the crude product (mPEG-
OSu, 94%) was precipitated with diethyl ether, filtered, and
recrystallized from ethanol. 1H NMR (DMSO-d6): δ = 2.80 (s, 4H),
3.30−3.55 (m, PEG), 4.25−4.55 (m, 2H, PEG-CH2OSu). 1,3-
Diaminopropane (48 μL, 0.57 mmol) and mPEG-OSu (1.0 g, 0.19
mmol), in a minimum amount of dry dichloromethane, were stirred
for 18 h at 25 °C under an argon atmosphere. The solution was cooled
in an ice-bath, and the crude mono-PEGylated 1,3-diaminopropane
(90%) was precipitated with diethyl ether, filtered, and recrystallized
from ethanol. 1H NMR (DMSO-d6): δ = 1.48−1.54 (m, 2H, CH2),
2.94−2.99 (m, 2H), 3.30−3.55 (m, PEG + CH2), 3.98−4.04 (m, 2H,
PEG-CH2OCONH), 7.17 ppm (m, 1H, NH). Triethylamine was
added to a solution of the activated carbonate 8 (0.52 g, 1.0 mmol)
and PEGylated 1,3-diaminopropane (1.0 g, 0.2 mmol) in the minimum
amount of dry pyridine, to pH 8. The mixture was stirred for 18 h at
25 °C under an argon atmosphere and then cooled in an ice bath, and
the crude product 9 (67%) was precipitated with diethyl ether, filtered,
and recrystallized from ethanol. 1H NMR (DMSO-d6): δ = 1.35−1.38
(m, 2H), 2.77−2.83 (m, 4H), 3.20−3.70 (m, PEG), 3.97−4.01 (m,
2H), 4.97−5.03 (m, 1H), 7.02−7.09 (m, 2H), 7.74 (d, 4H), 7.77 (s,
2H), 8.30 (d, 4H).
3- { (3E , 5E ) -3 ,5 -B i s [ (p -n i t ropheny l )methy lene ] -4 -
oxocyclohexyloxycarbonyl}propionic Acid (10). Succinic anhy-
dride (2.63 g, 26.3 mmol) and DMAP (0.32 g, 2.63 mmol) were added
to a solution of alcohol 2c (1.0 g, 2.63 mmol) and pyridine (1 mL) in
25 mL of 1:1 dichloromethane/acetonitrile, and the reaction mixture
was stirred at room temperature for 16 h and then extracted with 0.1
M HCl. The solid emisuccinate (370 mg) was collected, while the
organic layer was dried over anhydrous sodium sulfate and evaporated.
The solid residue was washed with hot methanol, giving a second crop
of product 10 (664 mg). The crude emisuccinate (82% overall) was
used without further purification. Mp: 195−198 °C. 1H NMR
(DMSO-d6): δ = 2.31−2.36 (m, 4H), 3.13 (dd, 2H), 3.20−3.25 (m,
2H), 5.14−5.18 (m, 1H), 7.76 (s, 2H), 7.79 (d, 2H), 8.27 (d, 4H),
12.1 ppm (s, 1H). 13C NMR (DMSO-d6): δ = 28.8, 32.3, 35.7, 67.0,
123.6, 131.2, 135.0, 135.9, 141.5, 147.0, 171.5, 173.3, 187.0 ppm. IR: ν
= 3502 (COOH), 1734 (CO), 1710 (CO), 1668 (CO), 1517
and 1347 cm−1 (NO2). MS: m/z 480 (M
+ 8%), 345 (100%).
2cPE (11). Emisuccinate 10 (0.96 g, 2 mmol), EDC (0.38 g, 2
mmol), and HOBT (0.27 g, 2 mmol) were added, in the order, to
mPEG5000-OH (1.0 g, 0.2 mmol) in a minimum amount of dry
dichloromethane. Triethylamine was added to pH 8 and the mixture
was stirred for 18 h, at 25 °C, under an argon atmosphere. The
solution was cooled in an ice bath and the crude product was
precipitated by adding diethyl ether, filtered, and recrystallized from
ethanol, giving 0.76 g of the conjugate 11 (70%). 1H NMR (DMSO-
d6): δ = 2.41 (2H), 2.50 (2H), 3.25−3.70 (m, PEG), 3.95−4.00 (m,
2H), 5.13−5.20 (m, 1H), 7.81 (d, 4H), 7.82 (s, 2H), 8.30 ppm (d,
4H).
Modeling. Calculations were carried out on a workstation
equipped with a Dual Opteron ASUS KFSN4-DRE/IKVM/IST
mother board and two AMD Opteron SixCore 2427 2.2 GHz &MB
75 W processors. The MMFF94 force field55 [as implemented in the
Spartan ’14 parallel suite (Wavefunction Inc.)] was used in all energy
minimizations. The crystallographic coordinates of the reference
covalent complex of phospholipase A2 with paraoxon46 were obtained
from the Protein Data Bank, Brookhaven National Laboratory (PDB
code 3D5E). Full details on the construction of the model for the
PLA2G7 catalyzed hydrolysis of 2cPE (11) are in the Supporting
Information.
Hydrolysis of 2cPE by PLA2G7. The enzyme (recombinant
human PLA2G7 from R&D Systems, code 5106-PL-010) was added at
a final 0.2 nM concentration to a 25 mM solution of 2cPE in
phosphate buffer, pH 7. The reaction was followed by ESI-MS on a
Bruker Esquire 400 instrument (see Supporting Information).
Biological Assays. Reagents and Antibodies. The following
reagents were used: bortezomib (LC Laboratories), DMSO (Sigma-
Aldrich), resazurin (Invitrogene), GST-UCHL5 (Ubiquigent), ISG15-
AMC (BostonBiochem), ubiquitin-AMC (Ubiquigent), zVAD-fmk
(Bachem). Primary antibodies were anti-actin (Sigma-Aldrich), anti-
ubiqutin (Covance), anti-p53 DO-1 (Santa Cruz), anti-Noxa (Merck
Millipore).
Cell Culture, Cell Death, and Caspase Activity. All cell lines
were grown in DMEM supplemented with 10% FBS, penicillin (100
U/mL), glutamine (2 mmol/L), and streptomycin (100 μg/mL) at 37
°C in 5% CO2 atmosphere. In all trypan blue exclusion assays, at least
400 cells from three independent experiments were counted. Data are
presented as mean value ± SD. A549 cells engineered to express
PLA2G7 were generated by retroviral infection using the pLPC vector
and selected for puromycin resistance. The cDNA of PLA2G7 was
obtained after retrotranscription of RNAs isolated form A375 cells and
PCR amplification using oligonucleotides covering the ORF. The
cDNA of PLA2G7 was cloned blunt/SalI. Sequencing of the PLA2G7
cDNA was performed to scrutinize for the presence of mutations. The
RT-PCR analysis confirming the expression of recombinant PLA2G7
in A549 cells is reported in the Supporting Information.
The caspase activity was evaluated using the Apo-ONE caspase-3/7
homogeneous assay (Promega). The assay includes a profluorescent
caspase-3/7 consensus substrate, rhodamine 110 bis-(N-Z-L-aspartyl-L-
glutamyl-L-valylaspartic acid amide). Cells grown in 96-well plates
were treated with the different compounds and tested for caspase
activity as recommended by the producer. Data are presented as mean
value ± sd, n = 3.
Western Blotting. Tissue and cellular extracts were generated in
Laemmli sample buffer. Before lysis, frozen small tissue fragments were
pulverized using a dedicated apparatus (TissueLyser Qiagen). Protein
extracts, after SDS−PAGE were transferred to a 0.2 μm nitrocellulose
membrane and incubated with the specific primary antibodies as
previously described.14 After washing, blots were incubated with
secondary antibody−peroxidase conjugates (Sigma). For primary
antibody stripping, blots were incubated for 30 min at 60 °C in
stripping solution (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 100 mM β-
mercaptoethanol).
Isopeptidase Inhibition. In a 96-well-plate, 20 nM UCHL1, 20
nM UCHL5, fused to GST, and 40 nM His-tagged USP2 catalytic
domain or 270 nM USP18 were preincubated with G5, 2c, or control
for 30 min before substrate Ub-AMC (200 nM) addition. ISG15-AMC
(400 nM) was used as substrate for USP18. Reaction buffer was 50
mM Tris, pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 1 mM DTT.
Enzymes relative activities were determined by measuring the RFU
values as average of the maximum values obtained within the initial
linear range. Enzymatic activities were determined every minute for 60
min, at 37 °C. Fluorescence values were read with an Enspire 2300
multilabel reader (excitation 380 nm, emission 460 nm). The RFU
values were normalized to 100% of activity for the isopeptidases
incubated with vehicle alone. IC50 values were calculated with
GraphPad Prism software using a nonlinear fit. Recombinant full-
length UCHL1 and USP2 catalytic domain were expressed in bacteria
and purified by affinity chromatography using GST or histidine
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binding resin, respectively. The human USP18 sequence encoding the
region 16-372 corresponding to the translated full-length protein
starting at the rare codon CUG was cloned using the Gateway system
in a baculovirus expression vector based on pVL1393 (GE
Healthcare). The recombinant protein was expressed in Sf9 insect
cells. For protein purification, cells were homogenized (Emulsiflex,
Avestin) in lysis buffer (500 mM NaCl, 10% glycerol, 0.01% Tween,
20 mM DTT, 20 μg/mL DNaseI, protease inhibitors in 50 mM Na
phosphate, pH 8.0). Cleared lysates were affinity purified on
gluthatione-Sepharose 4B (GE Healthcare) and eluted by cleavage
with HRV C3 protease. The protein was then purified on Superdex
200 10/30 GL (GE Healthcare) equilibrated in buffer (500 mM NaCl,
10% glycerol, 5 mM DTT in 50 mM Na phosphate, pH 8.0). The
eluted monomeric protein was concentrated to 3.5 mg/mL, and
aliquots were flash-frozen in liquid nitrogen. The quality assessment of
recombinant protein was performed by ESI LC/MS analysis using a
single quadrupole instrument with an electrospray ion source (1100
HPLC G1946 MSD Agilent system).
Gene Expression Studies. Microarray data sets used in this study
were downloaded manually from GEO.43a We analyzed expression
data obtained from GSE48433 (platform HG-U133_Plus_2, GPL570
array). We processed all the CEL files together by using standard tools
available within the Affy package.56 We used a UniGene ID centered
CDF (Chip Description file) in order to have only one intensity value
per gene.57 Details on microarray data processing and analysis are
reported in the Supporting Information. The list of lipases was
downloaded from Gene Ontology and integrated with HomoloGene;
only genes with direct enzymatic activity were considered, filtering out
lipases regulators and cofactors. In the end we obtained a list of 173
genes of which 159 were present in the array’s platform.
Statistical Analysis. All assays and control experiments were
carried out in triplicate. Results are expressed as the mean ± sd.
Statistical analysis was performed by Student’s t test and P values of
≤0.05 were considered statistically significant. Asterisks in the figures
indicate the following: (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.005.
A549 Human Lung Carcinoma Xenograft Tumors in Mice.
Six-week-old female athymic nude-foxn1nu mice (Harlan Ud Italy)
were utilized for in vivo xenograft experiments, whereas 9-week-old
female Balb/C OlaHsd mice were used for toxicity studies (Harlan Ud
Italy). Animal studies were carried out according to the guidelines
enforced in Italy (DDL 116 of Feb 21, 1992 and subsequent addenda)
and in compliance with the Guide for the Care and Use of Laboratory
Animals, Department of Health and Human Services Publication No.
86-23 (National Institutes of Health, Bethesda, MD, 1985). In vivo
xenograft tumor model was established from initial sc injection of in
vitro expanded A549 tumor cells. After tumor mass establishment,
solid mass was surgically removed, under sterile conditions, and cut
into fragments (2−3 mm), in sterile PBS. Tumor fragments obtained
from donor mice were then serially expanded or injected for
experimental purpose. Fifteen mice were implanted sc with A549
tumor fragments, obtained from donors at passage p8.
2cPE Toxicity Analysis. Animal’s body weights were recorded for
all animals three times a week from the first day of treatment. All
animals were checked daily, and eventual behavioral changes, ill health,
or mortality was recorded for each animal. On day 0, each animal was
weighed and the volume of the dose was adjusted to ensure proper
dosage in mg/kg. At the end of the experiments mice were sacrificed
and basic autopsy was performed on all mice: thoracic and abdominal
cavity was open, and all major organs were macroscopically examined.
Livers from all animals were collected and weighted.
2cPE Administration to Mice. Mice were treated iv or sc every 4
days, for three times with 170 mg/kg of 2cPE, starting from day 16
after tumor fragments injection (day 0), when tumor size was 0.1 cm3.
Each animal received one dose of 2cEP (170 mg/kg) on day 0,
another dose on day 4, and another dose on day 8. For both iv and sc,
2cPE was dissolved in PBS. Injected volume of compound solution
was 200 μL for each treatment. Control mice received PBS. Before
treatment, mice were randomly assigned to experimental groups (n = 3
with 4 mice/group). Tumor volume and body weights were recorded
for all animals beginning from the day of first treatment and then twice
or three times per week, until study termination. The percentage of
tumor growth inhibition (TGI) was calculated according to the
following equation:
= − ×
⎛
⎝⎜
⎞
⎠⎟%TGI 100
%TG, treated group
%TG, control group
100
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